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1 INTRODUCTION
END STAGE RENAL DISEASE
Kidneys are important for several processes in the human body. The main functions 
of kidneys are: the filtering of blood and the removal of (toxic) waste products and 
excess water through urine, the regulation of blood acidity, and the production of 
hormones and enzymes that help to regulate production of blood cells, blood pressure, 
bone metabolism and growth hormone. In case of kidney damage, reflected by a 
reduction of the glomerular filtration rate (GFR) for three or more months, a patient 
suffers from chronic kidney disease (CKD)[1]. The severity of CKD is classified in five 
stages. Some patient unfortunately progress towards stage 5, which is severe illness 
with poor life expectancy. The GFR in this stage is less than 15 ml/min/1.73 m2 as 
opposed to 90-140 ml/min/1.73 m2 in healthy individuals; this is also called end stage 
renal disease (ESRD). ESRD is a major health problem, affecting more than 16000 
patients in the Netherlands (www.nefrovisie.nl). This thesis is aimed at predicting 
long-term patient survival for end stage renal disease patients at the moment of the 
start of renal replacement therapy.
RENAL REPLACEMENT THERAPY
Patients with ESRD need renal replacement therapy (RRT) to survive. In the Netherlands 
every year approximately 2000 new ESRD patients start RRT (www.nefrovisie.nl). 
There are two types of RRT: dialysis and kidney transplantation, which both have 
become available since the 60’s of the last century. Both of them are life-sustaining 
therapies, giving the ESRD patient options to prolong his/her life substantially. 
The number of prevalent patients with RRT in the Netherlands shows a steady increase 
in the last 15 years and currently exceeds 16000, while the number of dialysis patients 
has stabilized in the last six or seven years (figure 1). The Netherlands has a high 
transplantation rate compared to most other countries in Europe; approximately 60% 
of all patients with RRT (in 2014: 967.2 per million population) were patients with a 
transplanted kidney (www.era-edta.com).
DIALYSIS
Dialysis is the process of clearing the blood from toxins and removing excess water 
and salt. This can either be done outside the body, filtering the blood with help of an 
artificial kidney (hemodialysis), or within the body using the peritoneal membrane as 
a filter (peritoneal dialysis).
Hemodialysis (HD) treatment can be received in a hospital or a dedicated outpatient 
dialysis centre, but it can also be performed at home. Each dialysis session takes 
three to eight hours. Usually at least three or four sessions per week are necessary. 
HD patients can suffer from ‘dialysis hangover’ after each dialysis session: due to 
changes in blood composition, they feel very tired after a dialysis session. They also 
have dietary restrictions as well as a very limited liquid intake to prevent an accumu-
lation of water and waste products in between dialysis sessions. Common compli-
cations of HD are hypotension and vascular access thrombosis. 
Peritoneal dialysis (PD) can be performed at home or in a nursing home. In case 
of PD the dialysis solution has to be infused into the patient’s abdominal cavity. The 
two most common forms of PD in the Netherlands are Continuous Ambulatory PD 
(CAPD) and Continuous Cyclic PD (CCPD). In case of CAPD the patient manually has 
to empty and fill two to three liters of dialysate every four to six hours during the day. 
In case of CCPD the changes of dialysate are performed (at night) by machine. The 
possibility to perform PD depends on the medical condition of the patient, on the 
social situation, and on the patient’s willingness and capability to be responsible for 
the dialysis treatment him/herself. Common complications are ultrafiltration failure, 
and peritonitis (often combined with catheter-exit-site infections). 
Figure 1. Prevalence of RRT in the Netherlands at the first of January (2001-2016) 
source: www.nefrovisie.nl
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‘extended criteria’ donors (ECD), as opposed to the standard criteria donors (SCD)
[15]. There are many ways to define a marginal donor, but usually these are older 
donors, with several complications. The use of marginal or ECD-donors in general 
has resulted in higher numbers of kidneys that do not function at all (primary non 
function, PNF), or have a delayed graft function (DGF) after transplantation, and a 
decrease in graft function and survival compared to SCD. For example, kidneys from 
ECD donors have been associated with more than 1.7 times the risk of graft failure 
compared to ‘ideal’ deceased donor kidneys[16]. In the last decades the pool has 
been further expanded with the use of donations after cardiac death (DCD), with also 
an increased PNF and DGF compared to donations after brain death (DBD)[17]. 
Besides deceased kidney transplantation there is a very active living donation program 
in the Netherlands, which has led to an enormous increase of the donor pool. Living 
donation was at first restricted to genetically related donors, but currently also unre-
lated, cross-over (exchange of organs between two living donor-recipient couples 
where direct donation is not possible[12]) and even anonymous living donors are 
accepted for transplantation (www.transplantatiestichting.nl). For the transplant 
recipient this is a good development; living donor grafts show superior graft survival[18] 
and because there is no waiting list ESRD patients can avoid health damage due to 
prolonged dialysis duration[19,20]. Since 2008 the number of kidney transplantations 
from living donors has exceeded the number of transplantations from deceased 
kidney donors (figure 2). 
The advantages of PD over (center) HD are the continuous character of the treatment, 
that less dietary/fluid intake restrictions are prescribed, that dialysis can be done at 
home, and that it takes less time. Despite the fact that many studies comparing HD 
and PD showed conflicting results[2-8], for most patient groups in the first period of 
RRT PD is preferred over HD[9-11]. 
KIDNEY TRANSPLANTATION
Kidney transplantation is the placement of a renal graft, which can be donated by 
either a deceased or a living donor, in the body of the patient. Kidney transplantation 
is a well-accepted form of RRT since the discovery of effective immunosuppressive 
medication (azathioprine and prednisone) in the sixties. In the Netherlands the first 
renal transplant was performed 50 years ago (1966) at the University Hospital of 
Leiden.
The Dutch Transplant Foundation (NTS), which is responsible for the organization of 
organ and tissue donation, allocation and transplantation in the Netherlands, was 
founded in 1997. For deceased organ transplantation the NTS has outsourced donor 
acceptance and organ allocation to Eurotransplant. 
As a consequence of the success of the kidney transplantation program, in the 
Netherlands the waiting list for deceased donor kidneys has grown and mean waiting 
time gradually increased from approximately 1 year in the eighties of the last century[12] 
to 4.5 years in 2006. Since then the mean waiting time has decreased to approxi-
mately 3.5 years in more recent years (www.transplantatiestichting.nl). The average 
waiting time varies with patient characteristics that influence allocation probability, 
like blood group, HLA classification, immunization, and medical urgency. Due to the 
improved outcome of transplantation as a result of more effective immunosuppressive 
drugs, as well as changes in the ESRD population (older, more diabetes and an 
increased number of co-morbid conditions), higher risk patients are being accepted 
for transplantation in recent years[13,14].
Not all patients are eligible for transplantation: some patients are not transplantable 
due to an inferior clinical condition, which is more often the case in elderly patients. 
In addition, about 25% of all waitlisted patients will unfortunately never be transplanted 
mainly because their clinical situation deteriorates while waiting and they are delisted 
or die on dialysis before a suitable kidney graft becomes available[13]. Due to the 
persistent donor shortage, criteria for the inclusion of organs of deceased donors 
have been extended, which led to the introduction of the term ‘marginal donors’ or 
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Figure 2. Number of kidney transplantations, differentiated by donor type, per year. 
(source: Nefrovisie and Dutch Transplant Foundation)
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conservative treatment[27-31]. Conservative treatment is comprised of medication 
as well as dietary restrictions and lifestyle changes that are directed to limiting the 
burden on kidneys, decreasing kidney disease symptoms and optimizing quality of 
life. With the appropriate treatment, patients who decline RRT can live a considerable 
time (months till even years). Conservative treatment therefore recently has been 
suggested as an important alternative to discuss when counseling (elderly) patients 
about renal replacement[27,29,30]. Actually, this was most likely the standard of care 
in the first decade(s) of RRT, when strict acceptance criteria were necessary to allo-
cate scarce resources to those patients most likely to benefit. With the growth of 
dialysis facilities, the number of older and higher risk patients on RRT has grown 
exponentially, but it is questionable whether renal replacement treatment is always 
the right choice for these patients. For the frail elderly ESRD patient, for whom kidney 
transplantation is not feasible and dialysis is too burdensome conservative therapy 
might be the preferential treatment. 
PREDICTION MODELING AND DECISION SUPPORT 
Good ESRD patient guidance could profit from discussing survival prospects and 
treatment options already at the beginning of the RRT. Generally, kidney transplan-
tation is the preferred treatment for most ESRD patients. However, at the start of 
renal replacement it is not clear yet which patients will eventually be transplanted. 
Therefore, a survival prediction model for all ESRD patients starting RRT, regardless 
of future treatment choices, is desirable. Such a RRT survival prediction model might 
help patients to understand the survival implications of ESRD, to (re)set survival 
expectations and it might be helpful in shared patient-physician discussion of future 
treatment perspectives. However, such a general model was not available yet. Existing 
prediction models were either focused on survival on the transplant waiting 
list[18,20,24,32], dialysis survival until transplantation[33], or survival after renal 
transplantation[34,35], and were therefore not suitable to predict overall survival at 
the start of RRT. The primary aim of this thesis is to develop and validate a model to 
predict long-term patient survival chances regardless of future treatment choices.
Although a general RRT survival prediction model is desirable at the start of RRT, it 
cannot be used to decide which treatment is preferable for a specific patient. Although 
physician and patient probably might agree that renal transplantation is the best 
treatment option, the decision whether or not to accept a donor kidney offer is rather 
complicated when it concerns a marginal donor kidney. Marginal donor kidneys are 
often associated with inferior graft survival, but waiting for a better kidney offer 
prolongs dialysis time, which is associated with inferior patient outcomes. It would 
CHOICE OF RENAL REPLACEMENT THERAPY:  
DIALYSIS VERSUS TRANSPLANTATION
Therapy choice depends on patient condition (urgency and eligibility), therapy possi-
bility (availability), and preference.
For most patients kidney transplantation is the preferred therapy, since patient survival 
and quality of life are better compared to dialysis[18,20-24]. A transplanted kidney 
replaces all functions of the native kidney and can restore kidney function within 
normal ranges, while with dialysis no more than 10% of normal clearance is reached. 
Dialysis patients generally rate their quality of life (QoL) lower than transplant 
patients[22,25], which is not surprising considering the health impact as a result of 
limited clearance and the necessity to adapt their daily life drastically. 
Despite the favorable outcomes of kidney transplantation in comparison with dialysis 
treatment, transplanted patients are exposed to several risks and complications both 
on the short and long term after transplantation[18,26]. Living with a transplanted 
kidney implies lifelong immunosuppressive drug intake (in order to prevent rejection 
of the graft), which increases the chance on (viral) infections, malignancies and cardi-
ovascular disease. Despite the use of immunosuppressive drugs, patients risk chronic 
graft rejection, which is also related to non-immunological factors (e.g. ischemic 
damage, nephrotoxicity due to the use of calcineurin inhibitors and donor age). Peri-
operative risks and short and long term complications after transplantation also lead 
to an increased mortality risk for transplanted patients compared to the general 
population.
When a marginal donor kidney is offered, a physician has to consider the advantages 
and disadvantages, in terms of survival as well as quality of life, of transplanting this 
organ with inferior prognosis in his/her patient compared to continuing dialysis and 
waiting for a better kidney offer. Careful consideration of the advantages and disad-
vantages of a specific transplantation is necessary and renal transplant candidates 
should be informed about the risks and benefits of renal transplantation compared 
to dialysis. 
CONSERVATIVE THERAPY AS AN ALTERNATIVE FOR RRT
Despite the fact that kidney failure will eventually lead to death if renal function is not 
being replaced, there is a trend towards careful consideration, in shared decision 
making, of withholding from dialysis and prolonging life at acceptable quality with 
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survival expectations. Furthermore, a survival prediction model could also be used 
in further RRT research, e.g. to stratify patients according to survival risks in clinical 
trials. In chapter 2-3 we investigate the possibilities to predict long-term survival for 
patients starting RRT. From RENINE we selected all patients from 1995-2005 and 
by split sample analysis we developed and internally validated a prediction model for 
renal patient survival based on a small set of readily available registry variables (chapter 
2). In NECOSAD data, we further explored the possibilities to enhance prediction 
model performance by using clinical data and laboratory data in addition to (or instead 
of) the registry variables (chapter 3). In chapter 4 we describe the external validation 
study of the earlier mentioned registry model, for the same timeframe, in 9 European 
countries reporting to the ERA-EDTA. 
A possible limitation of the presented prediction models is that changes in RRT 
practice might lead to deterioration of their performance in future cohorts. Chapter 
5, which is directed to explain the decline of PD-usage in the Netherlands, shows 
which changes actually have occurred in RRT in the last 15 years. 
The second aim of this thesis is to predict which patients might profit from certain 
marginal donor kidney transplants in order to support a difficult decision whether to 
accept a marginal donor kidney offer. In chapter 6 we therefore compare the survival 
of marginal (Extended Criteria Donor) and regular (Standard Criteria Donor) transplants 
in general and for specific patient groups.
In chapter 7 we summarize our main findings, discuss how they meet our aims, and 
identify future research opportunities.
therefore be very helpful for physicians to have the availability of a decision support 
system that accounts for all possible prognostic chances, e.g. dialysis survival, trans-
plant survival, transplant failure, average waiting time for a next (better) kidney offer, 
and death. The first step forward towards this goal would be to distinguish patient 
groups that do or do not have significant inferior outcomes after a marginal donor 
kidney transplantation. The secondary aim of this thesis is therefore to be able to 
select patients that would profit most from certain marginal donor kidneys with 
reduced waiting times.
REGISTRY DATA
A large share of the work in this thesis is based on data from the Dutch renal replace-
ment registry (RENINE), which is hosted by Nefrovisie. For renal transplantations 
there is an exchange of information between RENINE (from Nefrovisie) and the Dutch 
organ transplant registry (NOTR) from the Dutch Transplant Foundation. RENINE data 
are also forwarded to the European Renal Association / European Dialysis and Transplant 
Association (ERA-EDTA). An important strength of RENINE is the fact that it includes 
all renal replacement therapies in the Netherlands from the start of this program (the 
first Dutch dialysis patient) in 1964. Patient data and treatment history (therapy and 
centre changes) are collected from the first treatment until death of the patient. As 
RENINE was established in 1986, information over the period before 1986 consists 
of the corrected and supplementary data from the ERA-EDTA and Eurotransplant. 
Until 2014, the Dutch renal replacement registry collected only a limited number of 
variables. The advantage is that RENINE ensures high data quantity and quality, with 
low numbers of missing data. The drawback is that extensive adjustment in multi-
variable analysis is not possible. We therefore also used data from NECOSAD. In 
NECOSAD (Netherlands Cooperative Study on Adequacy of Dialysis) an extensive 
array of additional clinical data has been collected, but only for a study cohort of 
patients starting dialysis. 
AIMS AND OUTLINE OF THE THESIS
The general goal of this thesis is to contribute to the knowledge about ESRD patient 
survival prediction.
The first aim is to predict RRT patient survival from the start of RRT in order to 
support initial patient counseling. A general survival prediction is basic information, 
which might help patients to understand the implications of RRT, and to (re)set their 
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SURVIVAL PROGNOSIS AFTER THE START OF A RENAL REPLACEMENT THERAPY IN THE NETHERLANDS
Abstract
Background 
There is no single model available to predict the long term survival for patients starting 
renal replacement therapy (RRT). The available models either predict survival on dial-
ysis until transplantation, survival on the transplant waiting list, or survival after trans-
plantation. The aim of this study was to develop a model that includes dialysis survival 
and survival after an eventual transplantation.
Methods
From the Dutch renal replacement registry, patients of 16 years of age or older were 
included if they started RRT between 1995 and 2005, still underwent RRT at baseline 
(90 days after the start of RRT) and were not registered at a non-renal organ transplant 
waiting list (N=13868). A prediction model of 10-year patient survival after baseline 
was developed through multivariate Cox regression analysis, in one half of the research 
group. Age at start, sex, primary renal disease (PRD) and therapy at baseline were 
included as possible predictors. A sensitivity analysis has been performed to determine 
whether listing on the transplant waiting list should be added. The predictive perfor-
mance of the model was internally validated. Calibration and discrimination were 
computed in the other half of the research group. Another sensitivity analysis was to 
assess whether the outcomes differed if the model was developed and tested in two 
geographical regions, which were less similar than the original development and 
validation group . No external validation has been performed. 
Results
Survival probabilities were influenced by age, sex, PRD and therapy at baseline 
(p<0.001). The calibration and discrimination both showed very reasonable results for 
the prediction model (C-index = 0.720 and calibration slope for the prognostic index 
= 1.025, for the 10 year survival). Adding registration on the waiting list for renal 
transplantation as a predictor did not improve the discriminative power of the model 
and was therefore not included in the model. 
Conclusions
With the presented prediction model, it is possible to give a reasonably accurate 
estimation on the survival chances of patients who start with RRT, using a limited set 
of easily available data.
BACKGROUND
In the Netherlands, in recent years approximately 2000 new patients with end stage 
renal disease (ESRD) start chronic renal replacement therapy (RRT) every year. Even 
though the kidney replacement programs already exist for more than forty years, it 
is still not possible to predict the long term survival chances for all RRT patients during 
the initial phase of their therapy, using one single model. 
Existing prediction models look at dialysis survival until transplantation[1], patient 
survival on the transplant waiting list[2-5], patient survival after transplantation[6,7], 
or focus on a specific patient group in which differences in treatment modality are 
less likely[8]. However, none of the available predication models focus on survival for 
the complete group of incident RRT patients, taking into account survival after dialysis 
combined with survival after a possible transplantation. As it is not clear at therapy 
initiation whether a patient will stay on dialysis, or will be listed in time and actually 
be transplanted, the available models cannot be used to predict survival for all patients 
at the start of RRT. 
To be able to give a survival prognosis in an early stage of the renal replacement 
therapy to every patient, we need a model that predicts patient survival chances 
based on characteristics that are known at that point in time. In the present study, 
based on national data from the renal replacement registry, a prediction model on 
the survival prognosis for incident RRT patients in the Netherlands was developed 
and validated.
The objective of this study is to develop a prediction model that could be used by 
physicians to inform patients about their survival chances at the start of RRT, based 
on a few very easily obtainable variables. 
METHODS
In the Dutch renal replacement registry, all ESRD patients with chronic renal replace-
ment therapy, meaning kidney function replacement for at least 4 weeks consecutively, 
are registered. These patients have given written informed consent for submission 
of their data to the national registry. The Renine data control committee, which 
manages the registry, has approved the use of the data in the registry for this particular 
research. For this study, the baseline situation for the prognosis was the therapy at 
90 days after the start of renal replacement therapy, as the intention to treat. We 
chose 90 days as the baseline of our study to ensure enough time to switch from a 
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Exclusion criteria were not registered PRD (N=518), recovered kidney function (N=322), 
lost to follow-up (N=48), unknown kidney transplant type (N=20), transplant failure 
before baseline (N=3) or home hemodialysis as baseline therapy (N=4). The final 
study group consisted of 13868 patients (Table 1). The events from 90 days after the 
start of RRT till death or end of the study (1/1/2010) were analyzed; the follow-up 
period was maximized at 10 years. For the development and validation of the predic-
tion model, the study group was randomly divided in a development (N=6934) and 
a validation group (N=6934).
STATISTICAL ANALYSIS
The analysis was performed using SPSS 19 and STATA. Survival was analyzed with 
Kaplan Meier and log rank tests. Linearity of the influence of patient age on survival 
was assessed with Kaplan Meier stratified by different age groups. The proportionality 
assumption has been tested by visual inspection of the Schoenfeld residuals plot[9]. 
For the survival prognosis from 90 days after the start of RRT, multivariate Cox 
regression analysis was performed in the development group. The formula for the 
survival probability at time t, S(t), is S(t)=exp(-H(t)). Here H(t) is the cumulative hazard 
that is calculated from the baseline hazard (H0) as H(t)=H0(t)*exp(prognostic index). 
The prognostic index (PI) is the sum of the parameter estimates from the Cox regres-
sion multiplied by the patient characteristics for a specific patient. To validate the 
prediction model, the predictive performance was assessed by computing the cali-
bration and the discrimination of the prediction model for the 3, 5 and 10 year survival 
in the validation group[10,11]. Calibration refers to the agreement between observed 
outcomes and predicted survival probabilities. This was measured by a) the calibration 
in the large, which indicates the extent that predictions are systematically too low or 
too high, b) a calibration plot for ten deciles according to the predicted survival, which 
is plotted against the observed survival, which ideally should be on the 45-degree 
line, and c) the calibration slope, which should be 1. The discrimination is the ability 
of the model to distinguish subjects with different outcomes. This was measured by 
the concordance (or C-) index. A C-index of 0.5 indicates the model has no discrim-
inative power, while a model with a C-index of 1.0 has a perfect discriminative power. 
As a sensitivity analysis we assessed the consequences of our choice not to include 
information about registration on the waiting list as one of the predictors in the model 
and the choice for random (instead of geographical) development and validation group 
stratification.
temporary needed therapy to the intended treatment and to exclude patients who 
only have to undergo renal replacement therapy for a short period of time. The primary 
renal disease (PRD) is coded in the registry according to the ERA-EDTA coding system 
and for our analysis grouped into 6 categories. PRD ‘unknown’ is a specific category, 
as the nephrologist was not able to define the original kidney disease, so these are 
probably shrunken kidneys. If the PRD is missing, it could be any disease, and there-
fore it is different from PRD unknown. The included patients are Dutch residents of 
16 years of age or older at the start of RRT, who started RRT in the period of 1995-
2005, who still underwent a RRT at baseline, and who were not registered at the 
waiting list for another organ transplant than kidney (N=14783). Selected patient and 
treatment characteristics were sex, age at start of RRT, PRD and therapy at 90 days, 
and the outcome was patient survival. 
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Table 1 Demographics of patients, N=13868
Patients starting a renal replacement therapy in 
1995-2005, ≥16 years of age, with a registered 
primary renal disease and peritoneal dialysis, 
hemodialysis or a functioning kidney transplant 
at 90 days after the start
Total
N=13868
%
Development 
group
N= 6934
%
Validation 
group
N=6934
%
P-value
Sex Male 60.2 61.1 59.4 0.04
Age group
16-44 year 17.1 17.6 16.7 0.47
45-64 year 36.9 36.9 36.9
65-74 year 28.4 28.4 28.4
75 year or older 17.6 17.2 17.9
Primary renal 
disease
Diabetes 16.7 16.6 16.8 0.71
Renal vascular disease 25.3 25.2 25.3
Glomerulonephritis 12.3 12.5 12.1
Cystic kidney disease 9.0 8.8 9.2
Other diseases* 21.4 21.8 21.0
Unknown** 15.2 14.9 15.5
Start year renal 
replacement
1995 – 2000 50.3 50.9 49.6 0.15
2001 – 2005 49.7 49.1 50.4
Therapy at baseline
Transplantation 3.0 2.8 3.2 0.32
Hemodialysis 65.7 65.5 65.9
Peritoneal dialysis 31.3 31.7 31
*The group ‘other diseases’ consists of the subcategories interstitial nephritis (9.4%), other congenital and 
hereditary kidney diseases (1.5%), other multisystem diseases (5.4%) and other primary renal diseases (5.1%).
** The primary kidney disease ‘unknown’ is included as a separate category in the prognosis, as these are 
probably shrunken kidneys, whereby it was no longer possible to determine the original disease. This is a 
specific recognisable category of patients, and therefore this is a separate diagnosis in the prognostic formula. 
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Table 3 Baseline hazards for the referent patient group
Period Baseline hazard
1 year 0.0030365610
2 year 0.0062357605
3 year 0.0099612016
4 year 0.0137250602
5 year 0.0171945227
6 year 0.0210066776
7 year 0.0244553143
8 year 0.0277822094
9 year 0.0310576721
10 year 0.0333077563
To illustrate how these results can be used to compute a survival probability, consider 
the following example: a 50 year old male diabetic patient, that was initially treated 
with peritoneal dialysis has a prognostic index (PI) of ((age*0.054=)50*0.054=)2.7)+((-
male=)0.067)+((diabetes=)0.767+((peritoneal dialysis=)-0,131)=3.40. Then, the 1-year 
survival for this patient is: exp(-(0.0030*exp(3.40)))=exp(-0.09)=91%. The 5-year 
survival for this patient is: exp(-(0.0171*exp(3.40)))=exp(-0.51)=60%. The 10-year 
survival for this patient is: exp(-(0.0333*exp(3.40)))=exp(-1.0)=37%. The model can 
be used in a simple Excel sheet to draw an individual survival prediction curve.
To assess the predictive performance of the model, the calibration and discrimination 
were computed in the validation group. The calibration in the large, or overall calibra-
tion, was good with a 50.4% predicted versus 49.5% observed 5-year survival and 
32.9% predicted versus 34.4% observed 10-year survival.
Based on the prognostic index, ten deciles of patients were distinguished and the 
observed probability for 3, 5 and 10-year survival was plotted against the predicted 
probability in each risk stratum, constituting the calibration plot (Figure 1). The cali-
bration slope, which ideally is 1.0, was assessed by a Cox regression analysis using 
the prognostic index as the only variable, and had an outcome of 0.948, 0.990 and 
1.025 for the 3, 5 and 10-year survival respectively. The discriminative power of the 
prediction model was assessed with the concordance index and the resulting outcome 
of the C-index was 0.707 (95% CI: 0.698-0.717), 0.716 (95% CI: 0.708-0.724) and 
0.720 (95% CI: 0.712-0.728) for the 3, 5 and 10-year survival respectively. 
To show robustness of our model, we also performed sensitivity analyses.
RESULTS 
The overall 10-year survival of patients on RRT at baseline was 34%. From the total 
cohort (N=13868) 8418 patients died within 10 years (60.7%). The number of censored 
cases was 5450 (39.3%). The mean follow-up time was 5.6 years, the median was 
5 years, the minimum was 0.25 and the maximum was 10 years. A prediction model 
of 10-year patient survival after baseline (90 days after the start of RRT) was devel-
oped through multivariate Cox regression analysis (with age, sex, PRD, and therapy 
at baseline as possible predictors). Based on the visual inspection of the Schoenfeld 
residual plots the proportionality assumption has not been rejected . Age had a linear 
relationship with survival. The model was developed in the development group and 
validated in the validation group. In the development group the number of patients 
at risk at 1,3,5 and 10 year were: 6934, 5190, 3879 and 1223. In Table 1 the devel-
opment and validation group were compared and found to be not different except for 
a small variation in sex distribution. In Table 2 the Cox regression model is presented 
with the baseline hazards for the referent patient group (H0) in table 3. 
Table 2 Cox regression model for patient mortality 90 days after start of 
renal replacement therapy 
Patient 
characteristics
Parameter 
estimate*
Hazard 
ratio
95% 
Confidence 
Interval
P-value
Primary renal disease <0.001
Glomerulonephritis Reference
Cystic kidney disease -0.280 0.756 0.639-0.894 0.001
Renal vascular disease 0.331 1.392 1.232-1.573 <0.001
Diabetes 0.767 2.154 1.899-2.444 <0.001
Other diseases 0.407 1.502 1.324-1.705 <0.001
Unknown 0.296 1.345 1.178-1.535 <0.001
Therapy at 90 days <0.001
Hemodialysis Reference
Peritoneal dialysis -0.131 0.877 0.817-0.943 <0.001
Kidney transplantation -1.634 0.195 0.117-0.325 <0.001
Male sex 0.067 1.070 1.005-1.139 0.04
Age (per year) 0.054 1.055 1.052-1.058 <0.001
* The sum of (the product of) parameter estimates gives the value of the prognostic index of a patient 
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As a first sensitivity analysis the model has been extended with the registration on 
the kidney waiting list at 90 days, combined with the therapy at 90 days and presented 
together in the model as the status at 90 days. This model had a similar validity to 
our current model with a discrimination of 0.724 and a calibration in the large equal, 
and a calibration by deciles almost equal, to that of the current model.
As the development group and validation group were very similar, we also assessed 
the influence of dividing the research cohort into two geographical regions, based 
on the ZIP-codes of the patients’ addresses. The two resulting comparable sized 
regions differed from each other in age-distribution, PRD-distribution, starting period, 
therapy at 90 days and transplantation rate. One of these regions also differed from 
the development group on all mentioned items; the other only differed in PRD-distribution. 
Two sensitivity analyses have been performed. The first was the development of a 
model in one region and validating the outcome in the other region. Parameter esti-
mates of this alternative model did not differ substantially from our original (and final) 
model. This model had a similar validity to our final model with a discrimination of 
0.711 and a calibration almost equal to that of the final model. 
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Figure 1 Calibration plot prediction model: observed versus predicted 3, 5 and 10 year survival
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prediction models with and without registration on 90 days suggests that the chance 
to be in a better general condition and/or to be transplanted is not only reflected in 
registration on the waiting list, but is also covered by the other predictors (age at 
start, PRD and therapy at 90 days). Another reason not to include registration on the 
kidney transplant waiting list as a predictor in our model is the fact that the time point 
of registration is very arbitrary in the Netherlands. There was a very large variation 
in registration time in Dutch population, and many patients were registered on the 
waiting list for kidney transplantation after the period of 90 days, which was our 
baseline for inclusion. It is not very likely that there is a difference in condition between 
patients that are registered at 90 days or, for instance, at 91 days after the start of 
RRT. 
Some potential limitations of this study should also be noted.
First, the moderate discriminative power of the prediction model (C-index of 0.720) 
shows further improvement possibilities. In this study the age, PRD, and therapy at 
90 day are considered to be substitutes for more accurate clinical indicators on the 
condition of patients. Adding clinical patient characteristics, like GFR, proteinuria, and 
(historical) co-morbidities, would probably improve the individual prediction. An English 
study showed that the addition of comorbid condition data and laboratory data could 
indeed lead to improvement of the predictive power of the prognostic model from 
0.69 to 0.75[1]. On the other hand the additional effect may be limited, as age and 
PRD are highly correlated with comorbidity, as has also be shown by a European 
study[18] and a single centre study in the US[19]. It is therefore desirable to study for 
the Dutch situation whether clinical data correlate with data already used in this model 
and whether they can improve the discriminative power of the prediction model. 
Another limitation of the study is that the model is only internally validated in the 
validation group, and the model has not been externally validated in an external cohort. 
It would be desirable to test the model in another patient group. This could be a 
patient cohort from another country or another period. The generalizability of the 
model to another country, however, is doubtful, as countries differ in dialysis and 
transplantation possibilities. This should be subject for further research. The fact that 
our model focuses on long term survival, makes external validation in a more recent 
cohort difficult. Regular evaluation of the model is needed as treatments improve in 
time and RRT-population, treatment possibilities and choices, both in dialysis and 
transplantation, change. 
Finally, note that the prediction model presented in this study can only be used to 
inform patients about their survival chances from 90 days after their start of RRT. 
The final model was also validated in the two separate regions. The model performed 
well in both regions, with a similar discrimination (C=0.71) and calibration slopes of 
the prognostic index of 0.982 and 1.040 respectively (data not shown). 
DISCUSSION 
A prediction model was developed to estimate survival probabilities at 90 days based 
on a basic set of patient characteristics (age at start of RRT, sex and PRD) and the 
RRT therapy at 90 days. The main strength of the current prediction model is that it 
is based on the complete cohort of Dutch patients in 1995-2005. The predictive 
performance of the model is adequate, as demonstrated by validity tests on calibra-
tion and discrimination of this model, which could thus be used to inform patients 
about their survival prognosis at baseline. 
The model uses treatment information at 90 days after the start of RRT, as the inten-
tion to treat. There is a clear difference in survival between patients who are on 
dialysis or who are being transplanted in an early stage. From previous studies we 
know that a better survival for kidney transplantation can be related to both advantages 
of the therapy as well as the better condition of the patient[2,12]. There is also a 
survival difference between patients starting on hemodialysis and peritoneal dialysis, 
which is also known from literature on this topic. Research has shown that patients 
starting on hemodialysis have more co-morbidities than patients starting on peritoneal 
dialysis[13-15]. In the prognostic formula the therapy modality therefore is included 
as one of the indicators of patient condition, as no other clinical information is available 
in the complete Dutch patient cohort. Like the ERA-EDTA, the Dutch renal replace-
ment registry only collects a few parameters on all patients. Further research should 
establish whether the treatment at 90 days, in combination with age and PRD, is a 
good alternative for clinical parameters indicating the patient’s condition.
Registration on the kidney transplant waiting list at 90 days was not included as one 
of the predictors. Other studies have shown the survival benefit of patients registered 
at the waiting list, compared to dialysis patients not listed for transplantation[12,13,16], 
suggesting that this predictor is related to patient condition. For that reason we 
performed a sensitivity analysis to test the possible additional value of this predictor. 
The additional predictive performance, however, was negligible. Possibly this could 
indicate that there is an overlapping risk profile between dialysis patients listed and 
not listed for transplantation as has been showed by an American study[17], where 
they found that many ESRD patients viable for transplantation were not listed while 
higher risk patients had been listed rapidly. The comparable performance of the 
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The patients for whom the model can be used, should have survived the first 90 days 
of RRT and the therapy choice for their RRT therapy has been made earlier. This 
prediction model is not suitable to be used for the choice of the therapy modality at 
the start of the RRT or for the acceptance or decline of a specific transplant kidney 
offer. The therapy choice should be based on preferences of the patient and physician, 
as is also the case for the choice to accept or decline a specific transplant kidney 
offer. For the choices between therapies and the probability of death on therapies 
new designs are currently emerging, based on competing risks instead of the Kaplan 
Meier method[20]). 
CONCLUSIONS
In conclusion, with the presented prediction model it is possible to give a reasonably 
accurate estimation on the survival chances of patients who start with RRT, using a 
limited set of easily available data. Future research should establish whether it is 
possible to improve the predictive performance of the prediction model using more 
clinical parameters.
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Abstract
Background
Risk prediction models can be used to inform patients undergoing renal replacement 
therapy about their survival chances. Easily available predictors such as registry data 
are most convenient, but their predictive value may be limited. We aimed to improve 
a simple prediction model based on registry data by incrementally adding sets of 
clinical and laboratory variables.
Methods
Our dataset includes 1835 Dutch patients from NECOSAD. The potential survival 
predictors were categorized on availability. The first category includes easily available 
clinical data. The second set includes laboratory values like albumin. The most labo-
rious category contains GFR and Kt/V. Missing values were substituted using multiple 
imputation. Within 1225 patients we recalibrated the registry model and subsequently 
added parameter sets using multivariate Cox regression analyses with backward 
selection. On the other 610 patients, calibration and discrimination (C-index, integrated 
discrimination improvement (IDI) index and net reclassification improvement (NRI) 
index) were assessed for all models.
Results
The recalibrated registry model showed adequate calibration and discrimination 
(C-index = 0.724). Adding easily available parameters resulted in a model with 10 
predictors, with similar calibration and improved discrimination (C-index = 0.784). 
The IDI and NRI indices confirmed this, especially for short term survival. Adding 
laboratory values resulted in an alternative model with similar discrimination (C-index 
= 0.788), and only the NRI index showed minor improvement. Adding GFR and Kt/V 
as candidate predictors did not result in a different model.
Conclusion
A simple model based on registry data was enhanced by adding easily available 
clinical parameters.
INTRODUCTION
In the Netherlands, approximately 2000 new patients with end stage renal disease 
(ESRD) start chronic renal replacement therapy (RRT) every year. In order to inform 
these patients at the start of their treatment on their survival chances it is desirable 
to take into account information on survival irrespective of the renal replacement 
therapy. This is challenging as transplantation prolongs life expectancy considerably, 
but whether and when a given patient will be transplanted is unclear. Pre-existing 
models or comparative studies could not be used for this purpose. They are focused 
on one part of the treatment process by looking at dialysis survival until transplanta-
tion[1], patient survival from the time of wait listing[2-5], or survival after transplan-
tation[6,7]. A risk prediction model for mortality in all incident RRT patients in which 
dialysis and transplant mortality are included, would be a helpful tool for clinicians to 
give a survival prognosis at the start of RRT. Furthermore such a model could be 
used for stratification for either the comparison of patient populations in different 
dialysis or transplant centers, or baseline risks in comparative studies[8], or for patient 
selection within studies[9] on dialysis, wait listing or transplantation. 
For a prediction model to be useful in clinical practice it should have good predictive 
performance and preferably be based on easily available information. Routinely 
collected registry data, such as demography and primary kidney disease, are conven-
ient candidates but their predictive value may be limited. Investing in collecting extra 
information may improve performance of the model. A British study showed that the 
predictive power of a model could be improved by adding clinical patient character-
istics, like co-morbidities and laboratory data[1]. Also some studies on renal or cardi-
ovascular diseases assessed the additive prognostic power of new markers[10-12]. 
However, collecting additional data is not always worth the effort. This is relevant for 
both study design and reflections on quality indicators.
Previously, we explored the possibility to predict ten year RRT patient survival using 
the Dutch renal replacement registry (Renine), which collects a limited number of 
variables from all Dutch patients with chronic RRT[13]. The resulting model was based 
on four predictors: age at the start of RRT, primary renal disease (PRD), therapy at 
90 days after starting RRT and patient sex. Although its discriminative power was 
fairly adequate with a C-index of 0.720, there is room for improvement. 
Therefore, we aimed to analyze whether the performance of a model for ten year 
survival of patients starting RRT based on easily available registry data could be 
improved by incrementally adding sets of medical history, clinical and laboratory 
variables as potential predictors, using data from a Dutch study cohort in which these 
variables were prospectively collected. 
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In addition to the four registry variables, 19 candidate predictors collected for NECOSAD 
were used for model development (table 1). These candidate predictors were selected 
based on literature and clinical experience, and clustered in three variable groups 
based on data availability. The 3 additional variables sets were added incrementally, 
starting with the ‘easy’ parameters, which can all be obtained within the timeframe 
of 30 minutes (or one consult). 
STATISTICAL ANALYSIS
Several methods for model updating and testing their predictive ability exist[10-12,16-
18]. Potential new predictors should always be considered in relation to established 
predictors, instead of evaluating them in isolation[16]. We chose not to force predictors 
from a previous step into the next model, but allowed for substitution if the additional 
variables proved to be better predictors. The additional candidate predictors were 
clustered in three variable sets based on availability for the nephrologists (table 1).
As there were missing values on the additional candidate variables (table 1), we 
applied multiple imputation[19,20] before developing and validating the new models. 
Non-normally distributed variables were transformed to variables with a more normal 
distribution either logarithmically (cholesterol, phosphate, calcium and Kt/V) or by 
taking the square root (GFR and Karnofsky score) before imputing. Although the 
Karnofsky score was registered as a categorical variable, it is of an ordinal nature and 
was therefore imputed continuously[21]. After imputation, the imputed values were 
retransformed into the original units. We ran 10 imputations, resulting in 10 different 
datasets. According to Rubin’s rules the average results of the 10 datasets were used 
for both model development and model validation[22].
The dataset was randomly divided in a group for model development (N=1225) and 
a group for model validation (N=610). The development and validation group were 
compared with ANOVA and Chi-square test.
For the development of the prediction models multivariate Cox regression analyses 
were performed. The proportionality assumption was tested by visual inspection of 
the log–log plots[23]. As a first step the ‘registry’ model, with age, PRD, therapy at 
90 days and sex, was re-estimated in the development group. After that, three addi-
tional variable sets were added to the registry variables incrementally. In the first 
model extension (further referred as the ‘easy’ model) a set of easily available medical 
history and clinical candidate predictors was added: history of smoking, angina pectoris, 
cerebrovascular accidents, diabetes mellitus, malignancies, gastro-intestinal disease, 
SUBJECTS AND METHODS 
For this study we used data from the Netherlands Cooperative Study on the Adequacy 
of Dialysis (NECOSAD). NECOSAD is a multicenter, prospective cohort study in which 
38 Dutch dialysis centers participated and which contains detailed clinical data. 
Informed consent was obtained from all patients before inclusion, and the medical 
ethics committees of all participating centres approved the NECOSAD study. In 
NECOSAD, incident adult dialysis patients were included at the start of dialysis, 
between 1997 and 2007 and the database includes 2051 patients. Data on comor-
bidity, age and smoking status were collected at the start of dialysis. The Charlson 
comorbidity score at the onset of dialysis was based on a score list of 15 different 
comorbid conditions, completed by the patients’ nephrologists. Body mass index 
(BMI), blood pressure, functional status (Karnofsky score) and laboratory values were 
collected at three months. The Karnofsky score is a clinician-assessed 10 level scale 
of functional status, with scores ranging from 10 (moribund) to 100 (normal function-
ality, without limitations). The glomerular filtration rate (GFR), at three months was 
used, which was calculated as the mean of 24-hour creatinine and urea clearance. 
The adequacy of dialysis treatment at three months was estimated using the dialysis 
Kt/Vurea per week, calculated as urea dialysis clearance corrected for distribution 
volume (V) according to Watson. The weekly value is used since both hemodialysis 
(HD) and peritoneal dialysis (PD) patients are included in the study. The other part of 
the total Kt/V is urine Kt/V which is on average 0.8 in incident NECOSAD patients[14]. 
Details about NECOSAD methods have been described earlier (e.g. Korevaar et al[15]).
As a point of departure, we considered the previously developed prediction model 
based on four variables from the Renine data[13] to which we refer as the ‘registry’ 
model. As we aimed to make a comparison to the ‘registry’ model, patients were 
excluded from the NECOSAD cohort if one of the four predictors were missing: 208 
patients were excluded because of a non-registered PRD and 6 patients were excluded 
because of a missing therapy at 90 days. Additionally 2 patients were excluded 
because of erroneous data. Our study sample thus included 1835 patients (table 1). 
Like the registry model, we chose 90 days as the baseline of the study to ensure 
enough time to switch from a temporary needed therapy to the intended treatment 
and to exclude patients who only have to undergo RRT for a short period of time. 
Therefore, all possible predictors were determined at or before baseline. The events 
from 90 days after starting RRT till death were analyzed; 60.1% of the patients had 
an event. Patients were censored if they were lost to follow-up or recovered (N=21),or 
at the end of the study (1/1/2010) (N=352)(mean follow-up duration 7.1 years (st.dev. 
2.4)), or at the maximum follow-up length of 10 years (N=360); transplantation was 
not censored. 
IMPROVED MORTALITY PREDICTION IN DIALYSIS PATIENTS USING SPECIFIC CLINICAL AND LABORATORY DATA3
40 41
3
myocardial infarction, peripheral vascular disease, and further BMI, Charlson comor-
bidity score, ethnicity and Karnofsky score (table 1). In the second model extension 
(further referred as ‘elaborate’ model), on top of the above mentioned variables we 
added blood pressure and some laboratory measurements: cholesterol, phosphate, 
calcium, and albumin (table 1). In the final model extension we added the most labo-
rious variables to the candidate predictor list: GFR and Kt/V. Backward selection, with 
a conservative p-value of 0.15 to limit the risk of overfitting, was used to determine 
the variables that best predicted patient survival. We used all variables that were 
significant in at least 7 (out of 10) imputed datasets.
The predictive performance of each model was assessed for 10, 5 and 3 year survival[13] 
by determining their calibration and discrimination in the validation group[24,25]. Calibration 
refers to the agreement between observed and predicted outcomes. This was measured 
by a) the calibration in the large, indicating the extent that predictions are systematically 
too low or high, b) a calibration plot for ten deciles according to the predicted survival 
plotted against their observed survival, (ideally a 45-degree line), and c) the calibration 
slope, which is the regression coefficient with the prognostic index as the only predictor 
(ideally equals to 1). The discrimination is the ability of a model to distinguish between 
subjects with and without the outcome. This was measured by the concordance or 
C-index. A C-index of 0.5 indicates no discriminative power, while a C-index of 1.0 
indicates perfect discriminative power. In recent literature other performance parameters 
have been suggested to compare models, as very large ‘independent’ associations of 
the new markers with the outcome are required to result in a meaningfully larger C-index 
when a model with standard risk factors already has reasonably good discrimination[18]. 
Two new ways of assessing performance improvement are net reclassification improve-
ment (NRI) and integrated discrimination improvement (IDI)[26]. As the NRI is less useful 
when no established risk cut-offs exist, we tested the continuous NRI[27]. This is the 
sum of the percentage of persons with the event with a higher risk score in model B 
compared to model A and the percentage of persons without the event with a lower 
risk score in model B compared to model A. The NRI has a value between -2 and 2.The 
IDI is the difference between a) the predicted survival in the group of patients with an 
event minus the predicted survival in the group with no event in the new model and b) 
the same subtraction calculated for the previous model[18].
To assess the robustness of our results additional sensitivity analyses have been 
performed: limiting the backward selection removal criterion to p=0.10 and relaxing 
this criterion to p=0.20 and a complete case analysis.
Correlations have been tested with Pearson correlation coefficient for continuous 
variables and Spearman’s rho for ordinal variables.
Analyses were performed using SPSS 21® and Microsoft Access®. 
RESULTS
The NECOSAD patient cohort is described in table 1. Compared to the complete 
Dutch ESRD patient cohort (N=13868), which was the basis for development of the 
previously published ‘registry’ model, there were no differences on age or sex. 
However, there were differences in therapy at baseline and PRD. As expected, as 
pre-emptive transplantation was not included, there were less transplanted patients 
at baseline in the NECOSAD cohort (0.4% instead of 3% in the ESRD cohort), in 
favor of PD, while the HD% was similar. In NECOSAD there were less patients with 
diabetes and renal vascular disease (37.4% versus 42%) and there were more patients 
with glomerulonephritis and cystic kidney disease (24.2% versus 21.5%). Additionally 
the NECOSAD patients were more often transplanted with a deceased donor kidney 
(data not shown). The development and validation group of the NECOSAD cohort 
were not different with regard to all predictors except from the percentage suffering 
from angina pectoris (table 1). 
Table 1: Baseline characteristics of the study population, candidate predictors 
presented per model
Development 
group 
N=1225
Validation 
group 
N=610
Total 
cohort 
N=1835
Missing 
data total 
cohort
Recalibrated ‘registry’ model
Age (mean, (stdev))
59.4  
(15.4)
60.4  
(14.4)
59.7  
(15.1)
0
Sex (% male) 60.2 63.3 61.3 0
Primary renal  
disease (%)
Diabetes 16.3 15.6 16.1 0
Renal vascular disease 20.0 23.3 21.1
Glomerulonephritis 14.0 12.8 13.6
Cystic kidney disease 10.5 10.8 10.6
Other diseases 20.1 21.3 20.5
Unknown 19.0 16.2 18.1
Therapy at  
baseline (%)
Hemodialysis 64.2 65.1 64.5 0
Peritoneal dialysis 35.8 34.9 35.5
Extra variables Model ‘Easy’a
Smoking (%)
Never smoked 33.4 30.5 32.5 15
Smoking in past, 
longer than 3 months 
before RRT start
39.2 42.1 40.2
Smoking in past, 
shorter than 3 months 
before RRT start
4.8 5.0 4.8
Smoking 22.6 22.4 22.5
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Development 
group 
N=1225
Validation 
group 
N=610
Total 
cohort 
N=1835
Missing 
data total 
cohort
Extra variables Model ‘Elaborate’b
Mean Arterial Pressure (MAP)** - mmHg  
(mean, (stdev))
102.6  
(11.9)
102.9 
(13.2)
102.7 
(12.3)
109
Cholesterol - mmol/l (mean, (stdev))
5.01  
(1.31)
5.06  
(1.34)
5.03 
(1.32)
220
Phosphate - mmol/l (mean, (stdev))
1.82  
(0.56)
1.81  
(0.52)
1.82 
(0.55)
103
Calcium - mmol/l (mean, (stdev))
2.36  
(0.25)
2.37  
(0.26)
2.36 
(0.26)
102
Albumin - g/l (mean, (stdev))
36.1  
(5.1)
36.2  
(5.4)
36.1  
(5.2)
143
Extra variables Model ‘Extended’b
GFR - ml/min (mean, (stdev))
4.08  
(3.10)
4.15  
(3.72)
4.10 
(3.31)
377
Kt/V dialysis per week -Watson (mean, (stdev))
2.32  
(0.95)
2.35  
(0.94)
2.33 
(0.94)
241
a Only BMI and Karnofsky score are measured at 3 months, all other variables are measured at the start of RRT
b All extra variables in the elaborate and extended model are measured at 3 months after the start of RRT
* Different in development and validation group (p<0.05)
** MAP is calculated as: diastolic blood pressure + 1/3 (systolic - diastolic blood pressure)
The results of the recalibrated ‘registry’ model were in line with the original results 
(table 2). Although the regression coefficients for therapy and sex had no p-value 
below 0.05, they were similar to those of the original published registry model. 
The ‘easy’ model included 10 predictors: age, PRD, history of smoking, angina pectoris, 
malignancies, myocardial infarction, peripheral vascular disease, and BMI, Charlson 
comorbidity score, and Karnofsky score (table 3). The ‘elaborate’ model included 14 
predictors: age, therapy at 90 days, PRD, history of smoking, angina pectoris, malig-
nancies, myocardial infarction, and peripheral vascular disease, and BMI, Charlson 
comorbidity score, Karnofsky score, cholesterol, phosphate, and albumin (table 3). 
In the final extension of the model GFR and Kt/V were excluded from the model by 
backward selection, making the ‘extensive’ model the same as the ‘elaborate’ model 
and thus redundant. For the ‘easy’ and ‘elaborate’ model variables, the proportionality 
assumption was not rejected, based on visual inspection of the log-log plots.
Development 
group 
N=1225
Validation 
group 
N=610
Total 
cohort 
N=1835
Missing 
data total 
cohort
BMI - kg/m2 (%)
<20 10.4 7.7 9.5 138
20-30 80.3 81.9 80.8
30-35 7.2 7.2 7.2
>35 2.1 3.2 2.5
Angina pectoris  
(pain in rest or light 
physical activity) (%)
3.0 1.3* 2.4 18
Cerebrovascular 
accidents (%)
 8.7 8.4 8.6 18
Diabetes mellitus (%)  22.5 22.9 22.6 19
Malignancies (%)
No malignancy 91.5 88.0 90.3 20
Malignancy in past 6.0 8.6 6.9
Malignancy 2.5 3.5 2.8
Stomach-intestine 
events (%)
 6.4 4.6 5.8 18
Myocardial infarction (%) 13.3 12.7 13.1 18
Peripheral vascular 
disease (%)
15.7 14.1 15.2 17
Charlson comorbidity 
score (%)
0-1 20.2 17.7 19.3 0
2 13.1 12.3 12.8
3 13.8 13.6 13.7
4 15.9 16.2 16.0
5 13.7 15.9 14.4
6 11.6 12.0 11.7
7 6.5 6.6 6.5
8-11 5.2 5.7 5.4
Ethnicity other than 
white (%)
 7.7 7.5 7.7 88
Karnofsky score (%)
Normal till some 
complaints/illnesses 
(Karnofsky scores 
100, 90, 80)
66.6 64.2 65.8 125
Capable to take care 
of oneself but not  
to do work/normal 
activity till the need  
of much help and 
frequent medical care 
(Karnofsky scores  
70, 60, 50)
31.2 32.7 31.7
Not capable to do 
much by him/herself, 
needs special help 
and care  
(Karnofsky scores 
 40, 30, 20, 10, 0)
2.2 3.0 2.5
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Table 2: Re-calibrated ‘registry’ model estimated in Necosad cohort compared 
to published ‘registry’ model
Published ‘registry’ model Recalibrated ‘registry’ model  
- Necosad
Patient characteristics
Regression 
coefficient*
Hazard 
ratio
p-value
Regression 
coefficient*
Hazard 
ratio
p-value
Age (per year) 0.054 1.055 <0.001 0.064 1.066 <0.001
Primary renal disease <0.001   <0.001
Glomerulonephritis Reference Reference   
Cystic kidney disease -0.280 0.756 0.001 0.026 1.026 0.892
Renal vascular disease 0.331 1.392 <0.001 0.807 2.242 <0.001
Diabetes 0.767 2.154 <0.001 0.970 2.637 <0.001
Other diseases 0.407 1.502 <0.001 0.541 1.717 0.001
Unknown 0.296 1.345 <0.001 0.484 1.622 0.002
Therapy at 90 days <0.001
Hemodialysis Reference Reference   
Peritoneal dialysis -0.131 0.877 <0.001 -0.103 0.902 0.268
Kidney transplantation -1.634 0.195 <0.001    
Male sex 0.067 1.070 0.035 0.069 1.072 0.375
Baseline hazards
1 year 0.003 0.001
3 year 0.010 0.004
5 year 0.017 0.007
7 year 0.024 0.009
10 year 0.033 0.013
* the prognostic index of a patient, which is used for the survival prediction estimates, can be calculated from 
the regression coefficients; the calculation is shown in the online supplementary appendix
The evaluation of the three different models (‘registry’, ‘easy’, and ‘elaborate’) on 
calibration in the large, calibration slopes and discrimination (C-index), IDI and NRI in 
the validation group are shown in figure 1 (a-e); the tables with all results are presented 
in the online supplementary appendix (see www.karger.com/doi/10.1159/000439181). 
In all models the calibration plots were close to the 45 degree line (data not shown).
Although the calibration in the large was almost the same in all models, the calibration 
slopes (ideally 1) and discrimination results of the ‘easy’ and ‘elaborate’ model showed 
some improvement compared to the ‘registry’ model, with the largest improvement 
for five and three year survival prediction. The discrimination was tested with the 
C-index. A C-index of 0.7 is considered reasonable and 0.8 is considered good. Using 
a C-index of 0.5 as zero, the difference in C-index between the recalibrated ‘registry’ 
model (0.724) and the ‘easy’ model (0.784) for the ten year survival was plus 27%. 
The ‘elaborate’ model did not show much improvement compared to the ‘easy’ model. 
The calibration was comparable and the discrimination measured by the C-index was 
only slightly higher (plus 1.4% for ten year survival). IDI and NRI are relatively new 
discrimination measures; although no absolute values indicating good performance 
are available yet, these measures can be used to compare model improvements 
within a study[18,26,27]. In figure 1d the difference between the predicted survival 
in the group of patients with an event and the predicted survival in the group of 
patients with no event is presented and the resulting IDI has been shown. The IDI 
indicates that the gain in predictive power is much higher for the ‘easy’ model compared 
to the ‘registry’ model (0.115, 0.1, and 0.082 for the 3, 5 and 10 year survival respec-
tively) than for the ‘elaborate’ model compared to the ‘easy’ model (0.005, 0.004 and 
0.007). In figure 1e the outcome of the continuous NRI on a scale of -2 to +2 is 
presented, with both subcomponents of the total NRI for the changes between the 
models. The NRI also illustrates that the step from ‘registry’ till ‘easy’ model showed 
most improvement (mean total NRI 0.751 versus 0.195 for the step from ‘easy’ till 
‘elaborate’ model); the improvement was slightly better in the shorter term predictions.
Next, some sensitivity analyses have been performed to check stability of the results. 
Limiting our backward selection inclusion criterion till p=0.10 led to the same predictor 
selection for the ‘easy’ model; only 1 of the 14 predictors (angina pectoris) was 
eliminated from the selection of the ‘elaborate’ model. Relaxing our criterion till 
p=0.20 led to the same predictor selection for both the ‘easy’ and ‘elaborate’ model. 
Complete case analysis resulted in somewhat smaller models, but predominantly 
the same final predictor lists. Finally, as GFR and Kt/V were unexpectedly excluded 
from the final prediction model, we performed an additional analysis to assess their 
relationship with other model predictors. GFR was a significant predictor both univar-
iately (HR=0.953, p=0.001) and in addition to the variables from the ‘registry’ model, 
but lost its independent predictive value in addition to the ‘easy’ model variables. 
GFR correlates with Karnofsky score (Pearson Correlation= 0.20; p<0.001) and BMI 
(Spearman Rho= 0.15; p<0.001). Kt/V was univariately related to survival (HR=1.304, 
p<0.001), but lost its independent predictive value in combination with the ‘registry’ 
variables.
Finally, to illustrate that the models presented in the paper (table 2 and 3) can be used 
to compute individual patient survival probabilities, we considered two patients. The 
first is a 59 year old male patient starting hemodialysis with renal vascular disease, 
BMI=25, smoking longer than 3 months before RRT, no history of angina pectoris, 
peripheral vascular accident, malignancy and myocardial infarction, Charlson comor-
bidity score 2, Karnofsky score 80, cholesterol level 5 mmol/l, phosphate 1.8 mmol/l 
and albumin 36 g/l. 
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Model ‘easy’ Model ‘elaborate’
Patient characteristics
Regression 
coefficient*
Hazard 
ratio
p-value
Regression 
coefficient*
Hazard 
ratio
p-value
Angina pectoris  
(pain in rest or light 
physical activity)
0.293 1.341 0.118 0.262 1.299 0.165
Malignancies
No malignancy Reference Reference
Malignancy in past 0.009 1.009 0.955 -0.001 0.999 0.997
Malignancy 0.490 1.632 0.045 0.523 1.686 0.034
Myocardial infarction 0.216 1.241 0.069 0.200 1.222 0.093
Pheripheral vascular 
disease
0.250 1.284 0.023 0.224 1.250 0.042
Charlson comorbidity score
0-1 Reference Reference
2 0.995 2.704 <0.001 0.934 2.545 0.001
3 1.349 3.853 <0.001 1.291 3.635 <0.001
4 1.678 5.354 <0.001 1.633 5.118 <0.001
5 1.784 5.955 <0.001 1.789 5.985 <0.001
6 2.030 7.615 <0.001 1.994 7.343 <0.001
7 2.020 7.537 <0.001 2.007 7.440 <0.001
8-11 2.104 8.198 <0.001 2.060 7.847 <0.001
Karnofsky score 
(continuous)
-0.024 0.977 <0.001 -0.023 0.977 <0.001
Cholesterol -0.060 0.942 0.076
Phosphate 0.189 1.208 0.008
Albumin -0.019 0.981 0.027
Baseline hazards
1 year 0.017 0.026
3 year 0.064 0.097
5 year 0.123 0.188
7 year 0.175 0.269
10 year 0.257 0.400
*The prognostic index of a patient, which is used for the survival prediction estimates, can be calculated from 
the regression coefficients; the calculation is shown in the online supplementary appendix
The ‘registry’ model predicts 49% and 26% chances for five and ten year survival 
respectively. According to the ‘easy’ model the patient’s survival chances are 48% and 
22%, so reclassification to a higher risk. Compared to the ‘easy’ model the ‘elaborate’ 
model predicts slightly higher survival chances (51% and 24% respectively), so here a 
reclassification to a lower risk. The same patient with glomerulonephritis as PRD has 
five and ten year survival predictions of 73% and 54% according to the ‘registry’ model. 
The ‘easy’ and ‘elaborate’ model both reclassify the patient to a lower risk and predict 
81%-83% five year and 65%-67% ten year survival chance. In the online supplemen-
tary appendix (see www.karger.com/doi/10.1159/000439181) the computational details 
of the first example are shown as well as the IDI and NRI calculations.
 
Table 3: Model ‘Easy’ and Model ‘Elaborate’
Model ‘easy’ Model ‘elaborate’
Patient characteristics
Regression 
coefficient*
Hazard 
ratio
p-value
Regression 
coefficient*
Hazard 
ratio
p-value
Age (per year) 0.029 1.029 <0.001 0.031 1.032 <0.001
Therapy at 90 days PD 
instead of HD
0.182 1.200 0.073
PRD
Glomerulonephritis Reference Reference
Cystic kidney disease 0.057 1.058 0.773 0.121 1.129 0.538
Renal vascular disease 0.445 1.560 0.005 0.485 1.624 0.002
Diabetes 0.302 1.353 0.104 0.321 1.379 0.086
Other diseases 0.366 1.441 0.027 0.384 1.468 0.021
Unknown 0.357 1.429 0.025 0.386 1.471 0.016
Smoking
Never smoked Reference Reference
Smoking in past,  
>3 months before 
starting RRT
0.013 1.013 0.891 0.029 1.029 0.757
Smoking in past,  
< 3 months before 
starting RRT
0.205 1.227 0.280 0.210 1.234 0.267
Smoking 0.310 1.363 0.005 0.325 1.384 0.003
BMI, kg/m2
<20 Reference Reference
20-30 -0.270 0.764 0.040 -0.311 0.733 0.019
30-35 -0.250 0.779 0.193 -0.289 0.749 0.134
>35 0.175 1.192 0.548 0.175 1.191 0.551
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Figure 1a: Calibration in the large
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Figure 1d: IDI= difference in predicted survival in patients with and without the event
0.8
0.9
1.0
1.1
3 year 5 year 10 year
ideal calibration slope
predicted ’registry’ model
predicted ’easy’ model
predicted ’elaborate’ model 
Figure 1b: Calibration slope
50 51
3
DISCUSSION
While the recalibrated registry prediction model performed well in the NECOSAD 
cohort, the ‘easy’ model including readily available medical history and clinical predic-
tors showed superior performance. Adding laboratory measurements did however 
lead to models with only slightly improved predictive power.
The new models showed improved discrimination, whereas the calibration showed 
similar performance in all presented prediction models. This indicates that for the 
purpose of comparing patient groups in different countries, or different periods of 
time, the ‘registry’ model is adequate and preferable because it only uses very 
common variables. For the purpose of informing patients, the reclassifications and 
improved discrimination indicate that the ‘easy’ or ‘elaborate’ model are better capable 
to estimate individual survival chances.
When comparing the ‘easy’ model with the ‘registry’ model the improvements that 
were found (calibration slopes, discrimination, IDI, and NRI) were most striking for 
the five and three year survival intervals. An explanation for this could be that where 
age is the most determining predictor for the long term survival, the effect of other 
indicators for patient condition is stronger in the shorter term survival predictions.
The ‘elaborate’ model includes three additional laboratory values, which are less easy 
to obtain than the variables from the ‘easy’ model. The resulting model with 14 instead 
of 10 variables, is only performing slightly better than the ‘easy’ model. The fact that 
the laboratory values in the model did not have more impact on the model perfor-
mance is probably due to the fact that the variation of the laboratory values in this 
dialysis population is small. The sensitivity analyses that we performed showed that 
GFR and Kt/V are not included as predictors in a last model, due to the correlation 
with other model variables. The relationship of GFR and Karnofsky score has also 
been found in other studies[28,29]. 
The improvement in discriminative power of our model from a C-index of 0.724 to 
0.788 for the ‘elaborate’ model is comparable with the improvement reported by 
Wagner et al[1]. They elaborated a model with basic patient characteristics (with a 
C-index of 0.69) with comorbid condition data and laboratory measurements (C-index: 
0.75). However, in this study most improvements were made in the last step where 
laboratory values were added, while in our study most improvements were seen in 
the second step (‘easy’ model), and the additional laboratory values only led to a 
marginal further improvement. Probably this is due to the fact that the variables in 
the ‘easy’ model were very diverse and also includes the functional status (Karnofsky 
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the extra effort that is needed to obtain the extra markers. The advantage of the 
‘easy’ model is that it uses easily obtainable predictors. For comparison of large 
populations the ‘registry’ model can suffice, but for smaller populations or individual 
patient information we would advise the use of the ‘easy’ model. As all prediction 
models are presented in this paper, physicians could choose either one of the predic-
tion models, based on preference, outcome and the availability of the necessary data. 
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score). The improvements of a model for the prediction of the progression of chronic 
kidney disease to kidney failure (C-index varying from 0.89 to 0.92)[10-12] and the 
prediction of cardiovascular events in rheumatoid arthritis patients (Framingham risk 
score C-index: 0.73, elaborated with separate additional biomarkers: C-index varying 
from 0.73 to 0.81)[11] were roughly comparable to our results.
Our study also has a number of limitations. 
First, the NECOSAD patients cannot be considered to be a random sample of patients 
with end stage renal disease who were starting RRT. There is a possible center effect, 
because not all dialysis facilities in the Netherlands cooperated in this study. Also 
patient selection bias might influence the results, as patients had a choice whether 
they wanted to be included in this study. Finally there are some differences in patient 
characteristics. These differences might explain the fact that in the NECOSAD-cohort 
therapy at 90 days did not remain significant in all models. We do expect that the 
therapy at 90 days is still of importance in the total Dutch patient cohort, as patients 
transplanted preemptively or in an early stage have better survival results. However, 
despite the differences in patient characteristics, the registry model had an adequate 
performance in the NECOSAD group. 
A second limitation of the study is the fact that the models are only internally validated 
in the validation group of the NECOSAD-cohort. External validation should also be 
performed in a different patient cohort, for instance from another country or another 
period of time. 
Finally, note that the prediction models presented in this study can only be used to 
inform patients about their prognosis from 90 days after their start of RRT, given their 
medical history and/or measurement data. The predictors are the input for the survival 
prediction and the models do not provide evidence that intervening on those predic-
tors prior to the start of RRT will change the predicted outcome, so the models cannot 
be used for treatment decisions. Prediction models only focus on the combination 
of variables that best predicts the outcome of interest without proving a causal rela-
tionship. Etiological studies of the effect of risk factors on outcome should be used 
for that goal. Further studies in this area would be desirable to be able to identify 
patients which would profit most from certain therapies, like kidney transplantation.
In conclusion, the recalibrated simple prediction model, based on only four predictors 
collected in the Dutch renal replacement registry, was able to give a reasonably 
accurate estimation of the ten year survival chances of patients starting RRT. Our 
study showed that it was possible to improve the model with the addition of some 
easily available medical history and clinical predictors. Additional improvement possi-
bilities, with elaboration of the model with a set of laboratory measurements, were 
limited. Whether the established model improvements are satisfactory, depends on 
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Abstract
Background
An easy to use prediction model for long term renal patient survival, based on only 
four predictors (age, primary renal disease, sex, and therapy at 90 days after the start 
of renal replacement therapy (RRT)), has been developed in the Netherlands. To assess 
the usability of this model for use in Europe, we externally validated the model in a 
wide spectrum of European countries. 
Methods
Data from the ERA-EDTA (European Renal Association - European Dialysis and Transplant 
Association) Registry were used. Nine countries that reported individual patient data 
to the registry on patients starting RRT in the period of 1995-2005 were included. 
Patients under 16 years of age and/or with missing predictor variable data were 
excluded. The external validation of the prediction model was evaluated for the 10-year 
(primary endpoint of interest) and 5- and 3-year survival predictions by assessing the 
calibration and discrimination outcomes.
Results
We used a dataset of 109,022 patients from 9 countries. The calibration in the large 
and calibration plots for 10 deciles of predicted survival probabilities showed differ-
ences of on average 2.2%, 4.1% and 4.1% in observed versus predicted 10-, 5-, and 
3-year survival, with some small variation on country-level. The C-index, indicating 
the discriminatory power of the model, was 0.71 in the complete ERA-EDTA Registry 
cohort and varied according to country level between 0.70 and 0.75.
Conclusions
A prediction model for long-term renal patient survival developed in a single country, 
based on only four easily available variables, has a comparably adequate performance 
in a wide range of other European countries.
INTRODUCTION
End stage renal disease (ESRD) is a major health problem with high mortality rates, 
affecting approximately 1000 patients per million population (pmp) in European coun-
tries[1]. The overall yearly unadjusted incidence of new ESRD patients starting renal 
replacement therapy (RRT) is over 100 patients pmp. 
For nephrologists it could be helpful to be able to predict long term survival chances for 
all patients starting with RRT to inform the patient of his/her survival chances. As it is 
unclear at therapy initiation whether a patient will stay on dialysis or subsequently receive 
a kidney transplant, it is desirable to use a model for overall survival prediction after the 
start of RRT, irrespective of whether patients will change treatment modality in a later 
stage or not. Most existing models are focused on dialysis survival until transplantation[2], 
survival on the kidney transplant waiting list[3,4] or patient survival after renal transplan-
tation[5,6], or are designed for a specific patient group[7], and therefore cannot be used 
for overall RRT survival prediction. To this end, in 2013 a straightforward model to predict 
renal patient survival from the start of a RRT was developed, based on a cohort of 
incident RRT patients from 1995-2005 in the Netherlands[8]. It predicts 10-year survival 
based on four commonly available predictors: age at the start of RRT, sex, primary renal 
disease (PRD) and mode of renal replacement therapy at 90 days (hemodialysis (HD), 
peritoneal dialysis (PD), or transplantation). Unlike the existing models, this model predicts 
overall survival from the start of RRT, irrespective of whether patients will change 
treatment modality in a later stage or not. For individual patient survival predictions it is 
preferable to take additional clinical parameters into account, as concluded in a later 
study[9]. However, we think the original straightforward registry model is very valuable 
for group comparisons and risk stratification in studies.
In order to understand whether this prediction model developed in a patient group from 
one country is also suitable for use in other countries, it is essential to explore its gener-
alizability in an external validation study[10]. The predictive performance of the model 
in the Netherlands appeared to be adequate, as demonstrated by internal validation 
outcomes (good calibration results as well as discrimination (C-index: 0.720))[8]. However, 
internal validation merely relates to the ‘reproducibility’ of results, while the usability of 
the prediction model in another country is a question of ‘transportability’ of the model[11]. 
As countries differ in dialysis and transplantation possibilities (e.g. access to (home) 
dialysis, and possibility for renal transplantation (with a living or deceased donor)) as 
well as in patient population characteristics, this could influence survival prediction. In 
this external validation study, we therefore assessed the performance of the model as 
a European renal patient survival prediction model, using data from the European Renal 
Association - European Dialysis and Transplant Association (ERA-EDTA) Registry.
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SUBJECTS AND METHODS
We used ERA-EDTA Registry data from nine European countries with national or 
regional registries providing individual level patient data on patients who started RRT 
between 1995 and 2005 and who still were on RRT on day 90. We included last 
available follow-up information in the ERA-EDTA Registry until 1/1/2014. We excluded 
the country where the model was developed (the Netherlands) or with less than 1000 
incident patients in our period of interest. The remaining countries that were included 
in the validation study are: Austria, Belgium (data from the Dutch-speaking and 
French-speaking Belgian Registry), Denmark, Spain (data from the regional registries 
of Andalusia, Aragon, Asturias, Basque country, Catalonia, Cantabria, Castile and 
León, Castile-La Mancha, Extremadura, Valencia), Finland, France, Greece, Norway, 
and Sweden. Most countries had 100% completeness in the whole study period, 
with the exception of Spain (coverage increasing from 53% in 1995 to 68% in 2005), 
and France (coverage increasing from 17% in 2002 to 55% in 2005). We included 
the patients that were at least 16 years old at the start of RRT. We excluded patients 
that temporarily stopped renal replacement therapy within 3 months after the start 
of RRT (N=69, 0.06%), including patient death and patients with missing values on 
one or more of the remaining prediction variables (63 patients with missing PRD, 
0.06%). The events from 90 days after the start of RRT till death or end of the study 
were analyzed (1/1/2014); the follow-up period was maximized at 10 years. This 
resulted in a dataset of 109,022 patients.
The original model[8] was developed to predict 10-year patient survival from 90 days 
after the start of RRT. It was based on age at the start of RRT, primary renal disease 
(PRD), sex, and therapy at 90 days. The formula for the survival probability at time t, 
S(t), is S(t)=exp(-H(t)). Here H(t) is the cumulative hazard that is calculated from the 
baseline hazard (H0) as H(t)=H0(t)*exp(prognostic index). The prognostic index can 
be calculated, using the values of the four predictors for a specific patient (see table 
1) together with their parameter estimates. The primary endpoint of interest was 
10-year survival; additionally we evaluated the performance of the model for 5- and 
3-year survival. 
Table 1: Validated RRT survival prediction model as published in BMC 
Nephrology[8]
Patient characteristics Parameter estimate*
Age (per year) 0.054
Primary renal disease
Glomerulonephritis Reference
Cystic kidney disease -0.280
Renal vascular disease 0.331
Diabetes 0.767
Other diseases 0.407
Unknown 0.296
Therapy at 90 days
Hemodialysis Reference
Peritoneal dialysis -0.131
Kidney transplantation -1.634
Male sex 0.067
Baseline hazards
1 year 0.003
3 year 0.010
5 year 0.017
7 year 0.024
10 year 0.033
* prognostic index of a patient: the sum of (the product of) parameter estimates
The survival probability at a certain time point, S(t) can be calculated from the prognostic index and the 
baseline hazard, using the following equation: S(t)=exp(-H0(t)*exp(prognostic index)). 
E.g. a male 55 year old patient with Diabetes, that started on HD has a prognostic index of  
((55 year *0.054=2.97)+0.767 (PRD diabetes) +0.067 (male))=3.804;
The 10-year survival prognosis is: exp(-0.033*(exp(3.804)))= 23%
We analyzed the performance of the model both in the total ERA-EDTA Registry 
cohort, as well as in the separate countries (anonymously). In order to be transparent 
and enhance the usability of the model, we followed the recently published TRIPOD 
checklist[12,13]. In table 1 we therefore provide the renal patient survival prediction 
model which was also published in BMC Nephrology 2013[8]. The performance of 
the prediction model was evaluated by assessing both calibration and discrimination. 
Calibration is the agreement between the probability of developing the outcome of 
interest within a certain time period (in our case 10-, 5- and 3-year survival) as esti-
mated by the model and the observed outcome frequencies[14]. Measures to repre-
sent calibration in our study are the calibration in the large, calibration plots and 
calibration slopes. ‘Calibration in the large’ is the observed versus predicted survival 
for the complete patient cohort. The calibration plot is a graphical method to express 
calibration, by plotting the observed outcome frequencies against the mean predicted 
outcome probabilities, within subgroups of participants that are ranked by increasing 
estimated survival probability[14]. Ideally the plots follow a 45 degree line, with an 
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intercept of 0 and a slope of 1[15]. This is also reflected in the calibration slope, which 
represents the outcome of a Cox regression analysis with the prognostic (risk) index 
as the only predictor[15] and is thus ideally equal to 1. Discrimination is the ability of 
a model to distinguish individuals who experience the outcome from those who 
remain event free[14]. The concordance index (C-index) is the most widely used 
measure to evaluate discrimination. For a Cox model it represents the chance that, 
given two individuals, the model assigns a higher risk score to the one that develops 
the event of interest in the shortest period of time. A C-index of 0.5 indicates no 
discriminative power and a C-index of 1 indicates perfect discriminative power[16]. 
RESULTS
The distribution of the prediction model variables (age at the start of RRT, sex, primary 
renal disease (PRD) and the therapy at 90 days) over the 9 European countries that 
are used in our external validation study are shown in table 2. Most variation between 
countries as well as between validation and development cohort is seen in the distri-
bution of PRD and therapy at 90 days. 
Table 2: Distribution of prediction variables in ERA-EDTA Registry validation 
cohort; countries (random order) and total external validation cohort, compared 
to the development cohort[8]
Country A B C D E F G H I J
To
ta
l 
va
lid
at
io
n
 
co
h
o
rt
D
ev
el
o
 p
-  
m
en
t 
co
h
o
rt
[8
]
Age group %
16-45 14.5 10.9 17.2 15.2 19.2 11.3 12.5 19.3 14.5 19.3 14.1 17.6
45-65 39 30.1 38 33.2 41.3 28 31.1 33.8 33.3 34.3 33.2 36.9
65-75 27.9 30.5 27.1 31.1 26.7 28 34.6 25 26.6 26.9 29.8 28.4
75+ 18.6 28.5 17.6 20.5 12.8 32.8 21.8 21.9 25.5 19.6 22.9 17.2
PRD %
Glomerulonephritis 14.4 11.9 12.3 14.6 14.5 14.1 15.1 21.5 16.2 13.7 14.5 12.5
Cystic kidney disease 4.5 5.4 6.5 7.3 9.3 7.1 5.1 8.9 6.3 7.2 6.4 8.8
Renal vascular disease 16.2 22.7 13.1 17.4 5.8 24.5 12.2 25.2 10.9 11.7 16.9 25.2
Diabetes 32.1 22.8 23.2 19.1 34.4 21.9 25.4 13.5 24.6 19.8 23.3 16.6
Other diseases 21.7 28.8 24.8 20.4 24.8 22.5 14.9 27 31.1 25.8 22.8 21.8
Unknown 11.1 8.4 20.1 21.1 11.2 10 27.2 3.9 10.9 21.8 16.1 14.9
Therapy at 90 days (%)
Hemodialysis 88.7 86.9 64.5 86.7 70.5 81.7 88 68.6 64.1 65.3 81.8 65.5
Peritoneal dialysis 9 11.6 31.6 11.9 28.3 15.7 11.4 17.9 31.8 31.8 15.9 31.7
Transplantation 2.3 1.5 3.9 1.5 1.2 2.6 0.6 13.5 4.1 3 2.4 2.8
Sex, % male 60.5 58.1 63.1 61.3 62.5 60.9 61.5 67 64.3 61.1 61.4 61.1
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Figure 1: calibration plots for 10-, 5- and 3-year survival per decile of 
predicted survival for the complete ERA-EDTA Registry cohort
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The calibration in the large for the prediction model in the ERA-EDTA Registry cohort 
show adequate results, with a difference of 2.2%, 4.1% and 4.1% in observed versus 
predicted 10-, 5- and 3-year overall RRT survival respectively. The calibration plots for 
10 deciles of predicted survival for 10-, 5- and 3-year survival are shown in Figure 1.
The calibration results of the prediction model at the country level show varying 
results; in 4 countries (countries 1-4) the observed and predicted survival probabilities 
are similar with an overall difference of < 1% (Figure 2), so the performance of the 
original model is good. In the other 5 countries the predicted survival probabilities 
are either slightly higher (country 7) or slightly lower (countries 5, 6, 8, and 9). The 
average absolute difference between observed and predicted survival over the coun-
tries is 3% (0-6%) for 10-year survival, and 4% (0-9%) for 5- and 3-year survival.
The calibration slope, with the prognostic index as the only predictor, is 1.012 for the 
complete ERA-EDTA Registry cohort. For the separate countries the slopes differ 
from 0.922 till 1.088, which is close to the ideal 1.
The discrimination for 10-year survival, expressed as the C-index, shows adequate 
performance of the model, with values between 0.70 and 0.75 (Figure 3) for the 10 
different countries and 0.71 for the complete ERA-EDTA Registry cohort.
VALIDATION OF AN EASY TO USE PREDICTION MODEL FOR RENAL PATIENT SURVIVAL4
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
1 2 3 4 5 6 7 8 9
10
 y
ea
r 
su
rv
iv
al
country
10 year observed and predicted survival probabilities per country
10Y pred
10Y obs
5Y obs
0.00
0.10
0.20
0.30
0.40
0.50
0.60
1 2 3 4 5 6 7 8 9
5 
ye
ar
 s
u
rv
iv
al
country
5 year observed and predicted survival probabilities per country
5Y pred
3Y pred
3Y obs
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
1 2 3 4 5 6 7 8 9
3 
ye
ar
 s
u
rv
iv
al
country
3 year predicted  and observed survival probabilities per country
Figure 2: calibration in the large for 10-, 5-, and 3-year survival per country, sorted by overall performance 
(high-low; ‘overall performance’ is the average performance over the 3 periods of time)
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Figure 3: discrimination (C-index) outcomes for 10-year survival per country (sorted like Figure 2)
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DISCUSSION 
With this study we examined the external validity of a previously published renal 
patient survival prediction model based on four commonly available variables. The 
model performance in 9 European countries reporting to the ERA-EDTA Registry is 
adequate, with an overall C-index of 0.71 and an average 10-year calibration difference 
of 2.2%. The model performance for the long term survival prediction is slightly better 
than the short term survival prediction, as could be expected as the model has been 
developed for 10-year survival. The fact that these external validation outcomes are 
similar to the internal validation results in the country where the model was developed 
indicates robustness of the model.
These external validation outcomes are remarkable, taking into account the many 
differences between European countries in ESRD patient characteristics and treat-
ment[1,17-21], as well as mortality rates on dialysis[22]. The performance of the 
model outside the Netherlands could be hampered, if the differences relate to 
better treatment prospects, for example: more (living donor) transplants, higher 
quality of donated kidneys or patients starting RRT at earlier stages of disease. On 
the other hand, if differences are a consequence of population differences that are 
either directly or indirectly covered by the model, this should not impact model 
performance. 
The model corrects for differences in patient age, sex, PRD and therapy at 90 days 
after the start of RRT, as these are part of the prediction model. Indirectly the model 
probably also partly corrects for differences in patient condition, as some of the 
model variables (like PRD, therapy and age) are related to patient condition (e.g. 
hypertension, BMI, cardiovascular disease). Next to clinical variation, there are other 
differences that might affect ESRD patient care and survival such as, human and 
environmental factors (dietary habits[23], smoking, physical activity[24], socioeco-
nomic status[25] and birth weight[26], healthcare policies[27] and genetic differ-
ences[28]) and access to the waiting list and renal transplantation. Stel et al.[29] 
conclude from a study in four European countries that variation in transplantation 
rates may be due to a combination of factors, including legislation, donor availability, 
transplantation system organization and infrastructure, wealth and investment in 
health care, as well as underlying public attitudes/awareness to donation and trans-
plantation. The fact that reimbursement strategies play a role has been confirmed 
by a study among 5 European countries, the United States and Canada[30]. Finally, 
Kramer et al. have shown that macroeconomic factors as well as the intrinsic 
mortality of the dialysis population are associated with differences in the mortality 
on dialysis between countries[22]. Nevertheless, despite the fact that there probably 
are factors that influence renal patient care and the mortality on RRT, which are not 
covered by the model, we have shown that the renal patient survival prediction 
model is applicable in a wide range of countries. The many differences of the 
ERA-EDTA Registry cohort compared to the Dutch model development cohort 
actually makes it a very suitable data set for external validation, which in itself is a 
major strength of this study. 
Our validation study shows a comparably sufficient but moderate discriminative 
power (C-index: 0.71) of the prediction model in other European countries as was 
also the case in the Dutch cohort[8]. This indicates that there is room for improvement. 
In 2013 we showed, based on data from the Netherlands Cooperative Study on 
Adequacy of Dialysis treatment (NECOSAD) how the original survival prediction model 
could be improved by adding more clinical data[9]. Especially the reclassifications at 
patient level implied that individual survival probability is influenced substantially by 
the clinical condition of the patient, so an extended model is preferably used for 
individual survival prediction. However, as many countries do not register the required 
additional data on a regular basis yet, it is not possible to externally validate an extended 
prediction model in a wide spectrum of European countries. This may be different in 
the future. Although the validated model is less suitable to be used to predict individual 
patient survival, the validated renal patient survival model can be used by European 
countries to predict survival chances for groups of patients, to compare risk groups 
in different studies, or for risk stratification/selection. For example, the model can be 
used to select patients with a predicted 10-year mortality risk over 60% to participate 
in a study, or the model can be used to demonstrate time trends in the incident patient 
populations in a country by differentiation on risk group (defined by specified ranges 
of mortality rates). As has been pointed out in the two manuscripts describing the 
previous models, it is important to note that the model is not recommended for basing 
clinical treatment decisions[8,9]. 
The strength of this study is the validation of the renal patient survival model in 9 
different European countries, with good or acceptable results in all of these countries. 
Since we observed some variation at country-level, this study also stresses the 
importance of external model validation in more than just one country. External 
validation limited to one single country could lead to over- or underestimated model 
performance, when the mortality rate in this population is different from the reference 
population[10,31]. Based on our aim to externally validate the original prediction 
model, we have evaluated this model without any adjustments. Our validation results 
show good discrimination, and only slightly inferior calibration outcomes in some 
countries. Therefore in our opinion, model adjustment was not necessary. However, 
when the presented prediction model is used in another population with differing 
mortality rates resulting in inadequate calibration results, it would be recommended 
VALIDATION OF AN EASY TO USE PREDICTION MODEL FOR RENAL PATIENT SURVIVAL4
68 69
4
to recalibrate the model by adjusting the baseline hazard, using actual population 
data, as described by Toll et al.[32]. In fact, a purpose of future research could be to 
update the European model to optimize performance, in which case external valida-
tion is needed again.
Despite the fact that the prediction model has shown to be valuable in this external 
validation cohort, there are still some study weaknesses to be noted. The most 
important limitation of the study is that the model has only been validated in other 
countries, but not in another period of time. In our study this was not possible, since 
a more recent cohort does not have 10 years of follow-up yet. However, knowing 
that RRT population and treatment possibilities as well as treatment quality and 
survival[21] change over time, regular evaluation, and possible recalibration (as 
suggested earlier for other populations), of the model is recommended. A second 
limitation of this study is that for some countries we validated our results on patients 
from only a limited number of years or from a limited number of regions. Although 
that might introduce differences at country level, we don’t think that this changes 
the conclusions of the validation study. In fact model performance might be slightly 
underestimated in these countries, and for the complete ERA-EDTA Registry cohort, 
as model performance is more likely to deteriorate in other periods of time, as pointed 
out in the previous limitation. Finally we should mention the fact that the model uses 
mainly very straightforward variables, except for the PRD. There might be difficulties 
to adequately (and uniformly) describe the patient’s disease. However, the PRDs with 
most (either negative or positive) impact on the survival chances (Diabetes and Cystic 
Kidney Disease) are relatively easy to detect.
In conclusion, our external validation study shows that a straightforward prediction 
model for long term patient survival on RRT developed in a single country, based on 
only four easily available variables, has a comparably adequate performance in a wide 
range of European countries participating in the ERA-EDTA Registry. 
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5 CAUSES FOR THE DECREASED USE OF PERITONEAL DIALYSIS AS A KIDNEY REPLACEMENT THERAPY IN THE NETHERLANDS
INTRODUCTION
In July of 1979, peritoneal dialysis (PD) was introduced in the Netherlands as an 
alternative to hemodialysis (HD)[1]. The percentage of renal replacement therapy 
involving PD subsequently rose to a peak level of 15% among the patient population 
with end-stage kidney disease (including those who had received a transplant). Starting 
in 2002, the prevalence of PD has decreased again to 8%.
Is this decrease in PD percentage due to the increase in HD capacity since the aboli-
tion of the planning system for dialysis centres in 2002, which made it possible to 
open new dialysis centres without a permit? This question cannot be answered, given 
that the cause and effect of the increase in HD capacity and the use of HD cannot 
be viewed separately. However, we can look at the impact of other potential causes.
In a nation-wide study, we specifically studied the ageing of the patient population 
with end-stage kidney failure (source: www.nefrovisie.nl) and the increase in the 
number of preemptive kidney transplants (i.e. kidney transplants without prior dialysis) 
due to the increasing number of living donors in the Netherlands. Given that the 
prevalence of therapies is determined by the inflow and outflow of patients being 
treated, we also studied the inflow (incidence) for all kidney replacement therapies 
(PD, HD and kidney transplantation) and the dialysis outflow.
PATIENTS AND METHODS
Patient selection
For the retrospective study of the incidence, we selected all initial renal replacement 
treatments (including kidney transplantation) that took place in the Netherlands 
between 1 January 1995 and 1 January 2010. The data was obtained from the Dutch 
Renal Replacement Registry (Renine). The incidence in the study period involved a 
total of 24,068 patients with end-stage kidney failure, a condition which was consid-
ered to be present if the patient had received more than four consecutive weeks of 
renal replacement therapy. Table 1 shows the group of new patients (incidence), 
divided into different cohorts. The prevalence of the renal replacement treatments 
was measured for each year, as at 1 January. 
Abstract
Objective
Study on the extent and causes of the declining use of Peritoneal Dialysis (PD) as 
kidney replacement therapy in patients with end stage renal disease in the Netherlands.
Design
Retrospective cohort study.
Method
The prevalence and incidence of the different kidney replacement therapies in the 
Netherlands from 1995 to 2010 were described. Also 5-year outflow of patients on 
PD or hemodialysis (HD) in the period 1995-2006 was analyzed with cumulative 
endpoint and Cox regression analysis. 
Results
The absolute number of patients starting with PD between 1995 and 2008 has been 
relatively stable with about 400 per year. There is a relative decline in the use of PD 
in the prevalent dialysis population from 15% to 8%. This relates to a relative increase 
in HD inflow (67% before 2001, 74% in 2009), and kidney transplantations before 
dialysis (3% before 2002, 9% in 2009), as well as a decreased HD-outflow. The 
increased inflow on HD is associated with a 67% growth of the incident patient group 
of 65 years or older, of which the major part (80-85%) undertakes HD. Within the 
younger patient group (0-65 year) there is an increase in the share of HD, next to the 
increasing number of preemptive transplantations. 
Conclusion
The decline in the prevalence of PD is partly explained by the relative increase of HD 
inflow, associated with an ageing patient population, the declining HD outflow, and 
the increase of kidney transplantations before dialysis. The increasing HD-prevalence 
is made possible by the grown hemodialysis capacity.
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Characteristic 1995-1998 1999-2002 2003-2006 2007-2009*
Kidney transplantation as initial treatment
(N = 136) (N = 180) (N = 348) (N = 459)
Sex (7) 56.6 53.3 58.0 60.6
Age in years
0-14 8.8 12.2 7.5 4.8
15-44 53.7 41.1 38.5 34.4
45-64 36.0 42.2 45.7 48.4
65-74 1.5 4.4 8.3 12.0
≥ 75 0 0 0 0.4
Primary renal disease
Diabetes 17.6 10.6 6.3 4.6
Renal vascular disease 4.4 5.6 6.3 7.0
Glomerulonephritis 14.0 15.6 12.9 11.8
Cystic kidney disease 11.0 12.8 10.1 12.4
Other diseases 36.8 36.7 35.1 42.0
Unknown 7.4 9.4 9.5 17.2
Not registered 8.8 9.4 19.8 5.0
*Cohort from 3 instead of 4 years
METHODS
The goal of the analyses was to explain changes in prevalence. We compared the 
absolute number and the relative percentage of PD compared to HD and transplan-
tation with respect to prevalence and incidence. With respect to prevalence, a 
comparison was also made regarding the ratio of PD to HD at large centres (> 100 
patients) and small centres (< 70 patients). We regarded the incidence as a measure 
for the popularity of the treatment. The incidence of all renal replacement therapies 
was analysed, as well as the outflow of patients (within five years) who had been 
started on PD or HD between 1995 and 2006.
This study’s aim was not to assess patient survival rates, and as such the results 
cannot be used as a basis for choosing between the types of therapies.
STATISTICAL ANALYSIS
The outflow of PD and HD (as the initial therapy provided) was analysed using the 
SPSS18 software program. With the help of a cumulative-incidence-competitive-risk 
method[2], the chances of different mutually exclusive study outcomes (death, trans-
plantation and switching to a different type of dialysis) within five years were analysed. 
The outcomes were censored for recovery, data lost to follow-up and the end date 
Table 1 Characteristics of 24,068 incident ESRD patients starting a RRT in the 
Netherlands between 1 January 1995 and 31 December 2009; all numbers are 
percentages
Characteristic 1995-1998 1999-2002 2003-2006 2007-2009*
Hemodialysis as initial treatment
(N = 3795) (N = 4122) (N = 5029) (N = 4194)
Sex (7) 58.9 59.7 61.6 61.9
Age in years
0-14 0.8 0.7 0.6 0.6
15-44 13.7 13.5 12.5 9.9
45-64 32.7 32.0 29.4 29.7
65-74 33.9 31.1 30.2 27.9
≥ 75 18.8 22.7 27.2 31.9
Primary renal disease
Diabetes 15.4 16.9 18.0 19.2
Renal vascular disease 23.9 25.9 29.0 28.9
Glomerulonephritis 10.1 8.7 9.0 7.5
Cystic kidney disease 7.2 7.1 5.8 5.2
Other diseases 23.7 22.0 21.3 20.4
Unknown 15.0 15.6 14.9 12.7
Not registered 4.7 3.8 2.1 6.2
Characteristic 1995-1998 1999-2002 2003-2006 2007-2009*
Peritoneal dialysis as initial treatment
(N = 1600) (N = 1737) (N = 1399) (N = 1069)
Sex (7) 61.3 60.4 61.4 63.1
Age in years
0-14 3.8 2.9 2.9 2.4
15-44 25.9 23.9 18.4 14.4
45-64 44.6 43.8 42.7 41.1
65-74 19.6 21.3 24.5 23.2
≥ 75 6.2 8.1 11.4 18.9
Primary renal disease
Diabetes 16.3 17.3 17.3 17.0
Renal vascular disease 17.4 19.5 25.2 29.1
Glomerulonephritis 19.0 15.7 14.9 13.2
Cystic kidney disease 9.9 10.0 11.8 8.9
Other diseases 22.8 20.9 16.8 14.8
Unknown 11.3 13.4 12.3 11.4
Not registered 3.3 3.3 1.7 5.6
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Despite the increase in absolute number of HD patients, the relative percentage of 
HD has remained relatively stable over the past 15 years, at approximately 35%. 
Meanwhile, the relative percentage of patients with a functioning donor kidney 
increased from 50% in 1995-2000 to 57% on 1 January 2010. Since 2001, the number 
of patients living with a functioning kidney transplant has been larger than the number 
of patients on dialysis.
Inflow (incidence)
Over the past 15 years, the number of new (incident) patients that started with PD 
fluctuated around 400 (see Figure 1b). Percentage-wise, there was a decrease from 
30% in PD as initial therapy in the 1995-2000 period to 17% in 2009. The inflow for 
HD and the number of preemptive transplantations increased in both absolute and 
relative terms. 
In the group of patients younger than 65, the absolute and relative PD inflow decreased 
(Figure 2). At the same time, this group exhibited an absolute and relative increase 
in the number of preemptive transplantations and the number of patients starting 
with HD (approximately 12% and 8%, respectively). In the 65+ age group, the number 
of new patients increased considerably, particularly among those 75 and older. The 
65+ group started with PD less frequently than the young patients. On average, 19% 
of the 65-74 year-olds and 12% of the 75+ age group started with PD. These percent-
ages did not change during the 1995-2009 period. 
of the study (1 April 2011). Outflow due to death, transplantation and switching to a 
different type of dialysis is shown in graphs for three successive cohorts. The hazard 
ratio per year for these outcomes was calculated by means of a Cox regression 
analysis, with ‘calendar year’ and ‘old versus young patients’ as variables. In this 
context, a hazard ratio > 1 signifies a greater relative risk of a certain event, while a 
hazard ratio < 1 signifies a lower relative risk. In the Cox regression analysis, the 
‘calendar year x age category’ interaction term was added to correct for the possible 
relation between calendar year and the ageing of the population over time.
RESULTS
Prevalence 
The total patient population (HD, PD and patients with a functioning donor kidney) 
increased in the 1995-2010 period by 97%, from 7,512 to 14,782 (Figure 1a). The 
increase in the absolute number of HD patients, from 2,744 to 5,231 (a 91% increase), 
was similar to this general increase. The number of patients living with a functioning 
donor kidney rose by approximately 130%, from 3,640 to 8,400. The absolute number 
of PD patients (n = 1,151) on 1 January 2010 was nearly identical to the number (n = 
1,128) on 1 January 1995. However, the relative percentage of PD in the total patient 
population fell from approximately 15% in 1995 to 8% on 1 January 2010 (see Figure 
1a). This decrease in prevalence occurred at both large and small dialysis centres. 
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
number HD 2744 2874 2979 3157 3205 3312 3349 3430 3572 3725 3956 4166 4455 4577 4870 5231
number TXP 3640 3872 4077 4313 4516 4713 5002 5224 5500 5796 6127 6476 6846 7310 7860 8400
number PD 1128 1142 1186 1226 1352 1446 1474 1561 1522 1480 1367 1343 1323 1264 1216 1151
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Figure 1a Prevalence (reference date: 1 January of each year) of hemodialysis (HD), kidney transplantation 
(TXP) and peritoneal dialysis (PD) in the total population of patients undergoing renal replacement therapy in 
the Netherlands in 1995-2010.
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
number HD 874 945 1024 952 992 961 1034 1135 1181 1268 1262 1318 1369 1406 1419
number TXP 35 44 26 31 42 33 53 52 61 74 95 118 128 159 172
number PD 392 377 393 438 436 433 467 401 372 338 324 365 358 393 318
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Figure 1b Incidence of hemodialysis (HD), kidney transplantation (TXP) and peritoneal dialysis (PD) in the total 
population of patients undergoing renal replacement therapy in the Netherlands in 1995-2010.
80 81
5
5 CAUSES FOR THE DECREASED USE OF PERITONEAL DIALYSIS AS A KIDNEY REPLACEMENT THERAPY IN THE NETHERLANDS
0
100
200
300
400
500
600
700
800
900
1000
number of new patients <65 year per therapy modality
HD
TXP
PD
Figure 2a Number of new patients (inflow) <65 years old undergoing hemodialysis (HD), kidney transplantation 
(TXP) and peritoneal dialysis (PD) in the Netherlands from 1995-2010
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Figure 2b Number of new patients (inflow) ≥ 65 years old undergoing hemodialysis (HD), kidney transplantation 
(TXP) and peritoneal dialysis (PD) in the Netherlands from 1995-2010 
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Figure 2d Distribution in percentage of the type of therapy (hemodialysis (HD), kidney transplantation (TXP) 
and peritoneal dialysis (PD)) - patient aged ≥ 65 years old
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Figure 2c Distribution in percentage of the type of therapy (hemodialysis (HD), kidney transplantation (TXP) and 
peritoneal dialysis (PD)) - patient aged < 65 years old
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to PD was 0.985 (95% Confidence Interval (CI): 0.979-0.992), 1.001 (95%-CI: 0.988-
1.013) and 0.967 (95%-CI: 0.953-0.980), respectively. Corrected for age, there was 
a significantly elevated hazard ratio for transplantation and a significantly reduced 
hazard ratio for death and therapy switching to PD per calendar year (Table 2). This 
effect of calendar year and age group was not a result of interaction between both 
variables (see Table 2).
 
Table 2 Hazard ratio for death, transplantation or therapy change to another 
dialysis therapy within 5 years, for patients that have started with hemodial-
ysis (HD) or peritoneal dialysis (PD), calculated with multivariate Cox regres-
sion analysis without and with interaction term, over the years 1995-2006*
Initial therapy and  
regression variables
Hazard ratio (95%-CI)
Death Transplantation Therapy change 
Cox regression without 
interaction term
HD
Calendar year 0.979 (0.973-0.986) 1.015 (1.002-1.028) 0.974 (0.960-0.987)
65+ 2.553 (2.414-2.699) 0.101 (0.087-0.116) 0.333 (0.299-0.370)
PD
Calendar year 0.958 (0.940-0.975) 1.007 (0.991-1.023) 0.993 (0.978-1.007)
65+ 3.722 (3.295-4.203) 0.194 (0.158-0.238) 1.349 (1.219-1.493)
Cox regression with 
interaction term
HD
Calendar year 0.972 (0.944-1.001) 0.982 (0.936-1.031) 0.986 (0.945-1.029)
65+ 2.492 (2.240-2.772) 0.083 (0.061-0.114) 0.352 (0.287-0.433)
65+ x Calendar year 1.004 (0.988-1.021) 1.030 (0.987-1.075) 0.990 (0.960-1.021)
PD
Calendar year 0.987 (0.959-1.015) 1.003 (0.986-1.019) 1.003 (0.985-1.021)
65+ 4.854 (3.869-6.091) 0.128 (0.079-0.209) 1.599 (1.310-1.952)
65+ x Calendar year 0.950 (0.915-0.986) 1.066 (0.999-1.138) 0.970 (0.941-1.001)
*Significant values in bold
The PD outflow for the same three time periods is shown in Figure 3b. Univariate 
Cox regression analysis determined that the hazard ratio per calendar year of death, 
transplantation and therapy switching to HD was 0.985 (95%-CI: 0.968-1.003), 0.987 
(95%-CI: 0.971-1.002) and 0.998 (95%-CI: 0.984-1.013), respectively. Corrected for 
age, there was a significantly reduced chance of death per calendar year (see Table 
2), but this effect of calendar year differed per age group and was stronger in the 
older age group, as can be concluded from the interaction term between both vari-
ables (see Table 2).
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Figure 3a Outflow of patients in the five years after starting with hemodialysis (HD) to the end point of death, 
kidney transplantation (TXP) or peritoneal dialysis: cumulative incidence analysis subdivided into three periods: 
1995-1998 (P1); 1999-2002 (P2); 2003-2006 (P3)
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Figure 3b Outflow of patients in the five years after starting with peritoneal dialysis (PD) to the end point of 
death, kidney transplantation (TXP) or hemodialysis: cumulative incidence analysis subdivided into three 
periods: 1995-1998 (P1); 1999-2002 (P2); 2003-2006 (P3)
Therapy switching/outflow 
The HD outflow for three time periods (1995-1998, 1999-2002 and 2003-2006) is 
shown in Figure 3a. Univariate Cox regression analysis determined that the relative 
risk (hazard ratio) per calendar year of death, transplantation and therapy switching 
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At the same time, however, there was also an increase of HD incidence in the younger 
patients. This was not to be expected based on survival analyses and patient satisfac-
tion with respect to PD. The possible role of the promotion of HD, as opposed to PD, 
that has been suggested by the media is speculative. In the last 25 years, there have 
been many publications which compare the survival rates for HD and PD[3-5,7,11,13-
18]. The results in the USA were more varied than those in Canada and Western Europe. 
Canadian and Western European studies mostly found a survival advantage of 2-4 
years for PD, particularly with respect to non-diabetic patients. This survival advantage 
is largely due to the better preservation of residual kidney function in PD therapy. 
In some patients, however, a switch to HD is ultimately necessary. This can have an 
impact on the duration of PD treatment, but that does not appear to be the case in 
the Netherlands, given that there has been no change in the PD outflow due to a 
switch to HD therapy over the years. PD also appears to prevail over HD in studies 
on quality of life[19], or at least produce similar results[20].The reduced outflow of 
HD due to a switch to PD therapy in recent years, however, is possibly related to the 
increased possibility of home hemodialysis and night-time dialysis. 
International comparison 
The decrease in use of PD in the Netherlands over the past decade is not unique. While 
the global relative percentage of PD varies greatly, many countries have experienced a 
decrease in the PD portion of incident patients. In the United States, for instance, the 
relative percentage of PD use between 2000-2004 decreased by over 50%[18]. There 
has also been a decrease in Canada, Australia and New Zealand. The trends show more 
variation in Europe. The possible causes for this decrease are both medical in nature 
(age, comorbidity, fear of poorer results, such as encapsulating peritoneal sclerosis)[21] 
and non-medical in nature[6,10,18]. Examples of non-medical reasons are the preferences 
of the patient and caregivers[22], information and time for the decision-making process, 
social support and late referral or an acute start of renal replacement therapy[10]. 
A Dutch study found that more than half of the patients have no contra-indications for 
either PD or HD[9].The possible contra-indications usually pertain to PD and are asso-
ciated with an older age, higher comorbidity and the social situation (living alone). 
The strong increase of HD incidence coincides with the abolition of the planning system 
for dialysis centres in 2002 and the increase in the number of dialysis centres and their 
branches (> 2005). It is clear that both developments are related to each other, but based 
on the available data it is not possible to distinguish between possible cause and effect. 
The new centres/branches have absorbed the large inflow of elderly patients, though it 
is striking that they still start with the same ratio of HD to PD as in the past. The question 
is also whether the increasing popularity of HD in younger patients is related to more 
(or, as it may be, fewer) options due to this increased capacity. For this, more insight into 
the selection process of the physician and patient in the pre-dialysis phase is desired.
DISCUSSION
Analysis of the identified reduction in the relative percentage of peritoneal 
dialysis 
The absolute number of ‘prevalent’ patients with peritoneal dialysis and the number 
of new (‘incident’) patients remained nearly identical in the study period, while the 
number of patients undergoing alternative types of therapies rose significantly. As a 
result, the relative percentage of PD to both HD and transplantation declined. This 
drop could not be attributed to a specific category of centres in terms of size. The 
growth of the HD inflow (incidence) was, among other things, related to an increase 
of the 65+ age group of patients who are relatively less likely to start with PD. There 
was also a slight shift of younger patients to HD. The increase in the preemptive 
kidney transplantations was accompanied by a decrease of the PD incidence and 
prevalence in younger patients. In addition to the primary inflow in PD, the secondary 
inflow (after an initial start with HD) also declined. 
The majority of patients in the 65+ age group used HD. This percentage hardly 
changed over the 15 year period. The strong growth of this group was accompanied 
by a reduction of the percentage of PD across the entire patient population. Others 
also described that patients aged 65 and older are on average less likely to start with 
PD than younger patients[3-6]. In principle, PD is an appropriate form of dialysis for 
elderly patients in light of the lower cardiovascular burden[7]. Explanations for a low 
incidence in elderly patients are a higher chance of contra-indications due to an 
increase of comorbidity at an older age[8,9], which makes home dialysis more diffi-
cult, the sometimes limited availability of social support[10], and a greater preference 
for HD compared to other age groups[9]. A lower rate of survival is also suggested 
in elderly patients who use PD[11], but this has not been found in all studies. 
The fact that this elderly patient group has increased so considerably cannot be 
explained by the ageing of the population. Figures from Renine and Central Bureau 
of Statistics (CBS) Netherlands show that since 1995 the number of new patients 
per million residents has hardly changed in all age groups up to 75, while it has doubled 
in the 75+ age group (www.nefrovisie.nl). Possible alternative explanations include 
a higher incidence of kidney diseases in elderly patients and change to the treatment 
criteria for elderly patients with ESRD.
In the younger patients (< 65 years old), the relative percentage of those who were 
treated with PD decreased by approximately 20%. The percentage of preemptive 
transplantations in this group increased by approximately 12%. PD patients are 
generally younger and have less comorbidity than HD patients[4,5]. They are thus 
generally in better condition, which is a requirement for kidney transplantation[12]. It 
is probable that PD has been substituted by transplantation to a certain extent in the 
group of young patients.
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CONCLUSION
The decrease in the relative percentage of peritoneal dialysis in the prevalent patient 
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kidney transplantations in the younger patients.
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Abstract
Survival of Expanded Criteria Donor (ECD) kidneys and their recipients has not been 
thoroughly evaluated in Europe. Therefore, we compared the outcome of ECD and 
non-ECD kidney transplantations in a Dutch cohort, stratifying by age and diabetes.
In all first Dutch kidney transplants in recipients ≥ 18 years between 1995 and 2005, 
both relative risks (hazard ratios, HR) and adjusted absolute risk differences (RD) for 
ECD kidney transplantation were analysed. 
In 3062 transplantations (recipient age 49.0 (12.8) years; 20% ECD), ECD kidney 
transplantation was associated with graft failure including death (HR 1.62 [1.44 – 1.82]). 
The adjusted HR was lower in recipients ≥ 60 years of age (1.32 [1.07 – 1.63]) than 
in recipients 40-59 years (1.71 [1.44 – 2.02] P = 0.12 for comparison with ≥ 60 years) 
and recipients 18-39 years (1.92 [1.42 – 2.62] P = 0.03 for comparison with ≥ 60 years). 
RDs showed a similar pattern. In diabetics, the risks for graft failure and death were 
higher than in the non-diabetics. 
ECD kidney grafts have a poorer prognosis than non-ECD grafts, especially in younger 
recipients (< 60 years), and diabetic recipients. Further studies and ethical discussions 
should reveal whether ECD kidneys should preferentially be allocated to specific 
subgroups, such as elderly and non-diabetic individuals.
INTRODUCTION
In patients with end-stage renal disease, kidney transplantation is the optimal renal 
replacement therapy (RRT) with regard to survival[1], quality of life[2], and costs[3]. As 
a consequence, the demand for donor kidneys exceeds the more or less constant supply 
of organs donated after death[4]. To reduce the number of patients waiting for a kidney 
transplant, many transplant centres over the world started to accept suboptimal organ 
donors, referred to as expanded criteria donors (ECD) or marginal donors[5]. Results of 
these ECD kidney transplantations differ across studies in different regions: some studies 
reveal no differences in outcome between ECD and non-ECD kidney transplants[6-10], 
whereas other studies, including a systematic review and a meta-analysis, tend to show 
higher rates of graft failure and mortality in ECD kidney transplantations, especially in 
recipients with diabetes or recipients younger than 40 years of age[11-13]. In the 
Eurotransplant (ET) kidney exchange program, facilitating cross-border organ exchange 
from both ECD and non-ECD donors in eight European countries including the Netherlands, 
graft and patient survival according to ECD status have not been investigated. 
Analysing outcome of ECD kidney transplantation in several regions is relevant as 
kidney transplant procedures across the world differ, among other things, in allocation 
strategies, cold ischemia times, human leucocyte antigen (HLA) matching, and (initial) 
immunosuppressive regimens. In addition, a recent meta-analysis shows differences 
in outcome of ECD kidney transplantation between Europe and North America[13]. 
If results of a certain region appear to be better, it possibly provides clues for improving 
ECD kidney transplantation in other areas. If, however, outcome of ET ECD kidneys 
is similar as in other areas, ET could consider to adapt its allocation policy and allocate 
ECD kidneys to recipients in whom the influence of ECD status on outcome is minimal. 
The last decades, other adaptations of the ET-allocation strategy have proven to be 
successful. First, the acceptable mismatch program, giving priority to highly immu-
nized kidney recipients over the standard allocation procedure based on ABO matching, 
optimal HLA matching, and short cold ischaemia times, has considerably reduced 
waiting times in these patients[14]. Second, more recently, the ET Senior Program 
(ESP; ‘Old for old’) was implemented and its results are successful as well[15,16].
Therefore, the aim of this study was to evaluate outcome of ECD kidney donations 
in the Netherlands, part of the ET region, in subgroups of patients. In the Netherlands, 
data on kidney transplantations have been prospectively and retrospectively registered 
in the Dutch Organ Transplant Registry (NOTR) database. Besides patient and donor 
characteristics at the moment of kidney transplantation, this registry contains yearly 
follow-up data. The question of this study is whether graft and patient survival after 
deceased ECD kidney donations in the Netherlands, between 1995 and 2005, in 
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adult recipients receiving their first kidney transplantation differ from deceased 
non-ECD kidney donations in general, and in specific subgroups of kidney recipients, 
stratified by age and diabetes. 
METHODS
This study was performed on NOTR data containing baseline and follow-up data on 
kidney transplants in the Netherlands. All Dutch kidney transplant centres have 
committed themselves to provide the required data to this registry. Additional data 
of kidney transplants and kidney recipients from the ET and the Renine (Dutch Renal 
Replacement Registry) registries are routinely incorporated in the NOTR registry. As 
ET allocates all kidney grafts of deceased donors in its region, all deceased donor 
kidney transplants are registered in the NOTR database; because of the link with 
Renine, information on renal replacement therapy (RRT) in the recipient before trans-
plantation and death on RRT after graft failure is available in the NOTR. 
In this study, all deceased donor kidney transplantations performed in recipients of 18 
years and older receiving their first kidney transplant between 1 January 1995 and 31 
December 2004 in the Netherlands were included. The inclusion period was chosen to 
affirm a long follow-up period (up to 2013, at least 8 years). Combined kidney and 
pancreas transplantations were excluded. Both baseline data and annual follow-up data 
till February 2013 were used for this study. Most variables used in the analyses were 
without additional calculations available in the NOTR database, such as dates for graft 
failure and death. The primary endpoints of this study were time to graft failure and time 
to death. For graft failure, first both failure of the graft (need of renal replacement therapy) 
and death were considered as graft failure, and second, failure of the graft alone (with 
censoring for death). Delayed graft function was not considered as graft failure. The 
determinant of our analyses was ECD (yes/no). Donor kidneys were retrospectively 
classified as ECD kidneys if donor characteristics met one of the following criteria: (i) 
donor age ≥ 60 years at the moment of donation; (ii) donor age 50 – 59 years at the 
moment of donation and two out of (a) history of hypertension, (b) donor creatinine 
value ≥ 132 µmol/l / 1.5 mg/dl (if more than one donor creatinine value was available, 
the lowest value was taken for this criterion), and (c) donor death caused by a cere-
bro-vascular accident (CVA)[5,17]. A donor history of hypertension was considered to 
be present if hypertension was mentioned in the donor’s medical record or in case of 
antihypertensive treatment before admission in the hospital. CVA was considered to be 
the cause of death if the European Dialysis and Transplant Association (EDTA) death 
cause in the NOTR database was recorded as ‘CVA: Cerebro Vascular Accident Not 
Otherwise Specified’, ‘CVA: Intra Cerebral Bleeding’ or ‘CVA: Cerebral Ischemia’. Diabetes 
in the recipients was defined as diabetic renal disease as primary kidney disease or 
presence of diabetes before transplantation registered in the database. Diabetes was 
classified as type 1 if the primary renal disease in the database was ‘Diabetes type 1’. 
If the primary renal disease was registered as ‘diabetes type 2’ or the dichotomous field 
‘Diabetes before transplantation’ was ‘Yes’, diabetes was classified as type 2. 
Statistical analyses
Descriptive statistics are presented as numbers, percentages and means (standard 
deviation; SD). Relative risks were analysed using Cox proportional hazards models and 
given as hazard ratios with 95% CI. In these models, ECD kidney was analysed as a 
dichotomous determinant of the two outcome variables. Initially, crude models with 
ECD kidney as determinant were constructed. Thereafter, we adjusted for baseline 
confounders in two steps. Model 1 was adjusted for characteristics of the recipient 
(recipient age, previous dialysis duration, panel reactive antibodies (PRA), recipient blood 
group, diabetes); model 2 for all characteristics of model 1 and characteristics of the 
transplant procedure and matching (cold ischemia time, HLA sharing, donor blood group, 
donation after cardiac death (DCD) versus donation after brain death (DBD), year of 
transplantation). In the Netherlands, the date of registration on the waiting list is the 
same as the date of initiation of dialysis. Therefore, the time on the waiting list was not 
added as a separate confounder. Recipient age, sharing HLA, cold ischemia time (hours), 
and dialysis duration (years) were entered as continuous variables; panel-reactive anti-
body (PRA) category (0-5%, 6-84%, >85% PRA activity), transplant year, DCD (yes/
no), gender (male/female), donor and recipient blood group and diabetes (yes/no) as 
categorical variables. As in these analyses few data were missing, complete case anal-
yses were executed. Adjusted absolute risk differences (RD) at three time points (1, 5 
and 10 years of follow-up) between the ECD kidney donation and the non-ECD kidney 
donation were calculated from the obtained Cox models using the corrected group 
prognosis method as described by Austin[18]. Pointwise confidence intervals of the 
obtained risk differences were computed via bootstrap resampling (2000 cycles).
Subgroup analyses were performed with respect to recipient age and diabetes. Age 
was defined as age at the moment of kidney transplantation and divided into three 
subgroups: 18-39, 40-59 and ≥ 60 years. Statistical testing of HRs among subgroups 
was performed by adding an interaction term between ECD kidney and age category 
or diabetes to the Cox models using the appropriate group as reference. Statistical 
testing of RDs among the groups was performed with independent t-tests using the 
standard errors obtained with bootstrap resampling. 
We considered comparing kidney pairs allocated to an old and a younger recipient. 
However, in the ET-region kidneys of the same donor are often allocated to recipients 
in different countries. 
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Therefore, these data are not available in the NOTR (Dutch) database. As a conse-
quence, paired kidney analysis was impossible.
Survival graphs were constructed as raw Kaplan Meier curves without adjustments. 
Sensitivity analyses
To assess robustness of our results, a number of sensitivity analyses were performed. 
First, transplant year was replaced by confounders that possibly were more etiolog-
ically associated with improvements over time. To this end, we used dichotomous 
indicators of administration of initial immunosuppressive drugs, such as antibodies 
(antithymocyte globulin, basiliximab etc.), calcineurin inhibitors (ciclosporin, tacrolimus). 
Other factors, such as indicators of surgical techniques, the use of certain kidney 
preservation fluids may have contributed to improvements of the results, but are not 
available in the database. Second, donor kidney side was added to the confounders 
in the analyses of graft failure as right kidneys may have worse outcome[19]. As a 
third sensitivity analysis, absolute risk differences were analysed in prevalent patients 
in 4 periods after transplantation: 0-3 months, 3-12 months, 1-5 years and 5-10 years, 
to study whether absolute risk differences between the groups were present during 
the entire follow-up period. In these analyses, only patients without an event in the 
preceding period were analysed. Fourth, as graft failure and death are competing 
risks, which might influence the analysis of death-censored graft failure, graft failure 
was analysed with a competing risk analysis[20] using graft failure a primary outcome 
and death as competing outcome. Fifth, we analysed the effect of ECD kidney in 
strata of previous dialysis duration (< 2 years, 2-4 years, and > 4 years). Sixth, in order 
to avoid selection bias in type 1 diabetic patients due to the policy to preferentially 
execute a combined kidney and pancreas transplantation in these patients, analyses 
in diabetic patients were performed after exclusion of type 1 diabetic patients. 
Seventh, to evaluate the robustness of the determinant, we constructed a categorical 
determinant indicating the four possible combinations of ECD and DBD/DCD. Cox 
regression analyses were repeated with this categorical determinant using the 
non-ECD-DBD category as reference.
Eight, possible confounders with a high proportion of missing values, such as BMI 
and smoking, were analysed in a complete case analysis and after multiple imputation 
using chained equations (MICE)[21,22]. In the latter, weight, length and smoking 
were predicted with recipient age, recipient gender, previous dialysis duration, kidney 
disease, PRA activity, year of transplantation, donor hypertension, donor death cause 
CVA, DCD or DBD donor type, the dichotomous outcome indicator and the result of 
the cumulative hazard function[23]. In the Cox proportional hazard models, body mass 
index (weight/length2) and smoking were added as confounders to model 2. 
All analyses were performed using Stata® 13 and 14 statistical software (Stata Inc, 
College Station, TX, USA).
RESULTS
From a total of 3901 kidney transplantations of deceased donors, we identified 
3062 first procedures in recipients ≥ 18 years performed between 1 January 1995 
and 31 December 2004 (Figure 1, Table 1). 
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Figure 1: Selection of patients and available cases in the analyses.
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Table 1: Recipient, donor, transplant procedure characteristics and events
All kidney 
transplants
ECD Non-ECD
Kidney recipients
N
Male
Female
3062
1814 (59%)
1248 (41%)
619 (20% of total)
387 (62.5%)
232 (37.5%)
2443 (80% of total)
1427 (58.4%)
1016 (41.6%)
Age (years)
18-39 years (N)
40-59 years (N)
≥ 60 years (N)
49.0 (12.8)
746
1598
718
53.1 (13.0)
642
1312
489
48.0 (12.5)
104
286
229
BMI (kg/m2)* 24.0 (5.5) 24.4 (5.5) 24.0 (5.5)
Smoking (%)*
Yes
No
Unknown
11.7
35.3
53.0
13.3
37.5
49.2
11.3
34.8
53.7
Dialysis duration (years) 3.29 (2.30) 3.14 (2.12) 3.32 (2.35)
Previous dialysis modality (%):
HD
PD
None
Unknown
55.0
39.3
3.6
2.1
58.3
36.8
2.1
2.8
54.2
40.0
3.9
1.9
Diabetes (N) 333 (10.9%) 50 (8.1%) 283 (11.6%)
Blood group
O
A
B
AB
1282 (42%)
1260 (41%)
382 (12%)
138 (5%)
250 (40%)
247 (40%)
90 (15%)
32 (5%)
1032 (42%)
1013 (42%)
292 (12%)
106 (4%)
PRA (N)
0-5 % 
6-84 %
>85 %
2684 (87.6%)
348 (11.4%)
30 (1.0%) 
566 (91.4%)
49 (7.9%)
4 (0.7%)
2118 (86.7%)
299 (12.2%)
26 (1.1%)
Kidney donors
N 
Male
Female
3062
1612 (53%)
1450 (47%)
619
303 (49%)
316 (51%)
2443
1309 (54%)
1134 (46%)
Age (years) 43.1 (16.1) 62.7 (5.6) 38.1 (13.9)
Kidney side (left / right) 1570 / 1492 306 / 313 1264 / 1179
Lowest donor creatinine (µmol/l) 77.7 (42.0) 82.8 (28.6) 76.5 (44.6)
Blood group
O
A
B
AB
Unknown
1388 (45%)
1268 (42%)
317 (10)
88 (3%)
1 (0.03%)
280 (45%)
246 (40%)
75 (12%)
17 (3%)
1 (0.16%)
1108 (45%)
1022 (42%)
242 (10%)
71 (3%)
0 (0%)
Donor death cause CVA 1385 (45.2%) 417 (67.4%) 968 (39.6%)
Donation: 
After brain death (DBD)
After cardiac death (DCD)
2360 (77.1%)
702 (22.9%)
489 (79.0%)
130 (21.0%)
1871 (76.6%)
572 (23.4%)
All kidney 
transplants
ECD Non-ECD
Transplant procedure / other
Sharing HLA
0 (%)
1 (%)
2 (%)
3 (%)
4 (%)
5 (%)
6 (%)
2.2
4.6
15.1
35.8
25.9
11.6
4.9
1.9
4.5
19.1
34.9
24.1
11.3
4.2
2.3
4.6
14.1
36.0
26.3
11.7
5.0
Cold ischemia time (h) 22.2 (7.5) 22.7 (7.4) 22.0 (7.5)
Endpoints
Follow-up time (years)
(min - max)
7.8 (4.6)
(0 - 18)
6.5 (4.5)
(0 - 17.4)
8.2 (4.6)
(0 - 18)
Transplant failure (including death) (N) 1607 (52.5%) 414 (66.9%) 1193 (48.8%)
Graft failure 818 (26.7%) 223 (36.0%) 595 (24.4%)
Death (N) 1183 (38.6%) 301 (48.6%) 882 (36.1)
N: number
BMI: body mass index
HLA: Human Leucocyte Antigen
PRA: panel reactive antibodies
ECD: Expanded Criteria Donor 
Data are given as mean (SD)
* about 31% missing data for BMI, 50% for smoking
Data were extracted from the NOTR-database in April 2013. Considering data quality: 
6% of the cases was considered to be lost to follow-up by the treating transplant 
centres and NOTR; 68% of the patients without an event had their last follow-up in 
2011 or later; 24% in 2008-2010. Table 1 shows the characteristics of the kidney 
donors, kidney recipients and the transplantation procedures. Among these, ECD 
criteria were met in 619 kidney transplants (20%). The number of kidney pairs, that 
is kidneys from the same donor, could not be derived from the database. Over time, 
the distribution of criteria classifying a kidney as ECD kidney did not change (data not 
shown).
In general, missing data at the moment of transplantation were below 5%. However, 
recipient smoking at the moment of transplantation was unknown in about 50% of 
the cases, recipient body mass index (BMI) in about 30%, and donor diuresis in about 
18%. Therefore, smoking and BMI were analysed as confounders in the sensitivity 
analyses only. 
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Table 2 shows the relative risks (hazard ratios) obtained with multivariable Cox models, 
adjusting for possible confounders. These analyses confirm the finding that ECD 
kidneys perform worse. These effects are most striking in diabetic patients and the 
young (18-39 years) and middle age category (40-59 years). The adjusted HR for graft 
failure including death in recipients ≥ 60 years differed statistically significantly from 
the HR in recipients of 18-39 years of age (P = 0.03). All HRs between diabetic and 
nondiabetic patients were statistically significant (P ≤ 0.02).
Table 3 shows the adjusted absolute risk differences (RD) between ECD and non-ECD 
kidneys at three time points using model 2 from Table 2. In general, in these analyses, 
the risk of graft failure in ECD kidney recipients is higher. The RDs of graft failure 
between ECD and non-ECD kidneys were lowest in the oldest age group, and statis-
tically different from the youngest and middle age groups with respect to graft failure 
including death (P=0.04 and P=0.002 respectively). RD trends for graft failure (death 
censored) and death were similar as those for graft failure including death among the 
age subgroups, but not statistically significant. Death-censored graft failure and death 
differ statistically significantly between the diabetic and nondiabetic groups (P=0.02 
and P=0.001 respectively). 
Table 4 shows the adjusted hazard ratios of combinations of ECD and DCD/DBD 
kidneys. Overall, the highest risks of graft failure and death are observed in the groups 
with both ECD and DCD kidneys. In the age subgroups, this risk appeared to be more 
dependent on graft failure than on death. The results obtained in the diabetic patients 
must be interpreted with caution, as the ECD-DCD group consists of only 12 diabetic 
kidney recipients.
Figures 2 and 3 show the crude Kaplan Meier survival curves of kidney transplants 
and patients according to ECD status in all patients and after stratification for age 
categories or the presence of diabetes as primary kidney disease, illustrating the 
above-mentioned absolute and relative risk differences.
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Figure 2: Crude Kaplan-Meier graft survival graphs given as proportion not reaching 
the endpoint graft failure or death according to ECD kidney donation. P-values indicate 
the difference between ECD and non-ECD recipients and are derived from model 2 
(Table 2).
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Figure 3: Crude Kaplan-Meier patient survival graphs given as proportion not reaching 
the endpoint death according to ECD kidney donation. P-values indicate the difference 
between ECD and non-ECD recipients and are derived from model 2 (Table 2).
Sensitivity analyses
In the analyses with the initial immunosuppression as confounder, the confounding 
effect of ‘transplant year’ was explained in part, but not fully, by immunosuppression. 
Adding kidney side in the second sensitivity analysis did not change the results of 
model 2 (data not shown). The third sensitivity analysis (data not shown) looking at 
absolute risk differences of graft failure and mortality within time periods after trans-
plantation (0-3 months, 3-12 months etc.) showed that absolute risks were higher in 
the first months after transplantation. In all time periods, absolute risks were higher 
in the ECD kidney recipient group. The fourth sensitivity analysis, using competing 
risk analysis for graft failure and death as competing risks, showed similar patterns 
in the subhazard ratio of ECD kidney for graft failure as the Cox models for death-cen-
sored graft failure (data not shown). The fifth sensitivity analysis did not show differ-
ences among strata of previous dialysis duration. The sixth sensitivity analysis excluding 
type 1 diabetic patients showed that absolute risk differences between ECD kidney 
and non-ECD kidney were similar as in the analysis with all diabetics; the relative risk 
was slightly lower, but did not change the conclusion that the risk of graft failure and 
death is higher in diabetic patients than in nondiabetics. The seventh sensitivity 
analysis is described above (description of Table 4). Finally, both in the complete cases 
analyses and the imputed data sets, recipient smoking and recipient BMI did not 
appear to be important confounders of the association between ECD kidney and 
outcomes and effect estimates did not change substantially (data not shown). 
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DISCUSSION
This study shows that deceased donor kidney transplantation fulfilling ECD criteria 
is associated with a higher risk of graft failure and (long-term) death of the recipient 
(even after transplant failure and a subsequent period of dialysis treatment) in the 
Netherlands. In particular, recipients with diabetes and recipients in the youngest and 
middle age groups have higher absolute and relative risks. 
In the whole cohort, transplantation with ECD kidney grafts results in higher relative 
and absolute risks of graft failure including recipient death. After adjusting for 
confounders, the relative risk for graft failure and death tended to be higher in the 
youngest and middle age groups when compared to the highest age group (model 
2, HR 1.92 and 1.71 versus 1.32, P=0.03 and P=0.12 respectively). Absolute risk 
differences showed a similar pattern. These results suggest that the adverse 
outcome of ECD kidneys is at least more pronounced in the youngest age group 
and possibly in the middle age group than in the oldest group. This is in line with 
previous studies on the donor and recipient age match[24]. The oldest group has 
the lowest risk associated with ECD kidney transplantation. These effects are even 
more striking in the recipients receiving an ECD – DCD kidney. Probably, the oldest 
group has the highest risk for death and ECD kidney transplantation does not add 
substantially to this risk. 
In the diabetic group, both relative and absolute risks were higher than in the nondi-
abetic group. The differences in HR and RD were generally statistically significant 
after correction for confounders in a multivariable model. It indicates that ECD 
kidneys perform worse in diabetic recipients. Nevertheless, the findings of this 
study on diabetics should be interpreted carefully, as in our analysis, only 50 diabetic 
patients received an ECD kidney, and the number of diabetic patients was too low 
to evaluate interaction between ECD kidney and DCD kidney interaction in this 
subgroup (12 recipients). In case our results are not a chance finding, this means 
that the diabetic environment aggravates adverse consequences of ECD kidney 
transplantation. The mechanisms by which ECD kidney transplantations give rise 
to worse outcomes cannot be derived from this study. We hypothesize that ECD 
kidneys will have worse kidney function, even after an uncomplicated transplanta-
tion procedure, and that this impaired kidney function determines outcomes of graft 
and patient survival. In the diabetic patients, it seems plausible that the diabetic 
environment impairs recovery of tubular and other renal cells from the ischaemia 
during the transplant procedure, thereby inducing a higher risk of rejection and 
impaired renal function, which, in turn, induces premature death.
The results of the present study are in line with the general conclusion of a system-
atic review[12], a recent report on organ quality and recipient age in the United 
States[25], and an analysis of ECD kidney transplantation in retransplanted patients[26]. 
However, in the systematic review, the results of the studies analysed were not 
pooled. Therefore, we cannot compare the sizes of the HRs and RDs of the present 
study with a pooled counterpart of previous studies. Based on our results, subgroups 
receiving an ECD kidney that have the lowest relative risk for graft failure and death 
in comparison with non-ECD kidney recipients, are patients ≥ 60 years and patients 
without diabetes. Pascual et al. suggested that certain patients with long expected 
waiting times could be preferential subgroups for receiving an ECD kidney[12]. The 
hypothesis of Pascual might be supported by a Dutch study on the 5-year results of 
DCD transplantation that showed that transplantation with DCD grafts appeared to 
be better than waiting for a DBD kidney while remaining on dialysis[27]. Therefore 
we think it is a good idea to select patient groups that would profit most from ECD 
transplantation with shortened waiting times, compared to the alternative, which is 
continuing dialysis and waiting for a higher quality kidney graft. 
It has been postulated that other classifications than the ECD/non-ECD classification 
might be more discriminative for organ and recipient prognosis. The present study 
suggests that a classification using four ECD and DCD/DBD combinations is already 
better than ECD alone (Table 4). In the USA, the Kidney Donor Risk Index (KDRI) was 
developed[28] and implemented in 2014 in the UNOS kidney allocation system. In 
its five categories, almost all ECD donors are within one KDRI category. This means 
that KDRI’s discriminative capacity may be better in non-ECD kidneys, but not in ECD 
ones[28]. In practice, KDRI does not predict results of kidney transplantation correctly 
in all subgroups[29]. In our additional analyses (data not shown), donor age appeared 
to be the most important factor associated with death and graft failure. Therefore, 
we agree that ECD kidney is probably not the optimal marker for poor donor quality. 
Further studies and refinements of classification systems, such as KDRI, are neces-
sary to optimize risk classification before using those systems more extensively in 
allocation strategies.
Within the ET region, median donor age and, thereby the number of ECD kidney 
grafts, is steadily increasing in the ET region from 43 years in 1995 to 53 years in 
2013[30]. Based on our results, it could be advocated to allocate ECD kidneys, and 
especially ECD-DCD kidneys, preferentially to recipients of ≥ 60 years and to avoid 
ECD kidneys in diabetic recipients. The Eurotransplant Senior Program for kidneys 
from donors of 65 years and older is already an example of matching the age of 
donor and recipient. This concept of age matching could be extended to younger 
donors. Avoiding ECD kidneys in diabetic recipients will induce a longer waiting time 
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for diabetic patients, which might be more harmful than receiving an ECD kidney 
transplant. Furthermore, this strategy will result in more ECD kidney allocations in 
the group of nondiabetics, which also raises ethical questions. Another interesting 
strategy raising ethical questions in a situation of organ scarcity, is allocating a pair 
of ECD kidneys in younger recipients. In middle aged and older recipients, results 
of this type of transplantation have proven to be successful[31-33].
From a patient perspective, it is desirable to receive the optimal renal replacement 
therapy in a certain situation. Possibly, refusing a kidney transplant of poor quality, 
continuing dialysis and waiting for another kidney transplant might be the optimal 
solution in some situations. However, in order to evaluate several scenarios at the 
moment of a kidney transplant offer, complex mathematical simulation models taking 
into account consequences of a poor kidney transplant, a longer episode on mainte-
nance dialysis and the chance of getting a better transplant offer must be available. 
At this moment, those models have not been constructed. Two prediction models, 
the Deceased Donor Score and The Kidney Donor Risk Index predict survival of kidney 
transplants using donor characteristics[28,34-36]. These models only predict patient 
and graft outcomes after transplantation but do not take into account recipient char-
acteristics, waiting time on dialysis nor chances of getting a better transplant offer. 
Therefore, future research should focus on prediction models combining donor, 
recipient and procedure characteristics. The associations found in our study suggest 
that recipient characteristics should be evaluated as potential predictors in future 
prediction models and mathematical simulation models. 
Limitations and strengths of this study
The present study has some limitations and strengths. The first limitation is that, 
although allocation of kidney transplants by ET is executed according to several 
objective rules, the acceptance of the donor kidney by nephrologists is subjective. 
The possibility that some nephrologists induce confounding by indication by refusing 
ECD kidneys if allocated to recipients in a good clinical condition must be considered. 
As a consequence, adding an estimate of the physical condition of the recipient as 
a confounder to our analyses could be a reasonable solution, but is impossible since 
the NOTR database does not contain those data. Other estimates of physical condi-
tion such as data on comorbid conditions have a lot of, potentially non-random, 
missing values in the NOTR registry and, therefore, will not, even after data multiple 
imputation, alleviate this problem. On the other hand, recipient age is expected to 
be a strong predictor of physical condition and this variable was taken into account. 
Second, the number of diabetic patients receiving an ECD kidney is low (50). 
Especially, results of subgroups in this category (e.g. ECD-DCD subgroup) must be 
interpreted cautiously. Third, because of many missing values, two potential 
confounders could not be used in the main analyses: smoking behaviour and body 
mass index of the recipient. However, in the complete case analyses and the anal-
yses with imputed data, these characteristics did not emerge as important 
confounders. Fourth, transplant year appeared to be an important confounder. It 
indicates that kidney transplantation in general has become more successful over 
time. However, in our analyses the effects of this confounder could not be fully 
replaced by other confounders, such as induction immunosuppressive therapy with 
monoclonal antibodies and other initial immunosuppressive therapy. Maybe, other 
characteristics not included in our analyses, such as the use of kidney preservation 
fluids, surgical techniques, (early) changes in the immunosuppressive regimen and 
their dose during follow-up, and effectiveness of anti-rejection therapies, are part 
of the effect of ‘transplant year’. The transplant period is also associated with 
changes in kidney allocation. Before 1996 there was only obligatory exchange of 
full-house HLA matches. After 11 March 1996, allocation of all recipients was 
regulated with computerized allocation lists (Eurotransplant Kidney Allocation System, 
ETKAS). In January 1999 the Eurotransplant Senior Program (ESP) was introduced. 
The ESP allocates kidney from postmortem donors of 65 years and older to recip-
ients of 65 years and older, without the use of a donor HLA typing. The ESP aims 
at a cold ischemic period that is as short as possible. In the Netherlands, kidneys 
from ESP donors are allocated to ESP recipients according to the national waiting 
list. Kidneys from an ESP donor that cannot be allocated nationally are allocated 
through the regular ETKAS after reporting of the HLA typing. In the Netherlands, 
ESP donor kidneys are only allocated to never-immunized recipients awaiting a first 
kidney transplant. Since 1 February 2001, kidneys from both DCD (donation after 
cardiac death) and DBD (donation after brain death) donors in the Netherlands have 
been indiscriminately allocated through the standard renal allocation system. Although 
replacement of transplant year by variables such as immunosuppressive regimens 
and allocation strategies would gain insight in the mechanism of improvements of 
outcome over the years, we do not expect this to affect the estimates of ECD 
donation. Fifth, the effect of kidneys pairs, that is kidneys from the same donor, 
could not be analysed in our database. Finally, only variables known at the moment 
of kidney allocation were analysed as confounding variables. As a consequence, 
factors influencing graft survival, such as the number and type of acute rejections, 
and the presence of post-transplant anti-HLA donor specific antibodies, even if they 
were present in the database, were not included in the analyses. Including these 
covariates may be an interesting question for further research.
However, this study also has several strengths. The first strength is that all recipients 
of a kidney graft of a deceased donor in the Netherlands within a defined period were 
included. The inclusion period (1995-2005) affirms a long follow-up period of 8-18 years. 
6 INCREASED RISK OF GRAFT FAILURE AND MORTALITY IN DUTCH RECIPIENTS RECEIVING AN EXPANDED CRITERIA DONOR KIDNEY TRANSPLANT
110 111
6
Second, the main variables in the NOTR database have few missing values. Third, 
exchange with the Renine registry provides information on long term death, mostly 
not available in transplant registries. And fourth, we analysed both relative risks and 
absolute risk differences. Both point into the same direction. 
In conclusion, ECD, and especially ECD-DCD kidney transplantation, is associated 
with a higher risk of graft failure and death. This effect is most striking in young and 
middle-aged recipients (< 60 years) and in patients with diabetes. In case of persisting 
scarcity of donor kidneys, further analyses should reveal whether preferential alloca-
tion of ECD kidneys to specific subgroups, such as older, nondiabetic patients, is a 
safe and ethically justified strategy. 
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SUMMARY AND DISCUSSION
Patients with end stage renal disease (ESRD) chronically need renal replacement 
therapy (RRT) to survive. As pointed out in the introduction (chapter 1) there are 
three renal replacement treatment options: kidney transplantation, hemodialysis, and 
peritoneal dialysis. Generally kidney transplantation is the preferred treatment with 
the best results, but unfortunately this is not feasible for all patients. However, at the 
start of RRT it is not clear yet which patients will eventually be waitlisted and trans-
planted. The first aim of this thesis is therefore to predict survival from the start of 
renal replacement therapy, irrespective of treatment choices, in order to support initial 
patient counseling. A general survival prediction is desirable for patients to understand 
the survival implications of ESRD, and to (re)set their survival expectations. It can 
further be used for shared patient-physician discussion of future treatment perspec-
tives. Furthermore, a survival prediction model could also be used to stratify patients 
according to survival risks in clinical trials, which is important to support further 
research in this ESRD patient group. The second aim of this thesis is to predict which 
patients might profit from a marginal kidney donor transplant in order to support the 
difficult decision making process in renal patient care whether or not to accept a 
marginal kidney donor offer for a specific patient.
For the treating physician it would be helpful to be able to predict long-term survival 
chances from the start of chronic replacement therapy in order to inform the patient 
about his/her prognosis. In chapter 2 we present a prediction model for long-term 
survival of patients starting a renal replacement therapy (RRT) in the Netherlands, 
using a limited set of easily available registry data from the Dutch Renal replacement 
Registry (RENINE). The model was developed, and internally validated, on a very 
large retrospective Dutch patient cohort starting RRT in the period 1995-2005. The 
complete cohort was randomly divided in a development group and a validation group 
of equal size. The model was developed for the Dutch patient population aged 16 
years or older, starting a chronic renal replacement therapy. With the developed 
prediction model, using patient age, sex, primary renal disease (PRD), and renal 
replacement therapy (RRT) at 90 days as variables to calculate mortality risk, it is 
possible to give an estimation of the 10-year survival (which was the primary interest), 
as well as 5- and 3-year survival chances for patients starting RRT in the Netherlands. 
Internal validation was performed by assessing the calibration and discrimination. 
The calibration showed acceptable outcomes. There were no major deviations between 
observed and predicted survival probabilities in the calibration plots for all 3 time 
intervals, and the 10-year calibration slope was 1.025. The discrimination of the model 
in the validation cohort, measured by the concordance (C-) index, was 0.720 for the 
10-year survival prediction, which is reasonable for a prognostic study with such a 
long time horizon. Two sensitivity analyses have been performed, to indicate how 
robust the presented model actually is. In a first sensitivity analysis the influence of 
the inclusion of the waiting list registration status was analyzed. The model improve-
ment using this variable was negligible. Although it is well understood that patients 
that are (or will be) registered on the waiting list have a better prognosis compared 
to patients that are never registered, the time point of this waiting list registration is 
very arbitrary and the situation at baseline is consequently not very differentiating. 
As a second sensitivity analysis the random division of the patient cohort in a devel-
opment and validation cohort was changed into a regional division. This did not result 
in any major differences of the original model or the performance estimates, showing 
robustness of the original model. The objective of this study was to develop a predic-
tion model that could be used by physicians to inform patients about their survival 
chances at the start of RRT. The conclusion was that the internal validation results 
show that the model is suitable for this objective. 
In chapter 3 the possibilities to enhance the earlier presented registry model by 
adding clinical information are presented. Data from the Netherlands Cooperative 
Study on the Adequacy of Dialysis (NECOSAD) were used for this purpose. NECOSAD 
is a prospective study, which contains detailed clinical data on a subset of the Dutch 
patients starting dialysis; all incident adult patients from 1997-2007 from the NECOSAD 
database were included. The disadvantage is that the NECOSAD domain is slightly 
different from the domain for which the original model was developed. Only incident 
dialysis patients were included and no preemptively transplanted patients, which is 
a growing group in present time as has been shown in chapter 1 and 5. Since the 
NECOSAD cohort is different from the complete Dutch cohort, model performance 
of the registry model in this specific cohort was evaluated first. Further, to have a 
fair comparison of the original model and the new models, the ‘registry model ’ was 
re-estimated and validated, which was the starting point for evaluation of the predic-
tive performance of the newly developed models. The results of the re-estimated 
registry model were in line with the original model performance in the Dutch patient 
population (C-index for 10-year survival: 0.724). From the large set of candidate 
predictors available in the NECOSAD group, 19 variables were selected based on 
literature and clinical experience, and subsequently clustered in three variable groups 
based on data availability. First we added a set of easily available medical history and 
clinical predictors to the original four registry variables, which resulted in a new model, 
the ‘easy model ’, with 10 predictors: age, PRD, history of smoking, angina pectoris, 
malignancies, myocardial infarction, peripheral vascular disease, and further BMI, 
Charlson co-morbidity score, and the Karnofsky (functional) score. The calibration 
and discrimination outcomes in the validation set showed some improvement in the 
calibration performance, especially for the 3- and 5-year survival, and a better discrim-
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ination (C-index: 0.784). Also some new measures to estimate the additional value 
of new predictors, the net reclassification improvement index (NRI) and integrated 
discrimination improvement index (IDI), indicate that the gain in predictive power was 
the highest for the shorter term survival intervals. In a second extension of the model 
blood pressure and some extra laboratory measurements were added, and this 
resulted in a new prediction model, the ‘elaborate model ’ with 14 variables. In addi-
tion to the previous model, therapy at 90 days, cholesterol, phosphate, and albumin 
were included. This model only showed very modest improvements compared to 
the previous model (C-index: 0.788, small NRI- and negligible IDI-improvement). In 
a final extension the glomerular filtration rate (GFR) and Kt/V were added, but this 
did not lead to another model. Sensitivity analyses (relaxing and strengthening the 
inclusion criteria for variable selection, as well as a complete case analysis, as opposed 
to the original analysis on imputed data) showed stability of the results. We concluded 
that the original registry model is useful for group comparisons, risk differentiation, 
and to select patients for a study population. For individual patient prediction, a model 
containing more clinical variables is preferential. The additional improvement possi-
bilities of laboratory values are limited. 
In prediction modeling next to model development, model validation is very impor-
tant[1-4]. Internal validation, which was performed originally (chapter 2), is essential 
to indicate stability of the results, but does not guarantee model performance outside 
the source population[1-3,5]. External validation is needed to indicate generalizability 
of the results[1-3,5,6].
In chapter 4 the usability of the original registry model (chapter 2) outside the country 
of development (the Netherlands) is analyzed by external validation in a cohort of nine 
European countries providing individual patient data to the ERA-EDTA Registry for 
the same time period as the original model development. This was a suitable external 
validation cohort, as there are many differences between European countries in ESRD 
patient characteristics and treatments, as well as in mortality rates on dialysis. Where 
these differences are undesirable in etiologic studies comparing different therapies, 
these differences are an advantage in model validation; adequate model performance 
in an entirely different population is prove of the generalizability of a model. What 
has been shown is a remarkable similarity in discrimination and calibration outcomes 
for the complete ERA-EDTA cohort. The performance outcomes for the complete 
ERA-EDTA cohort were a C-index of 0.71 and a calibration slope of 0.995. For the 
individual countries the performance was also very acceptable: the C-index varied 
between 0.70 and 0.75 and calibration slopes ranged from 0.922 till 1.088. These 
outcomes indicate robustness of the validated registry model. This result implies that 
the straightforward prediction model for long term patient survival in RRT, the registry 
model, is also usable for the comparison of risk groups in different studies, countries 
or periods of time, as well as for risk stratification or selection purposes, in a wide 
range of European countries. 
One of the predictors for the Registry model presented in chapter 2 is the therapy 
at 90 days, which actually is the intended treatment. Model performance could be 
hampered when RRT practice changes in time, leading to either different treatment 
choices for certain patients (and thus different outcomes), or different therapy 
outcomes due to therapy changes (e.g. medication improvements). In chapter 5 is 
shown that despite the fact that peritoneal dialysis (PD) is a good alternative for 
hemodialysis (HD), and sometimes even indicated as preferential, for most patient 
groups in the first period of RRT[7-14], the relative use of PD has declined in the 
Netherlands from 15% in 1995 to 8% in 2010. The reasons for the decline in the 
relative contribution of PD in the past decade in the Netherlands were studied, and 
we considered whether this could be related to the increasing HD capacity due to 
the abolition of the planning system for dialysis centres in 2002. This decrease was 
seen in both large and small centres and was related to a relative increase in the 
numbers undergoing HD and preemptive kidney transplantation (transplantation 
before dialysis), as well as to decrease in change of therapy from HD to PD. The 
increased number of patients starting on HD was associated with the growth of the 
incident patient group aged 65 years or older, most of whom (80-85%) underwent 
HD. Within the younger group (0-65 years) there were increasing numbers of patients 
on HD and preemptively transplanted patients. We concluded from our study that 
part of the explanation was the fact that in recent years the younger patients, other-
wise eligible for PD, have been transplanted preemptively, which is a positive devel-
opment. Another part of the explanation is that the dialysis population is ageing, 
resulting in a lower eligibility for PD. However, these developments do not explain 
all growth of HD. This could also be associated with the increased HD capacity, but 
is it not clear yet whether this is either a limitation of patient choice (if PD is not 
being considered as optional alternative) or an extension of freedom of choice (if the 
larger share of PD in the past was a consequence of limited choice due to a shortage 
in HD facilities). 
As stated in the introduction (chapter 1), due to the shortage of deceased kidney 
donor grafts, donor criteria have been stretched and marginal donor kidneys (e.g. 
extended criteria donor (ECD) kidneys[15]) have been accepted for transplantation 
by many transplant centres all over the world[16]. Although there are also studies 
that show no difference in outcome of ECD and standard criteria donor (SCD) trans-
plants, generally ECD kidney grafts are thought to have a poorer prognosis than SCD 
grafts, which is supported by a systematic review and meta-analysis, especially for 
patients with diabetes or younger than 40 years of age[16,17]. 
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In the Eurotransplant kidney exchange program, facilitating cross-border exchange 
from both ECD and non-ECD donors in eight European countries including the 
Netherlands, graft and patient survival according to ECD status had not yet been 
investigated. Since kidney transplant procedures differ across the world it is essential 
to analyze the outcomes in different regions. In chapter 6 the differences in survival 
of ECD and SCD kidney transplantations in recipients of 18 years of age or older in 
the period 1995-2005 in the Netherlands are presented. To that end the differences 
in deceased ECD kidney transplantation and SCD transplantation were analyzed in 
general, and stratified by recipient age and diabetes. The study was performed on 
data from the Dutch Organ Transplant Registry (NOTR). The primary endpoints were 
time until graft failure and time until death. Donor kidneys were retrospectively clas-
sified as ECD-kidneys based on the registered donor characteristics. The relative 
risks of ECD kidney transplantation were analyzed using Cox proportional hazards 
models both univariate (crude models) and multivariate (models adjusted for 
confounders) and adjusted absolute risk differences were calculated. Several sensi-
tivity analyses have been performed to show robustness of the results. The presented 
outcomes confirm the primary thought that in general ECD kidney grafts have a 
poorer prognosis than SCD grafts. The adjusted differences in graft failure and death 
(both absolute and relative) were higher for younger recipients and diabetic recipients, 
which is in line with findings from the literature. Overall, the highest risk of graft failure 
and death is observed in the group with extended Donation after Circulatory Death 
(DCD) kidneys, but further refinements of the donor quality classification might be 
more discriminative for organ and recipient prognosis and therefore more useful in 
allocation strategies. The study findings raise the question whether ECD kidneys 
should preferentially be allocated to specific subgroups, such as the elderly and 
non-diabetic patients, but the question is whether this is safe and ethically desirable. 
Having summarized all previous chapters from this thesis, in the following paragraphs 
we will discuss our main findings, categorized by the aims of this thesis, as well as 
the future research perspectives.
SURVIVAL PREDICTION MODELS FOR LONG-TERM ESRD PATIENT 
SURVIVAL FROM THE START OF RENAL REPLACEMENT THERAPY
Comparison of models 
Chapter 2 and 3 present the results of the development and validation of prediction 
models for long term RRT patient survival: a ‘registry model ’ based on only readily 
available predictors (chapter 2) and two alternative models which include clinical 
variables: the ‘easy model ‘and the ‘elaborate model ‘(chapter 3). These models are 
all aimed at providing individualized survival prediction for patients at the start of renal 
replacement therapy. For the Netherlands the average population-based 10-year 
survival is approximately 34%. With the use of our models a more individualized 
prognosis is possible; the 10 deciles of predicted survival according to our registry 
model (chapter 2) show a wide variation of survival prediction from 2% in the highest 
risk decile till 86% in the lowest risk decile. Sharing this information will fulfill the 
need of patients to be more accurately informed about life expectancy[18], irrespec-
tive of future therapy choices, and thus can facilitate initial patient counseling. For 
stratification, selection, and group comparison purposes the registry model with only 
4 predictors suffices for a wide range of European countries (chapter 4). For informa-
tion on individual survival probabilities the easy model, based on more clinical varia-
bles (chapter 3), is recommended. 
Already existing prediction models were focused on either dialysis, waiting list, or 
transplant survival. Table 1, comparing some of these models with regard to patient 
domain, baseline and outcome, shows why these models are not applicable to inform 
all patients starting RRT about their  survival prospects.
Table 1: comparison of some pre-existing prediction models with our ‘registry’ 
and ‘easy’ model
(Prediction) Model Domain Start Outcome
Wagner et al.: Predicting 
mortality in incident dialysis 
patients: an analysis of the  
UK renal registry[19]
Adult incident dialysis 
patients still at dialysis 
after 3 months  
(UK 2002-2004)
Dialysis 
initiation
3-year all cause 
mortality, censored 
for transplantation 
and recovery
van Walraven et al.:  
Predicting potential survival 
benefit of renal transplantation 
with CKD[20]
Adult ESRD patients 
eligible for 
transplantation  
(US 1995-2006)
Waiting list 
registration / 
pre-emptive 
transplantation
5-year all cause 
mortality
Jassal et al: Predicting mortality 
after kidney transplantation:  
a clinical tool[21]
Transplanted patients 
(Canada 1988-1998, RRT 
start after 1988)
Transplantation 1-, 3-, 5-year 
mortality
Kasiske et al.: A simple tool to 
predict outcomes after kidney 
transplant[22]
Adult patients 
undergoing deceased 
kidney transplants  
(US 2000-2006)
Transplantation 
(and 7 days and 
1-year post-
transplant)
5-year graft loss 
(including death 
with functioning 
graft)
‘registry’ prediction model as 
presented in this thesis
Incident RRT patients  
>16 years still at RRT 
after 3 months 
(Netherlands, 1995-2005)
RRT initiation 10- (and 5- and 3-) 
year mortality
‘easy’ prediction model as 
presented in this thesis
Incident dialysis patients 
> 16 years, still at RRT 
after 3 months 
(Netherlands 1997-2007)
Dialysis 
initiation
10- (and 5- and 3-) 
year mortality
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Wagner et al.[19] predict 3-year mortality in incident dialysis patients in the UK, which 
actually reflects dialysis survival only, since transplant survival is not taken into account. 
The dialysis survival is a combination of patient survival for the incident dialysis patients 
that didn’t undergo transplantation, combined with (100%) dialysis survival until 
transplantation for the patients that eventually were transplanted; dialysis survival is 
probably underestimated due to the fact that the ‘best’ patients are being transplanted 
and their survival is only included until transplantation. Since we are interested in the 
complete patient survival irrespective of treatment, the model is not suitable for our 
aim.
In van Walraven’s prediction model[20] 5-year ESRD patient survival is limited to 
patients eligible for renal transplantation. The motivation to limit the prediction of 
(integrated) RRT-survival to the waitlisted patients only (an alternative for using 
propensity scores[23]), is to enable a fair comparison between dialysis and transplant 
survival by excluding patients that are not transplantable at all. This has also been 
advocated in other papers in which dialysis and transplant treatments are 
compared[24,25]. Although this is a sensible restriction for the comparison of dialysis 
and transplant survival, this makes the model non-applicable to our patient domain. 
Our domain consists of the complete group of ESRD patients starting RRT, which 
includes a large group of patients with a non-transplantable status (older and/or frail 
patients). Another disadvantage for our purpose is that the starting point for the 
survival prediction in van Walraven’s model is not the start of RRT but the time of 
registration at the waiting list. This is a different point of time for every patient in the 
Netherlands where the time on dialysis is used for kidney allocation instead of regis-
tration time. Due to these reasons the model from van Walraven is not applicable in 
the initial counseling of the complete group of RRT patients. 
There are many papers focused on predicting patient (or graft) survival after trans-
plantation. One example is the paper by Jassal et al.[21] which presents a visualization 
of 1-, 3-, and 5-year patient survival probabilities in the form of a table, differentiated 
by PRD, Charlson comorbidity score and age group. This model cannot be used in 
initial patient counseling since at the time of start with RRT it is not known yet which 
patients will eventually be transplanted, except for the preemptively transplanted 
patients. 
The model of Kasiske et al.[22] predicts 5-year graft survival and is the basis for the 
development of a practical calculator for the risk prediction of graft loss, death censored 
graft failure and mortality after deceased donor kidney transplantation. Predictions 
are made from transplantation and at 1 week and 1-year post-transplantation. Therefore 
this model is primarily helpful for pre- and post-transplant decision making and not 
to inform patients about their survival probabilities at the start of RRT. 
Added value of survival prediction models presented in this thesis 
To our knowledge our prediction models are the first models aimed at predicting long 
term survival chances for the complete group of RRT patients during the initial phase 
of their therapy, taking into account survival after dialysis combined with survival after 
a possible transplantation. The models presented in this thesis therefore fill a gap 
and, unlike the other mentioned models, these are especially useful in the initial 
counseling of ESRD patients to give a more individualized prediction of long term 
survival chances. External validation outcomes have also indicated that the use of 
the registry model is not restricted to the Netherlands, but has comparable perfor-
mance in a wide range of other European countries.
The performance of the presented models was evaluated by calibration and discrim-
ination measures[1,3-5,26]. Calibration indicates the reliability of the model and 
measures the agreement between observed and predicted outcome, and was 
assessed by the calibration in the large (observed versus predicted survival percent-
ages), calibration plots for 10 deciles of predicted survival versus observed survival 
(ideally a 45-degree line), and the calibration slope which is the regression coeffi-
cient with the prognostic (risk) index as the only predictor (ideally equal to 1). 
Discrimination was assessed by a concordance (or C-) index, Harrell’s C-statistic, 
which can be calculated for Cox regression models and reflects the probability that 
for a random pair of patients, the one who has the outcome event first has the 
highest predicted probability of the outcome[27,28]. A value of 0.5 indicates no 
discrimination and a value of 1.0 indicates perfect discrimination. Independent 
criteria for the evaluation of adequate (reasonable or good) discrimination are lacking, 
although there is some consensus that 0.7 is reasonable and 0.8 is good. In line 
with this, we interpret a C-index of 0.68-0.75 as fair, but modest, discriminatory 
power. It seems rather low compared to the high C-indices obtained in many 
diagnostic studies. However because there is not a very close temporal relationship 
between predictors and outcome in our prognostic setting, one would not expect 
very high C-indices[28]. 
For all models we concluded that performance was sufficient, but limited. Therefore, 
it could be argued that these models might not perform much better than ‘physician’s 
gut feeling’. A paper showing the effective use of the ‘surprise question’ (‘Would I 
be surprised if this patient died in the next year’)[29] in dialysis patients[30,31], 
confirms the importance of physician judgement. The additional value of our models 
is to aid especially the young and inexperienced physicians with objective survival 
predictions, but even for experienced physicians an objective survival probability 
estimate might be useful. Generally prediction models can be used for both patient 
counseling and research purposes[5,26,28,32]. Using these models would provide 
uniform risk predictions, which can be useful for an objective comparison of risk 
assessments between studies or countries.
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Potential to use the registry prediction model for group comparison, selection 
and stratification purposes in trials
For group comparisons, restriction and stratification we would recommend the use 
of the registry model. Patient risk categorization according to this easy to use registry 
model with only 4 variables is adequate, as has been indicated with the sufficient 
calibration and discrimination outcomes (chapter 2). Furthermore this model has the 
advantage of proven applicability (by external validation) for a wide range of European 
countries (chapter 4). When the model is used on group level consequences of 
potential misclassification are limited. 
Potential to use the easy prediction model for initial patient counseling
At the individual level the use of the easy model (including clinical variables) is 
recommended, despite the fact that preemptively transplanted patients were not 
included in model development. We based this conclusion on slightly improved 
outcomes on calibration and discrimination as compared to the registry model, 
combined with the two relatively new measures to compare model performance: 
the Net Reclassification Improvement Index (NRI) and the Integrated Discrimination 
Improvement Index (IDI)[5,26,33-36]. In chapter 3 we have shown that, compared 
to the registry model, the easy and elaborate model both correctly reclassify many 
patients to a higher or lower risk group, which indicates a better survival prediction 
on individual level. The elaborate model requires more information but is performing 
only slightly better than the easy model. Therefore we recommend the use of the 
easy model for this aim.
Potential to use the easy prediction model for the decision to start or refrain 
from RRT
As has been explained in the introductory section, a recent trend in renal patient 
care and shared patient-physician decision making is careful consideration of conserv-
ative treatment for the frail elderly ESRD patient as an alternative for RRT[18,30,37-
39]. A Canadian study on end-of life care preferences and needs has shown that 
more than 90% of the adult stage 4 and 5 CKD patients presenting at a (pre-)dialysis 
or transplant facility considered it important to be informed on prognosis and 61% 
of the dialysis patients regretted their decision to start dialysis[18]. Unfortunately 
dialysis does not always seem to prolong life[40], and only 13% of the elderly 
patients maintains functional ability after one year of dialysis[41]. Although our 
prediction models on RRT survival are primarily aimed at predicting long term 
survival, these models might still be helpful to select patient groups that, according 
to current care practices, only have a very limited RRT survival prognosis. For these 
patients conservative treatment might prove an attractive alternative[30,39], due 
to the fact that hospitalization is avoided and provided that a certain quality of life 
could be maintained. A timely decision is desired; a review of studies on conserv-
ative management of ESRD without dialysis pointed out that unlike withdrawal of 
dialysis in which imminent death is expected, patients who decline dialysis initiation 
can live for months to years with appropriate supportive care[42]. Insight in survival 
probabilities might facilitate the discussion on this with patients and their families/
caretakers. Therefore the prediction model should be used in the pre-dialysis facility 
(only for the intended domain of patients eligible for RRT), since timing is very 
important and the creation of vascular access should be done after treatment options 
are carefully considered[43]. In this stage it is not possible to use the elaborate 
model, which is based on laboratory values at three months after the start of RRT, 
which might be different in pre-dialysis care. The easy model, however, uses mainly 
variables at the start of RRT, except for BMI and Karnofsky score, and therefore 
this model is recommended for the aim of patient counseling in the pre-dialysis 
phase.
Our registry model is not suitable to be used for choosing a specific RRT 
modality
Our registry model should not be interpreted as proof for better outcomes of early 
transplantation instead of dialysis, or PD instead of HD. Our study just shows the 
possibility to include the therapy at 90 days (the intended treatment) as a predictor 
for long- term survival. Therapy at 90 days (instead of the start) was chosen as the 
baseline to ensure enough time to switch from a temporary needed therapy to the 
intended treatment, and to exclude acute patients who only have to undergo RRT 
for a short period of time. Predictors are variables that show a correlation with the 
outcome. Prediction models however are not etiologic (like intervention studies), 
but descriptive[44]. They do not prove causality, but they give a prognosis based 
on a set of patient and/or treatment characteristics. Patients were not randomly 
assigned to the treatment modalities, but were given a certain treatment based on 
their clinical condition. Waitlisted patients are often considered to be in a better 
condition and their survival on dialysis would presumably also be better than the 
survival of patients that have to stay on dialysis because they are not in a trans-
plantable condition[24,25]. This is even more so the case for transplanted patients, 
which group is probably even in a better medical condition, with less co-morbidities, 
than the complete group of waitlisted patients[45]. Although physicians might be 
tempted to use the registry model to ground a treatment decision at start of RRT, 
the treatment modalities in the model are only a proxy for medical condition. The 
same holds for subsequent treatment choices. The registry model provides long 
term survival probabilities from the start of RRT irrespective of the treatment contin-
uation, and assumes that future treatment choices are related to patient character-
istics that are included in the model. When individual choices differ from the usual 
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practice (on which the model is based) this could influence patient outcome (either 
positively or negatively compared to the predicted survival). So, although our models 
are useful to get insight in expected survival probabilities, which might support the 
discussion of treatment possibilities with patients, the treatment choices themselves 
should not be based on the prediction models outcomes, but on the results of 
intervention studies. 
Choosing beneficial treatments; recent developments
As mentioned earlier, to ground any treatment decisions (either at the start of RRT 
or later) intervention or etiological studies aimed at comparing the different therapy 
outcomes on patient prognosis should be used. Despite a relatively high mortality 
risk in the first months after transplant surgery, in general transplantation is the 
preferred treatment option for ESRD patients in the long term[24,25,46]. Even the 
elderly ESRD patients generally profit from transplantation[47-51]. However, there 
are some recent developments indicating that there still is a desire to develop some 
support for this (shared) therapy decision process. First illustration of this is the 
research by Patzer et al.[52] published in 2016 that led to the development of a 
mobile clinical decision aid. This aid, called iChoose Kidney, compares individualized 
mortality risk estimates for dialysis versus transplantation. This innovation indicates 
the desire to have an interactive easy to use technological device to illustrate survival 
differences based on therapy choices. On the other hand this model does not take 
the quality of a deceased donor kidney into account, and it is likely to overestimate 
the transplant survival in the frail elderly patient[53]. All dialysis patients are selected 
and their dialysis survival is compared to the transplant survival of the patients who 
were both eligible for transplantation and ‘lucky enough’ to actually receive a donor 
kidney. Patients not eligible for transplantation often have an inferior clinical condition. 
Therefore the tool probably (over)quantifies the average survival advantage of trans-
plantation over dialysis considering specific patient characteristics, and it doesn’t 
point out the patients that would profit from waiting for another kidney in case of a 
marginal kidney offer. Another example of the recent interest in information to facil-
itate the decision making process is the ‘Nierwijzer’ (www.nierwijzer.nl), which has 
been launched in the Netherlands in October 2016. This is a website developed by 
the Dutch kidney patient cooperation together with medical professionals and others, 
and it contains a series of video fragments to illustrate the consequences of different 
renal replacement therapies on several topics from the patient’s perspective. These 
new approaches to visualize or illustrate consequences of treatment choices could 
facilitate the physician-patient counseling and shared decision-making process for 
ESRD patients. 
LIMITATIONS OF OUR SURVIVAL PREDICTION MODELS
The prediction models are based on past practices
Past and current renal care practices form the basis for the predicted survival prob-
abilities. In our case we predict ten year survival using data from a cohort from 1995-
2005. Consequently model performance can be hampered when renal care practices 
change. In fact renal care practices have changed in time, and might be expected to 
further change in the future[54]. In chapter 5, for instance, we have seen that espe-
cially the younger patients have been transplanted preemptively (with kidneys from 
living donors) more in recent years, where they were more likely to undergo peritoneal 
dialysis before. Also transplantation rates and donated kidney quality might vary in 
time. Including RRT starting year in the model has been considered. However, we 
decided not to include starting year in the model. In our opinion the prerequisite of 
a linear improvement in time is doubtful. For the dialysis treatment itself this might 
be true, due to developments of medication and machines, as well as optimization 
of dialysate, dialysis frequency and duration[55-58]. Also for the allocation and oper-
ation procedure of kidney transplantation as well as the transplantation follow-up 
treatment this probably holds[59]. On the other hand, the organ quality of transplanted 
deceased donor kidneys has deteriorated in time (both due to expansion of donor 
criteria and population changes) and also waiting times/dialysis vintage can fluctuate 
in time. Changes can either have a positive or negative influence on survival. Other 
complicating factors are the fact that treatment improvements often are not equally 
available to all ESRD patients, like illustrated in chapter 5, that patient mix might 
change (since the success of a treatment can increase its demand), and that special 
kidney transplant allocation program might be introduced, comparable to the intro-
duction of the old for old, Eurotransplant Senior Program (ESP), in the past decade[60]. 
All these changes might improve prognosis for only certain patient groups, while 
prognosis will be the same, or worse, for some other groups. Therefore we would 
plea for temporal validation[3,6] (e.g. every 5 year) rather than including RRT start 
year in the model. Despite this, the similar external validation performance outcomes 
in 9 different European countries with varying renal care practices and patient profiles 
(chapter 4) are very re-assuring and indicate robustness of the model.
The models are based on past patient profiles
Furthermore, not only the condition of the donor, but also the condition of patients 
has changed in time, like for example starting condition[61]. Some of these changes 
will be corrected by the prediction model, when they are included as variables, but 
other changes will not. The performance of the registry model might be influenced 
more than the other models by changing patient profiles: the age, sex, PRD, and 
initial chronic RRT are included, but underlying co-morbidities and conditional factors 
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with impact on survival probabilities (like for example high BMI and cardio-vascular 
problems) are not included in the model. Temporal validation[3,6] on more recent 
cohorts and, if necessary, model updating[4,6,62,63] is also important, especially for 
the registry model, to deal with changing patient profiles in time.
The models only predict patient survival, not quality of life
Another remark concerning the applicability of the prediction models presented in 
this thesis in the initial consultation of ESRD patients, is the fact that these models 
present long-term patient survival outcomes. Another important question that patients 
starting RRT might have is what the expected impact of RRT is on their quality of 
life. However, we did not include this outcome in a prediction model. Unlike death, 
which is a very objective endpoint, the quality of life is a subjective outcome measure 
which will vary among patients. Also transplanted patients generally experience a 
better quality of life[64]. For patients it might be helpful to gain insight in the different 
treatment consequences from a patient’s perspective. Interesting to point out in this 
context is the earlier mentioned ‘Nierwijzer’ (www.nierwijzer.nl), which is a website 
developed by the Dutch kidney patient cooperation together with medical professionals 
and other stakeholders, and contains a series of video fragments to illustrate the 
different renal replacement therapies from the patient’s perspective. 
PREDICTION ON WHICH PATIENTS MIGHT PROFIT FROM 
MARGINAL KIDNEY TRANSPLANTATION
Due to donor organ shortage the criteria for accepting kidneys for transplantation 
have been extended to allow the use of organs from ‘marginal donors’. Marginal, 
often older, donor kidney transplants are often associated with inferior graft outcomes. 
This leads to re-transplantation and increased risk to get immunized. From a patient’s 
perspective it is therefore clear that a better quality kidney offer is preferential, but 
waiting for a better kidney will take more (dialysis) time; not everybody can afford to 
wait for the next offer. Categorizing marginal kidney donors according to anticipated 
inferior outcome would help physicians with patient counseling and informed deci-
sion-making in case of an organ transplant offer.
What is a marginal donor kidney?
Although the criteria for ‘marginal donors’ are not well defined, there is a definition 
for Extended (or expanded) Criteria Donor (ECD) and Standard Criteria Donor (SCD) 
by the United Network for Organ Sharing (UNOS)[65]. ECD Donors are older donors 
or donors with significant comorbidities, whose relative risk of graft failure was 
higher compared with a standard donor. The definition of ECD, codified in 2002, is 
employed to describe kidneys from donors over the age of 60 years without comor-
bidities or donors over the age of 50 years with two comorbidities among hyperten-
sion, death from cerebrovascular accident, or terminal serum creatinine levels >1.5 mg/
dL (133 µmol/L), and is associated with more than 1.7 times the risk of graft failure 
compared to SCD donors[15]. The categorization of deceased donor kidneys as either 
SCD or ECD has the advantage of simplicity, but does not adequately reflect the 
wide spectrum of donor kidney quality[66]. It is known to misclassify kidneys in both 
directions: some kidneys labeled as SCD have a reduced graft survival, while some 
ECD kidneys perform well[67,68]. This has led to the development of more refined 
approaches to assess the quality of deceased donor kidneys. Nyberg has described 
the development of a Deceased Donor Score (DDS) categorizing donors in 4 risk 
categories (grade A-D) using 5 predictors for donor quality[69,70], and Schold et al. 
have designed a model to calculate the ‘donor risk grade’ (I to IV)[68]. However, 
these scores have not been replicated in independent cohorts and neither of these 
two scores has been widely used in daily practice[67]. The Kidney Donor Risk Index 
(KDRI) developed by Rao et al.[71] is a ‘clinician-friendly’ refined evaluation of donor 
quality without requiring donor histology[67] and includes 14 variables, 10 donor 
factors and HLA B and DR mismatching, cold ischemia time, en bloc transplant, and 
double kidney transplant[71]. Since these last 4 variables are generally not known 
at the time that a donor offer is made, and candidate specific, the implemented 
version is a donor-only KDRI[67]. This US KDRI is based on 10 readily available donor 
factors and estimates the relative risk of graft survival from a particular deceased 
donor compared with the median donor, adjusted for recipient characteristics and 
year of transplant. It is not proposed as the only metric for determining donor suit-
ability, but it should be used as an additional score next to all other factors that have 
implications for graft outcome. Later a simplified KDRI index (the UKKDRI) based 
on 5 donor variables has been developed on UK data, with similar performance (a 
C-index of 0.62)[72]. These KDR indices provide simple clinically useful tools that 
allow prediction of transplant outcome and thus could aid transplant physicians in 
patient counseling and the (shared) decision making process.
What is the expected survival after a marginal donor kidney transplant 
(compared to standard kidney transplantation and dialysis)?
Survival of marginal donor kidney transplants has been compared in several studies 
with the survival of non-marginal kidney transplants and of dialysis. The results 
differ across studies: some studies show no difference in outcomes of ECD and 
SCD transplants[73-76], whereas others show higher graft failure and/or mortality 
rates, especially in younger and diabetic patients[16,17,77,78]. Although the survival 
benefits seen in recipients of marginal kidney transplants, at least in some patient 
groups, seem to be inferior compared with those in recipients of SCD kidneys, their 
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long-term survival is significantly better than in those remaining on hemodial-
ysis[79,80]. However, the fact that there are excess deaths in ECD recipients during 
the peri-operative period[78], highlights the need of a careful recipient selection 
before transplantation[17]. Furthermore, ECD’s also seem less suitable in case of 
re-transplantations[17]. 
However, it cannot be ruled out that the reported inferior outcomes of marginal 
kidney transplantation versus SCD and favorable outcomes of marginal kidney 
transplantation versus dialysis are confounded by indication. The findings are based 
on cohort studies instead of clinical trials with random treatment assignment. 
Transplanted patients usually differ from waitlisted patients, and it is not unlikely 
that physicians have made some patient selections in their acceptance of ECD 
kidneys, which might lead to biased comparison results. A problem is that the 
preferable randomized controlled trial (RCT) is unethical in transplantation versus 
dialysis comparisons, and this also might be the problem in the comparison of ECD 
and SCD transplantations. 
For which patient should a marginal donor kidney be accepted for 
transplantation?
The implicit rationale underlying a decision to accept a marginal kidney offer despite 
eventual inferior graft outcome is that patient prospects for long-term survival for 
the patient could be enhanced by undergoing such a transplant immediately rather 
than pursuing dialysis while waiting for a better kidney offer[78]. In fact Schold et 
al.[81] found that 65 year old patients had longer life expectancy when they accepted 
an ECD within 2 years of ESRD onset compared with waiting for a SCD or a living 
donation after 4 years of dialysis. The waiting time for a marginal kidney transplant 
is often shorter. The advantage of an early transplant is a shorter dialysis vintage, 
and consequently presumably less health damage before this (first) transplant. For 
some patients staying on dialysis might even result in deterioration to a non-trans-
plantable condition, or even death, which obviously should be prevented. However, 
this worst-case scenario will not be the case for every waitlisted patient. Dialysis 
survival depends on patient characteristics and medical condition; some patients 
can wait longer for a ‘perfect’ match, due to the fact that they deteriorate less rapidly 
on dialysis combined with sufficient matchability for a next offer. 
Besides these health considerations there also might be (patient) preference for 
early transplantation because of the positive impact on the quality of life. Deciding 
whether or not to accept a marginal kidney donor offer asks for a complicated deci-
sion support system based on several prediction rules e.g. waiting list/dialysis survival, 
estimated waiting time for a standard criteria donor kidney, transplant (graft and 
patient) survival from a marginal compared to a standard criteria donor, and quality 
of life estimates.
Combining kidney donor risk scores with recipient risk scores
Combining recipient and donor risk scores might help to define which patients will 
profit most from a marginal kidney donor in comparison to continuing dialysis[66], 
or who will suffer most from a marginal kidney donor in comparison to a standard 
criteria donor. It might be suggested to define a minimum KDRI threshold on patient 
level. If this information is registered on the waiting list and used in the kidney allo-
cation algorithm, this could even help in declining marginal kidney donor discard 
rates, which are relatively high[15,82]. Currently in the Netherlands only donor age 
above 65 years of age, donation after cardiac death (DCD) and donation after brain 
death (DBD) kidneys are explicitly mentioned when an offer is being made. Also, it 
is possible to register on the waiting list whether a recipient or center accepts DCD 
donors or not. But due to the arbitrary dichotomy of this characterization many 
physicians do not use this option and choose to weigh the separate donor charac-
teristics for every offer they get for their patients. The additional subdivision SCD/
ECD is better than age alone and may prove easy to use in the future. However, 
other, more refined, scores like the KDRI might be more discriminatory. A desirable 
decision support system would be a system that includes both donor and recipient 
risk scores to assist physicians in the difficult decision making process in case of a 
marginal donor kidney offer. One step further, and beyond the scope of this thesis, 
would be the use of KDRI scores in combination with recipient risk scores to improve 
the allocation efficiency. Suggestions of integrating this utility approach in the allo-
cation scheme have been described by Baskin-Bey et. al[83] combining the DDS 
with a Recipient Risk Score (RRS). The Eurotransplant Senior Program (ESP) is a 
currently used example of the allocation of marginal grafts of 65+ donors to 65+ 
patients with lower expected survival prospects. Others[84], however, indicate risks 
of the utility approach.
Conclusive remarks
In conclusion, several donor risk scores have been developed (ESP, ECD versus SCD, 
DDS and KDRI) and some of them have been combined with recipient characteristics 
or risk scores in order to indicate which patients might profit from a certain marginal 
kidney offer. Although most study results are promising, these results might partly 
be biased by confounding by indication: it is likely that patients that have received 
marginal donor kidneys in the past differ from the patients that received a better 
quality donor kidney or stayed on dialysis. Randomized clinical trials are the golden 
standard in the comparison of treatments. In the comparison between dialysis and 
kidney transplantation RCT’s are unethical since transplantation is the treatment of 
choice for most patients, which makes it impossible to withhold eligible transplant 
patients an eventual transplant offer. This might also be the case, but maybe to a 
lesser extent, for the comparison between different quality donors. 
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FUTURE PERSPECTIVES
We recommend to do further (etiologic) research to provide the transplant community 
with a tool that can point out which patient on the waiting list profits most from a 
given marginal donor kidney offer. This is a very complicated procedure, as discussed 
earlier, but such a prediction model would be extremely helpful to support the (shared) 
decision-making process concerning donor kidney offers. The study we presented 
in chapter 6 was aimed at identifying recipients for whom the adjusted risk differences 
of an ECD versus a SCD transplantation is relatively low, so for whom it might be 
beneficial to accept any kidney offer (either SCD of ECD) as soon as possible, avoiding 
the risk of continuation of the dialysis treatment. Further research is needed to indi-
cate the best marginal donor definition for the Netherlands. This might either be a 
division like the current subdivision in ECD versus SCD kidneys or ESP kidneys, or 
the use of a more refined categorization like the KDRI. Further research is needed to 
discriminate between those waitlisted patients that will benefit from a marginal donor 
kidney transplantation and those patients that can afford to wait and benefit from a 
better offer. The resulting prediction model combining the two should at least incor-
porate variables describing the clinical condition of the patient, donor and organ quality, 
expected patient survival on dialysis or after transplantation, graft survival, and 
expected waiting time for a qualitatively better kidney offer.
In general prediction models can be used for comparisons, stratification and patient 
selection purposes. Our registry model can be used to further support intervention 
research for ESRD patients in Europe, aimed at improving future survival outcomes. 
Lenihan et al.[85] also stated that the focus in renal transplantation has shifted towards 
predicting and the use of these predictions to improve long time survival. Prediction 
offers the opportunity to alter therapy, to select individual patients for further diag-
nostic testing, to motivate lifestyle modification, and to manage patient expectations. 
The easy model could be used to facilitate patient counseling in clinical practice, when 
choices in RRT have been made and the patients prognosis is being discussed. 
Especially for patients in the highest risk groups such predictions can be helpful. 
Secondly the easy model could possibly be used in pre-dialysis care to facilitate 
patients in making a choice between RRT and conservative therapy. These patients 
should be informed about the possibilities of conservative therapy in the light of 
inferior RRT survival prospects. For this application we would recommend evaluating 
the ‘clinical’ usefulness of the model. 
For all possible applications we would recommend periodic re-evaluation (temporal 
validation), and eventual model updating[6,62,63,86], since treatment policies and 
patient characteristics may change over time. External validation in other European 
countries showed the robustness of the registry model, despite differences in ESRD 
care and patients, which makes it worthwhile to update the model in the future instead 
of just making a new one and discarding this knowledge.
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SAMENVATTING
Patiënten met eindstadium nierfalen hebben een nierfunctievervangende behan-
deling nodig om te overleven. Van de drie vormen, hemodialyse, peritoneale dialyse 
en niertransplantatie, heeft de laatste de voorkeur vanwege de beste overlevings-
perspectieven en kwaliteit van leven. Helaas is dit niet voor elke patiënt mogelijk 
en op het moment dat de behandeling wordt gestart is nog niet helder welke 
patiënten uiteindelijk op de niertransplantatiewachtlijst geplaatst, en getransplan-
teerd, zullen worden. Een algemene overlevingsvoorspelling is gewenst voor deze 
patiënten om de overlevingsverwachtingen vast of bij te stellen en om behandel-
consequenties beter te kunnen interpreteren. De eerste doelstelling van dit proef-
schrift (hoofdstuk 1) is daarom het maken en testen (valideren) van een model om 
de patiëntoverleving vanaf start nierfunctievervanging te voorspellen. Een dergelijk 
model kan ook ingezet worden om patiënten te selecteren of onder te verdelen 
naar overlevingsrisico, bijvoorbeeld bij klinisch onderzoek. Daarnaast is de tweede 
doelstelling van dit proefschrift om te bepalen welke patiënten het meest gebaat 
zijn bij transplantatie met een nier van een marginale (oudere en/of conditioneel 
minder optimale) donor. 
In hoofdstuk 2 wordt de ontwikkeling en validatie van een eerste predictiemodel 
ten aanzien van de 10-jaarsoverleving van patiënten die starten met nierfunctiever-
vanging in Nederland beschreven. Bij de ontwikkeling van dit model is gebruik gemaakt 
van een zeer beperkte set van makkelijke verkrijgbare data van de Registratie 
Nierfunctievervanging Nederland (RENINE). Het model, welke in de tekst wordt 
aangeduid als het registry model, is ontwikkeld en intern gevalideerd op een groot 
retrospectief cohort van Nederlandse patiënten van 16 jaar of ouder die zijn gestart 
met nierfunctievervanging in de periode 1995-2005. Het registry model voorspelt 
het overlijdensrisico in de eerste tien jaar op basis van leeftijd, geslacht, primaire 
nierziekte en de therapievorm op 90 dagen na de start. De voorspelkwaliteit van het 
gepresenteerde model is geëvalueerd met behulp van calibratie- en discriminatie-
maten[1-5]. De calibratie geeft een inschatting van de betrouwbaarheid van het model 
en is een maat voor de overeenstemming tussen de geobserveerde en de voorspelde 
overleving. De discriminatie, oftewel het onderscheidend vermogen, wordt gemeten 
aan de hand van de ‘concordance’ (of C-) index; dit is een weergave van hoe vaak 
het model juist voorspelt welke van twee patiënten het langst overleeft[6,7]. Aan de 
hand van deze uitkomsten is geconcludeerd dat het registry model voldoet, maar 
gezien het bescheiden onderscheidend vermogen van het model werd verder onder-
zoek naar verbeteringsmogelijkheden aanbevolen. 
Hoofdstuk 3 beschrijft hoe het predictiemodel verder verbeterd kan worden door 
toevoeging van klinische informatie. Voor dit doel is gebruik gemaakt van data van 
de Nederlandse Coöperatieve Studie naar de Adequaatheid van Dialyse (NECOSAD). 
Dit is een prospectieve studie waarin gedetailleerde klinische informatie is opge-
nomen van een subset van de Nederlandse patiënten die zijn gestart met dialyse. 
Dat betekent wel dat pre-emptieve transplantatiepatiënten (patiënten die zijn getrans-
planteerd zonder voorafgaande dialyse) niet zijn geïncludeerd, terwijl dit toch een 
groeiende patiëntengroep is in Nederland. Ondanks dit verschil tussen het NECOSAD-
cohort en de complete Nederlandse patiëntenpopulatie bleek het registry model ook 
in deze populatie inzetbaar. Op basis van literatuur en klinische ervaring zijn 19 
kandidaat-variabelen geselecteerd uit de NECOSAD-data en onderverdeeld in drie 
groepen. Eerst is het registry model uitgebreid met eenvoudig verkrijgbare data over 
de medische voorgeschiedenis en klinische voorspellers (‘easy model ’). Vervolgens 
werden bloeddruk en een aantal extra laboratoriumwaarden toegevoegd (‘elaborate 
model ’) en tenslotte werden ook de glomerulaire filtratiesnelheid (GFR) evenals een 
maat voor de adequaatheid van dialyse (Kt/V) toegevoegd (‘extended model ’). Het 
onderscheidend vermogen van het easy model was iets beter dan het (opnieuw 
geschatte) registry model. De extra voorspellende waarde van het elaborate model 
ten opzichte van het easy model was zeer beperkt. Het extended model gaf geen 
verdere verbetering van de voorspelling. We concludeerden dat het originele registry 
model vooral geschikt is voor groepsvergelijkingen, risicodifferentiatie en patiënt-
selecties en dat het easy model met meer klinische variabelen de voorkeur heeft 
voor individuele patiëntvoorspellingen. 
Bij voorspelmodellen is validatie in een geheel andere populatie (externe validatie) 
van groot belang om de generaliseerbaarheid te testen[1,2,4,8,9]. In hoofdstuk 4 is 
het originele registry model extern gevalideerd in een cohort van negen Europese 
landen met data van de ERA-EDTA Registratie. Aangezien er veel verschillen bestaan 
tussen de Europese landen met betrekking tot patiëntkarakteristieken, behandeling 
en behandeluitkomsten van patiënten is dit ERA-EDTA cohort heel geschikt voor 
externe validatie. De resultaten van het model in de andere Europese landen zijn 
vergelijkbaar met die in Nederland. Dit impliceert dat het registry model ook bruikbaar 
is, voor de eerder genoemde doelen, in een groot aantal Europese landen.
Hoofdstuk 5 beschrijft dat ondanks het feit dat peritoneale dialyse een goed alterna-
tief is voor hemodialyse[10-17], het relatieve aandeel van peritoneale dialyse in Nederland 
is afgenomen van 15% in 1995 tot 8% in 2010. De redenen hiervoor worden in dit 
hoofdstuk onderzocht. Een deel van de verklaring is dat jongere patiënten, die anders 
in aanmerking zouden komen voor peritoneale dialyse, in recentere jaren vaker pre-emp-
tief (zonder voorafgaande dialyse) getransplanteerd worden, hetgeen een positieve 
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ontwikkeling is. Een ander deel van de verklaring is dat er sprake is van vergrijzing van 
de dialysepopulatie, resulterend in minder geschiktheid voor peritoneale dialyse. Deze 
ontwikkelingen verklaren echter niet de totale groei van hemodialyse. Dit zou ook 
geassocieerd kunnen zijn met de toegenomen hemodialysecapaciteit sinds 2002, 
maar het is niet helder of dit heeft geleid tot een beperking van de keuzevrijheid voor 
de patiënt (als peritoneale dialyse minder vaak als optie wordt aangeboden), of juist 
een toegenomen keuzevrijheid (als het grotere aandeel peritoneale dialyse in het 
verleden een consequentie was van de destijds beperkte hemodialyse-capaciteit). 
Het tekort aan postmortale orgaandonoren heeft geleid tot het verruimen van de 
donorcriteria met als gevolg dat marginale donornieren wereldwijd door veel trans-
plantatiecentra worden geaccepteerd voor transplantatie[18,19]. In hoofdstuk 6 zijn 
de resultaten gepresenteerd van niertransplantaties met een specifiek type marginale 
donor (de zogenaamde ‘extended criteria donor’) in vergelijking met standaard criteria 
donoren in Nederland. Uit de Nederlandse Orgaantransplantatie Registratie (NOTR) 
is informatie verkregen over alle niertransplantaties uit de periode 1995-2005 bij 
volwassen ontvangers. Transplantaties met ‘extended criteria donor’ nieren leidden 
over het algemeen tot slechtere prognoses dan de reguliere niertransplantaties. De 
gevonden verschillen in nierfalen en overlijdensrisico waren groter voor de jongere 
en de diabetische patiënten, overeenkomstig bevindingen uit de internationale lite-
ratuur. Het grootste risico werd gevonden in de groep met ‘extended’ nieren van 
donoren na circulatoire dood. De studiebevindingen roepen de vraag op of ‘extended 
criteria donor’ nieren bij voorkeur toegewezen zouden moeten worden aan bepaalde 
patiënten, zoals de oudere en niet-diabetische patiënten, maar het is de vraag of dit 
ethisch wenselijk is. 
Na deze samenvatting van alle voorgaande hoofdstukken in dit proefschrift, worden 
in de volgende paragrafen de belangrijkste bevindingen bediscussieerd en gerang-
schikt naar de doelstellingen van dit proefschrift, en worden de toekomstige onder-
zoeksmogelijkheden gepresenteerd.
DISCUSSIE
Toegevoegde waarde van de overlevingsvoorspellingsmodellen 
gepresenteerd in dit proefschrift
Voor zover bekend zijn de predictiemodellen in dit proefschrift de eerste modellen 
bedoeld om de lange-termijn patiëntoverleving te voorspellen voor de hele groep van 
patiënten met nierfunctievervanging in hun initiële behandelfase, rekening houdend 
met zowel hun dialyseoverleving als hun mogelijke overleving na niertransplantatie. 
Eerder ontwikkelde predictiemodellen zijn vooral gefocust op alleen dialyse- of wacht-
lijstoverleving, of overleving na transplantatie[20-23]. De modellen in dit proefschrift 
zijn juist gericht op patiëntoverlevingsvoorspellingen bij aanvang nierfunctievervanging, 
als nog niet duidelijk is welke therapieën patiënten in de toekomst zullen krijgen. 
Potentieel voor gebruik van de modellen (algemeen of individueel)
Over het algemeen zijn predictiemodellen geschikt voor patiëntvoorlichting en voor 
onderzoeksdoeleinden[4,5,7,24]. Ten behoeve van onderzoeksdoeleinden en groeps-
vergelijkingen bevelen we het gebruik van het registry model aan. De risicodifferen-
tiatie van patiënten volgens dit eenvoudig toepasbare registry model met slechts vier 
variabelen is voldoende, zoals is aangegeven met behulp van de calibratie- en discri-
minatie-uitkomsten, zowel in Nederland (hoofdstuk 2), als in een groot aantal Europese 
landen (hoofdstuk 4). Vergeleken met het registry model, kunnen met het easy en 
het elaborate model, welke beiden veel klinische gegevens gebruiken, veel patiënten 
terecht naar hogere of lagere risicogroepen gereclassificeerd worden, hetgeen wijst 
op een betere voorspelling op individueel niveau. Het elaborate model vereist meer 
informatie dan het easy model en geeft slechts een marginale prestatieverbetering. 
Op individueel niveau wordt daarom het gebruik van het easy model geadviseerd.
Potentieel van het gebruik van het easy model voor de beslissing om al dan 
niet te starten met nierfunctievervangende behandelingen
Een recente trend in de nierzorg is dat in geval van zwakkere en/of oudere patiënten, 
conservatieve behandeling zorgvuldig wordt overwogen als behandelalternatief[25-29]. 
Een Canadese studie over de behandelvoorkeuren en -behoeften in de laatste levensfase 
heeft aangetoond dat meer dan 90% van de volwassen patiënten met ernstig nierfalen 
het belangrijk vond om over hun prognose geïnformeerd te worden en 61% had achteraf 
spijt van de beslissing om te starten met dialyse[25]. Onze predictiemodellen zijn vooral 
gericht op het voorspellen van de overleving op lange termijn na start nierfunctievervan-
ging, en zijn dus mogelijk ook bruikbaar ten behoeve van de selectie van patiëntgroepen 
die, met de actuele behandelingsmogelijkheden, slechts een beperkte overlevingsprog-
nose hebben. Voor deze patiënten kan conservatieve therapie een aantrekkelijk alterna-
tief zijn[26,29]. Het easy model heeft voor deze toepassing de voorkeur. 
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Ons registry model is niet geschikt voor de keuze van een specifieke 
therapievorm
Ons registry model kan niet gebruikt worden als bewijs voor betere uitkomst van 
vroege transplantatie ten opzichte van dialyse of peritoneale dialyse in plaats van 
hemodialyse. Patiënten zijn niet willekeurig verdeeld over de verschillende behandel-
vormen, maar hebben naar aanleiding van hun klinische conditie een bepaalde 
behandeling ondergaan. Op de wachtlijst geregistreerde patiënten worden vaak 
gezonder geacht dan de patiënten die aan de dialyse moeten blijven[30,31] en de 
getransplanteerde patiënten hebben waarschijnlijk een nog betere conditie[32]. Met 
andere woorden, de behandelmodaliteiten in het model kunnen worden beschouwd 
als een indicatie van medische conditie. De therapiekeuzes zelf moeten vooral geba-
seerd worden op bevindingen uit interventiestudies en niet op predictiestudies.
Het kiezen van de meest gunstige behandeling voor een patiënt;  
recente ontwikkelingen
Een paar recente ontwikkelingen laten zien dat er wel behoefte is aan een hulpmiddel 
ter onderbouwing van de keuze tussen transplantatie en dialyse. Zo is in 2016 een 
publicatie verschenen over een besluitvormingsondersteunende applicatie, genaamd 
‘iChoose Kidney’, welke de geïndividualiseerde overlijdensrisico’s van dialyse en 
niertransplantatie vergelijkt[33]. De applicatie houdt echter geen rekening met de 
kwaliteit van het donororgaan en het feit dat dialysepatiënten vaak een slechtere 
klinische conditie hebben en niet transplantabel zijn en zal daarom mogelijk voor 
sommige patiëntgroepen een te positief beeld van het overlevingsvoordeel van 
transplantatie ten opzichte van dialyse geven[34]. Een ander voorbeeld van de recente 
interesse in informatie om het besluitvormingsproces te ondersteunen is de ‘Nierwijzer’ 
(www.nierwijzer.nl) welke in Nederland is geïmplementeerd in oktober 2016. Dat is 
een website ontwikkeld door de Nierpatiëntenvereniging Nederland, samen met 
onder andere medisch professionals, en het omvat een serie videofragmenten over 
verschillende onderwerpen om de gevolgen van de nierfunctievervangende therapieën 
vanuit het patiëntperspectief te illustreren.
De predictiemodellen zijn gebaseerd op voormalige behandelingsmogelijk-
heden en -keuzes
Eerdere en huidige behandelingsmogelijkheden voor, en behandelkeuzes van, de 
patiënten met eindstadium nierfalen vormen de basis voor de berekening van over-
levingskansen. In ons geval voorspellen we de 10-jaarsoverleving gebruik makend 
van een patiëntencohort van 1995-2005. Modelprestaties zouden kunnen tegenvallen 
als de behandelingsmogelijkheden en -keuzes veranderen. Dit soort veranderingen 
komen zeker voor[35]. In hoofdstuk 5 hebben we bijvoorbeeld gezien dat vooral 
jongere patiënten tegenwoordig pre-emptief getransplanteerd worden met nieren 
van levende donoren, terwijl ze in het verleden vaker werden behandeld met perito-
neale dialyse. Ook veranderen de transplantatiekansen en de nierkwaliteit van de 
gedoneerde nieren met de tijd. Naast veranderingen op behandelingsniveau zullen 
ook op patiëntniveau veranderingen optreden, zoals bijvoorbeeld de patiëntconditie 
bij aanvang van de nierfunctievervangende behandeling. Een aantal veranderingen 
zullen automatisch door het model gecorrigeerd worden, aangezien ze als variabelen 
in het model opgenomen zijn, maar voor andere veranderingen wordt niet gecorri-
geerd. Daarom pleiten we voor temporele validatie, gecombineerd met eventuele 
modelaanpassing (bijvoorbeeld elke 5 jaar). In dit verband is het echter wel bijzonder 
dat de resultaten van de externe validatie in negen andere Europese landen (hoofd-
stuk 4) zo goed waren, ondanks verschillen in behandeling en indicatiestelling. Dit 
impliceert de robuustheid van het huidige registry model. 
De modellen voorspellen alleen overleving, niet de kwaliteit van leven
Een andere opmerking betreffende de toepasbaarheid van de voorspelmodellen uit 
dit proefschrift ten behoeve van de begeleiding van de patiënt is het feit dat deze 
uitsluitend gericht zijn op de patiëntoverleving en niet op de kwaliteit van leven. Waar 
overlijden een heel objectieve uitkomstmaat is, is de kwaliteit van leven een subjec-
tieve maat en de perceptie van de kwaliteit van leven zal van patiënt tot patiënt 
verschillen. Net als bij de overleving is de kwaliteit van leven over het algemeen beter 
na een niertransplantatie[36]. Voor patiënten kan het echter helpen om geïnformeerd 
te zijn over de verschillende behandelconsequenties. De eerder genoemde ‘Nierwijzer’ 
kan hierbij helpen doordat hierin de consequenties van de verschillende behandelingen 
vanuit het patiëntperspectief worden belicht.
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Voorspelling welke patiënten baat zouden kunnen hebben bij een marginale 
niertransplantatie
Vanwege het orgaantekort zijn de donoracceptatiecriteria verruimd en worden nu ook 
nieren van ‘marginale’ (oudere en/of kwalitatief slechtere) donoren voor transplantatie 
geaccepteerd. Deze worden vaak geassocieerd met slechtere uitkomsten. Een kortere 
transplantaatoverleving kan leiden tot de behoefte aan een re-transplantatie en een 
toegenomen risico om geïmmuniseerd te raken. 
Wat is een marginale donornier?
Hoewel de criteria voor ‘marginale donoren’ niet heel duidelijk gedefinieerd zijn, is er 
een definitie voor de uitgebreide (Extended Criteria) donoren van de United Network 
for Organ Sharing (UNOS); deze beschrijft nieren van donoren ouder dan 60 jaar 
zonder comorbiditeiten of donoren van 50 jaar of ouder met twee van de volgende 
comorbiditeiten: hypertensie, overlijden door een CVA of terminale serumcreatinine-
waardes van >1,5 mg/dL, welke zijn geassocieerd met een 1,7 keer hogere kans op 
transplantaatfalen in vergelijking met standaard donoren[18]. De indeling in ‘extended’ 
en standaard donoren is weliswaar eenvoudig, maar niet per se een goede weergave 
van het brede spectrum van donorkwaliteiten[37]. Nieren kunnen aan beide kanten 
gemisclassificeerd worden: sommige standaard nieren hebben een verminderde 
transplantaatoverleving, terwijl andere ‘extended criteria donor’ nieren juist hele goede 
uitkomsten hebben[38,39]. Dit heeft geleid tot de ontwikkeling van meer verfijnde 
benaderingen, zoals de nierdonor-risico-index[38,40,41], die artsen zouden kunnen 
helpen in hun patiëntbegeleiding en bij (gezamenlijke) besluitvorming; hier zou in 
Nederland ook verder naar gekeken moeten worden.
Voor welke patiënten zou een marginale donornier geaccepteerd moeten 
worden voor transplantatie?
De onderliggende gedachte bij het besluit om een marginale donornier voor transplantatie 
te accepteren, ondanks de eventueel slechtere transplantaatoverleving, is dat de lange-ter-
mijn patiëntprognose kan worden verbeterd door een dergelijke transplantatie direct te 
ondergaan in plaats van langer te dialyseren in afwachting van een betere donornier[42,43]. 
De wachttijd voor een marginale donornier is namelijk meestal korter. Voor sommige 
patiënten kan langdurige dialyse leiden tot verslechtering van de gezondheid en uitein-
delijk tot een niet-transplantabele conditie, of zelfs overlijden. Naast deze gezondheids-
overwegingen, kan er ook een wens (van de patiënt) zijn om snel getransplanteerd te 
worden, vanwege de positieve uitwerking op de kwaliteit van leven. Een besluit om een 
marginaal nieraanbod te accepteren, vereist een ingewikkeld besluitvormingsondersteu-
nend systeem, dat onder andere rekening houdt met wachtlijst- of dialyseoverleving, de 
geschatte wachttijd voor een standaard nier, de transplantatieoverleving met een margi-
nale nier vergeleken met die met een standaard nier, en de kwaliteit van leven.
Concluderende opmerkingen met betrekking tot acceptatie marginale 
donornieren
Verschillende donor-risicoscores zijn ontwikkeld en sommige daarvan zijn gecombi-
neerd met ontvangerkarakteristieken om vast te stellen welke patiënten het meest 
kunnen profiteren van een bepaald marginaal nieraanbod. Hoewel de meeste studie-
resultaten veelbelovend zijn, kunnen ze een vertekend beeld geven doordat patiënten 
die in het verleden een marginaal nieraanbod hebben ontvangen verschillen van de 
patiënten die een nier van een betere kwaliteit hebben ontvangen of juist aan de 
dialyse zijn gebleven. Gerandomiseerd onderzoek is de gouden standaard voor de 
vergelijking van behandelingen, maar dit is hier (net als bij de vergelijking van dialyse 
en niertransplantatie) onethisch.
Toekomstperspectieven
We zouden aanbevelen om, op basis van de resultaten beschreven in hoofdstuk 6, 
verder onderzoek te doen om te beoordelen welk patiënten op de wachtlijst baat 
hebben bij acceptatie van een bepaald marginaal donornieraanbod en daardoor een 
verkorte wachttijd. Een dergelijk voorspelmodel zou zeer wenselijk zijn om de (geza-
menlijke) besluitvorming betreffende het al dan niet accepteren van een nieraanbod, 
te ondersteunen. Ook is ten behoeve van bovenstaande verder onderzoek nodig om 
de beste definitie van marginale donoren, ofwel verschillende donorkwaliteiten, in 
Nederland te bepalen. 
Over het algemeen zijn predictiemodellen geschikt voor patiëntvoorlichting en voor 
onderzoeksdoeleinden. Ons registry model is voldoende voor de laatstgenoemde 
toepassing en kan worden gebruikt bij het doen van verder interventieonderzoek 
gericht op toekomstige overlevingsverbeteringen bij patiënten met eindstadium 
nierfalen in Europa. Het easy model heeft de voorkeur in de patiëntbegeleiding bij 
de bespreking van behandelkeuzes en patiëntprognoses. Zeker voor patiënten in de 
hoogste risicogroepen kunnen dergelijke overlevingsvoorspellingen nuttig zijn. Zo kan 
het easy model mogelijk ook al in de pre-dialyse zorg worden gebruikt om de keuze 
tussen het starten van een nierfunctievervangende therapie ofwel een conservatieve 
behandeling te bespreken met hoge-risico patiënten. Bruikbaarheid van het model 
voor deze toepassing in de ‘klinische’ praktijk zal nog wel onderzocht moeten worden. 
Voor alle toepassingen is periodieke re-evaluatie en eventuele modelaanpassing 
aanbevolen[9,44-46]. 
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DANKWOORD
Ik kan het zelf bijna niet geloven, maar mijn proefschrift is nu toch echt af! Dit was 
echter nooit mogelijk geweest zonder de hulp en steun van velen, die ik in dit laatste 
hoofdstuk daarvoor van harte wil bedanken. 
Allereerst wil ik dit dankwoord richten tot mijn promotor, Prof. dr. Andries Hoitsma 
en eerste copromotor Dr. Martin Heemskerk. Andries en Martin, zonder jullie geduld 
en begeleiding was dit proefschrift nooit tot stand gekomen! Deze promotie is voor 
jullie, net als voor mij, geen gemakkelijke ‘bevalling’ geweest. Ik heb er zelf heel lang 
aan getwijfeld of het er ooit van zou komen, maar jullie zijn daar altijd in blijven geloven! 
Heel veel dank voor jullie hulp, steun en vertrouwen! Ik zal ons wekelijks onderzoeks-
overleg gaan missen. 
Andries, onze samenwerking startte zo’n 16 jaar geleden. Je stond samen met mij 
‘aan de wieg van de NOTR’ en was vanuit het Renine- (en later Nefrovisie-)bestuur 
jarenlang mijn sparring partner voor de coördinatie van Renine. Dit promotietraject 
was een bijna logisch vervolg hierop aangezien we nu als gebruiker van deze data-
bases de waarde hiervan konden aantonen. Je hebt in al deze functies altijd veel voor 
mij betekend en ik bewonder het feit dat jij altijd overal tijd voor wist te maken: of het 
nou ging om een antwoord op een vraag of het becommentariëren van (de zoveelste 
versie!) van een stuk, altijd was dit snel! Aangezien dat ook vaak ’s avonds, in het 
weekend (‘op een regenachtige zondag’) of in je vakantie was, denk ik dat het ook 
terecht is om Stieneke te bedanken voor het feit dat zij je daarvoor de ruimte gaf! Ik 
ben blij dat jij mijn promotor was, en ik één van jouw laatste promovendi, en ik hoop 
dat we onze fijne samenwerking (nu in een Europees project) nog enige tijd kunnen 
vervolgen. 
Martin, ik weet nog dat jij zelf promoveerde toen je nog maar net in dienst was bij 
de NTS en nu ben ik jouw eerste promovenda! Ik heb onze samenwerking erg 
gewaardeerd; het was fijn om allerlei nieuwe dingen te leren met betrekking tot het 
predictie-onderzoek (en om ons beiden te verdiepen in de epidemiologie). Je hebt 
me verder altijd erg geholpen met jouw geweldige relativeringsvermogen en je vaar-
digheid om hoofd- en bijzaken te onderscheiden (waardoor jij in staat was vele woorden 
in mijn artikelen te schrappen, hetgeen zeker niet mijn sterkste punt is). Ik hoop dat 
wij bij de NTS als onderzoekers nog vele jaren kunnen blijven samenwerken!
Dat brengt me bij mijn tweede copromotor, Dr. Merel van Diepen, en de afdeling 
epidemiologie van het LUMC, met name Prof. dr. Friedo Dekker, welke heel belang-
rijk zijn geweest voor dit onderzoek. 
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Friedo, ik vond het heel fijn dat jij zo enthousiast die samenwerking met ons bent 
aangegaan en dat je een essentiële inbreng hebt gehad in al mijn artikelen in dit 
proefschrift. Je hebt gedurende het onderzoek in diverse overleggen altijd kritisch 
met ons meegedacht en had vaak een hele frisse kijk op de materie. En heel veel 
dank natuurlijk voor het toevoegen van Merel aan ons team!
Merel, jouw kennis van predictiemodellen was heel belangrijk voor dit onderzoek. Je 
hebt ons veel geleerd en het was fijn dat we altijd bij je langs konden komen voor 
advies of praktische hulp. Ook je hulp bij het schrijven van de artikelen was onmisbaar. 
Heel fijn dat jij, naast Martin, mijn copromotor wilde zijn! 
Mijn promotieonderzoek heb ik uitgevoerd bij de NTS en aan deze organisatie ben ik 
dan ook veel dank verschuldigd voor het mogelijk maken van dit onderzoek. In het 
bijzonder wil ik Brigitte en Bernadette bedanken voor hun ondersteuning tijdens het 
promotietraject. Hoewel jullie niet direct inhoudelijk betrokken waren, is jullie voor-
waardenscheppende, stimulerende en ondersteunende rol wel degelijk zeer essen-
tieel geweest voor dit onderzoek! Dank aan alle leden van het wetenschappelijk 
overleg voor hun input bij het oefenen van voordrachten. De NTS is in de tijd dat ik 
er werk enorm gegroeid, dus het wordt teveel om iedereen bij naam te noemen. Bij 
deze wil ik daarom alle NTS-collega’s (en ook ex-collega’s) danken voor de belang-
stelling, de fijne samenwerking, praktische hulp en de gezelligheid o.a. bij de lunch, 
borrels en congressen. Hetzelfde geldt voor de ET-collega’s (hoewel het directe 
contact de laatste jaren wat minder intensief is nu bijvoorbeeld onze keukens gescheiden 
zijn en we elkaar niet meer tegenkomen bij het koffie-apparaat) en mijn ex-collega’s 
van Nefrovisie. 
Verder ben ik veel dank verschuldigd aan de ERA-EDTA voor hun hulp bij mijn externe 
validatiestudie. In het bijzonder dank aan Anneke Kramer, Maria Pippias en Vianda 
Stel, voor het leveren van de data, het meedenken en meewerken aan het externe 
validatie-artikel en de communicatie met de diverse co-auteurs. 
Alle leden van de manuscriptcommissie, Prof. dr. Irma Joosten, Dr. Michiel Warlé en 
Prof. dr. Kitty Jager, wil ik graag danken voor hun tijd voor het beoordelen van mijn 
proefschrift en hun bereidheid om zitting te nemen in mijn promotiecommissie. 
Verder hierbij nog een woord van dank voor de co-auteurs van de verschillende arti-
kelen, die ik tot nu toe nog niet bedankt heb. Willem Weimar, bedankt voor de 
discussies en de samenwerking ten behoeve van het eerste predictie-artikel (hoofd-
stuk 2) en het feit dat jij tevens de andere (concept)artikelen van het proefschrift 
tussentijds hebt willen lezen. Voor hoofdstuk 4 dank aan de diverse ERA-EDTA 
Registry-vertegenwoordigers die met hun kritische vragen een goede bijdrage hebben 
geleverd aan de huidige versie van het artikel. Voor hoofdstuk 5 dank aan W.J.W. Bos 
en R.T. Krediet voor onze ‘samenwerking op afstand’ en met betrekking tot hoofdstuk 
6 wil ik met name Frans van Ittersum hartelijk danken voor de prettige samenwerking 
en het feit dat ik als tweede auteur heb mogen participeren in zijn onderzoek.
Ik vond, en vind, promoveren doodeng. Wat heerlijk dat ik dan daarin wordt bijgestaan 
door 2 paranimfen: mijn lieve zus Karin en collega Cynthia. 
Karin, na enig twijfelen gezien de onbekendheid van de rol van een paranimf, heb je 
toch besloten deze ‘rol’ te pakken. Daar ben ik echt heel blij mee, aangezien je (al 
meer dan 45 jaar!) heel belangrijk bent voor mij en ik het dan ook leuk vind dat je 
hierbij weer mijn ‘getuige’ bent. Frank, ook dank voor jouw steun. 
Cynthia, ook jij aarzelde even, maar deze rol staat jou op je lijf geschreven; voor mij 
was het evident dat ik ook jou hier graag aan mijn zijde zou willen hebben, gezien 
onze jarenlange samenwerking/vriendschap bij de NTS! Zoals helemaal bij jou past, 
heb je je helemaal in deze rol gestort (met een hele brede ‘functieomschrijving’); 
extra dank daarom voor alle praktische steun bij afronding van het proefschrift.
Mijn (schoon)familie en vrienden wil ik hartelijk danken voor hun interesse en morele 
steun. Hoewel het onderzoek niet altijd ter sprake kwam, kwam het zeker aan de 
orde als er iets meer tijd was voor diepgaande gesprekken bijv. tijdens wandelingen, 
etentjes, uitjes, (sauna-) bezoekjes. Dank aan jullie allen voor jullie altijd luisterende 
oor en advies. Vaak ging het in deze gesprekken echter meer over het proces dan 
over de inhoud; ik hoop dat het jullie met dit boekje wat duidelijker is geworden waar 
ik mij nu al die tijd mee bezig heb gehouden. Marcel, ik vond het leuk nu ook een 
keer met jou samen te werken op jouw werkterrein; bedankt voor de mooie vorm-
geving! 
Lieve papa en mama, eigenlijk is het dankzij jullie dat ik dit heb kunnen doen. Jullie 
hebben me een onbezorgde jeugd, veel liefde en alle kansen tot ontwikkeling gegeven. 
Daarbij hebben jullie me altijd onvoorwaardelijk gesteund in alle keuzes die ik gemaakt 
heb. Ik vind het dan ook heel fijn dat jullie nu getuige kunnen zijn van de afronding 
van mijn proefschrift.
Lieve Arjan, Marit en Dena; mijn allerlaatste dankwoord gaat uit naar jullie! 
Arjan, al weet je dit waarschijnlijk niet meer, jij hebt destijds de doorslag gegeven bij 
het starten van mijn promotietraject. Discussiërend over de zin van het leven en wat 
ik nou echt graag zou/had willen doen, kwam jij met de suggestie dat ik door middel 
van onderzoek ook zou kunnen proberen een (indirecte) bijdrage aan de geneeskunde 
te leveren. Ik weet niet of je na die tijd nog wel eens getwijfeld hebt aan je advies, 
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CURRICULUM VITAE
Aline Cornelia Hemke werd op 17 juni 1968 geboren in Hoorn. Ze heeft in 1986 aan 
de Rijksscholen Gemeenschap West-Friesland in Hoorn het VWO (Atheneum) afgerond 
en heeft vervolgens in Tuscaloosa, Alabama (USA) haar High School diploma gehaald 
in 1987. In augustus 1987 startte zij met de studie Gezondheidswetenschappen aan 
de Rijksuniversiteit Limburg te Maastricht. Voor deze studie deed ze onder begeleiding 
van Prof. Ir. Hasman en Drs. Groothuis in 1991 een onderzoeksstage in het Academisch 
Ziekenhuis Utrecht (nu Universitair Medisch Centrum Utrecht) met als onderwerp 
automatisering van de verpleegkundige informatievoorziening. In 1992 heeft ze nog 
een extra keuzestage gedaan bij de medische informaticafaculteit van de Universiteit 
van Bari (Italië), gericht op de uitlegfaciliteit van een expertsysteem voor medicatie-
voorschriften. In september 1992 heeft ze haar bul Gezondheidswetenschappen, 
afstudeerrichting Beleid en Beheer, in ontvangst genomen. Van september 1992-februari 
1999 heeft ze gewerkt als medewerker informatiemanagement in het Academisch 
Ziekenhuis Utrecht bij de Concerndienst Informatisering & Automatisering. In maart 
1999 is ze begonnen bij de Nederlandse Transplantatiestichting (NTS), waar ze onder 
andere is gestart is met de ontwikkeling van de Nederlandse Orgaantransplantatie 
Registratie (NOTR). Vanaf 2008 (tot eind 2015) werd ze daarnaast als coördinator 
(mede)verantwoordelijk voor RENINE (Registratie Nierfunctievervanging Nederland) 
in de periode dat deze bij de NTS was ondergebracht. Vanaf 2011 is ze gestart met 
haar promotie-onderzoek onder leiding van Prof. dr. Andries J. Hoitsma en werd 
daarmee ook ‘gebruiker’ van bovengenoemde twee waardevolle bronnen van infor-
matie op het gebied van dialyse en transplantatie: RENINE en de NOTR. 
Aline Hemke is getrouwd met Arjan Schoonbeek. Zij hebben twee dochters, Marit 
(2001) en Dena (2004).
8 DANKWOORD
maar je hebt me altijd onvoorwaardelijk gesteund, zowel in praktische als in morele 
zin met je heerlijk nuchtere kijk op de dingen als ik weer eens beren op de weg zag. 
Je bent echt mijn rots in de branding! Lieve Marit en Dena, mijn mooie, lieve dochters. 
Hoe fijn is het om jullie moeder te zijn! Ik ben zeker wel eens tekort geschoten in 
mijn aandacht voor jullie, vooral in de laatste fase van mijn onderzoek, maar dat hebben 
jullie me nooit kwalijk genomen. Ik hoop dat jullie je ook zullen kunnen ontwikkelen 
in de richting die jullie ambiëren. Maar laten we, voordat het zover is en jullie uitvliegen, 
nog heel veel mooie dingen beleven samen als gezin!
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